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Summary
It is clear, from a wide range of studies, that the protein kinase C (PKC) family has an 
important role in the regulation of cell growth, differentiation and ftmction. However, 
as of yet, relatively little is known about the functions of the individual members of 
the PKC family in any system.
The aim of this study was to investigate the roles of specific PKC isoforms in the 
regulation of adipocyte development and function using 3T3-F442A cells which 
differentiate in culture into cells with the charateristics of adipocytes. Initially, the 
PKC complement of 3T3-F442A cells was thoroughly characterised using a panel of 
isoform-specific antibodies with application of strict criteria to ensure the appropriate 
identification of PKC isoforms. Both undifferentiated 3T3-F442A preadipocytes and 
fully differentiated 3T3-F442A adipocytes were found to express PKC 
a , y, Ô, 8, Ç and \x but not PKC P, rj, 0 or i/X . The PKC complement of 3T3-F442A 
adipocytes was found to be identical to that of rat adipocytes. This supported the 
suitability of using 3T3-F442A cells as a model system of adipocyte development and 
function.
Initially, in order to gain an indication of the functional roles of individual PKC 
isoforms in the process of preadipocyte differentiation, the temporal changes in 
cellular levels of PKC isoforms were examined throughout the time-course of 
differentiation of 3T3-F442A cells. The a , y and 5 isoforms displayed similar 
temporal patterns of expression during the differentiation of 3T3-F442A cells; all 
increased rapidly, peaking at day two of differentiation. Subsequently, the expression 
of these isoforms decreased, resulting in markedly reduced levels in fully 
differentiated adipocytes as compared to preadipocytes. The expression of PKC 8 
increased steadily during differentiation, resulting in markedly elevated levels in 
adipocytes. Although expression of PKC p increased during differentiation, this was 
attributable to prolonged confluence rather than to the differentiation process per se. 
No change was observed in the expression of PKC Ç during adipocyte development. 
That selective changes in PKC isoform expression accompanied the differentiation 
process in 3T3-F442A cells implied distinct functional roles for PKC isoforms in the 
regulation of adipocyte development and function.
To define the dependence of 3T3-F442A preadipoc>4e differentiation on PKC
isoforms, antisense oligodeoxynucleotides (ODNs) were used to deplete the 
individual PKC subtypes selectively from 3T3-F442A preadipocytes prior to the 
induction of differentiation. Each of the ODNs depleted effectively the appropriate 
PKC isoform and did not affect the expression of other PKC subtypes. By this 
approach it was demonstrated that PKC Ç is not essential for the differentiation of 
3T3-F442A preadipocytes. PKC a , 5 and p each exert an inhibitory influence upon 
the early stages of adipocyte development and are therefore likely to modulate this 
stage of the differentiation process. PKC 8 and PKC y are both essential for 3T3- 
F442A preadipocyte differentiation. Further antisense studies revealed that PKC y is 
necessary for the clonal expansion of differentiating cells. PKC 8 is not required for 
clonal expansion but is essential for later stages of the differentiation process, when 
its expression is markedly elevated, for the attainment of the adipocyte phenotype.
In order to gain an indication of the functional roles of PKC isoforms in adipocytes, 
their involvement in the signalling mechanisms by which two important hormonal 
regulators of adipocyte metabolism, growth hormone (GH) and insulin, alter the rate 
of lipid synthesis was examined in 3T3-F442A adipocytes. By selective depletion of 
individual PKC isoforms from 3T3-F442A adipocytes using antisense ODNs, it was 
established that PKC a , 5 and are not essential for the stimulation of lipogenesis by 
insulin or the suppression of basal or insulin-stimulated lipogenesis by GH. PKC 8 is 
one of a number of components required by insulin to increase the rate of lipogenesis. 
PKC y is an essential component of the signalling mechanism utilised by GH to 
antagonise the stimulation of lipogenesis by insulin. PKC p is, at least in part, 
required for the suppression of basal lipogenesis by GH. PKC p is also an essential 
component of the signal transduction mechanism by which insulin stimulates 
lipogenesis in 3T3-F442A adipocytes.
The results of these studies clearly demonstrate that individual PKC subtypes assume 
distinct functional roles in 3T3-F442A cells and are therefore likely to target different 
cellular substrates. These findings may, therefore, have relevance to our 
understanding of the diseased state of obesity which involves both adipocyte 
hyperplasia and hypertrophy and selective changes in expression of PKC isoforms.
11
Declaration
This thesis has been compiled by myself and is based on work carried out on an 
original line of research. This thesis has not been offered in any previous application 
for a degree. All sources of information are referenced and help provided by other 
people has been duly acknowledged.
Iona M Millar
111
A cknowledgements
On completion of this thesis, I would like to take the opportunity to thank everybody 
who has helped me along the way. I would firstly like to acknowledge the continued 
support, guidance and encouragement of Professor Houslay, at the University of 
Glasgow, and Dr Kilgour and Dr Vernon, at the Hannah Research Institute.
I would like to thank everyone at the Hannah Research Institute for both technical 
support and advice and generally keeping me (almost) sane. In particular, thanks go to 
Elaine Ferguson, Derek and Kevin, Ellis, Kathy and Lynn, who, in addition to giving 
me a huge helping hand, generally made life much more pleasant. Thanks are also due 
to Margaret, for aid with IGF-I assays, and Maureen (and all those in G 10), for advice 
both in and out of the pub.
I would also like to thank the Director of the Institute, Professor Malcolm Peaker, for 
providing the facilities to carry out the study and both the BBSRC and the Hannah 
Research Institute for providing me with funding.
In addition, I would like to thank, if you have not been mentioned already, all my 
friends and family for continued support. In particular, my mum, who, despite the fact 
I moved four hundred miles away, managed to nag me into submitting this thesis in 
time!
The biggest and most heart-felt thank you, however, must go to my husband, Ian, 
without whose support I never would have made it. It has not been an easy year, but 
he has managed to stay helpful and (reasonably) cheerful right to the bitter end - 
amazing!
IV
Table o f  Contents
Summary.............................................................................................................i
Declaration....................................................................................................... iii
Acknowledgements..........................................................................................iv
Table of Contents.............................................................................................. v
List of Figures...................................................................................................ix
List of Tables................................................................................................. xiii
List of Abbreviations..................................................................................... xv
List of Publications........................................................................................xix
1 Introduction
1.1 General introduction................................................................................. 1
1.2 Adipose tissue metabolism....................................................................... 1
1.2.1 Hormonal regulation of adipocyte metabolism................................................... 2
1.2.1.1 Modulation of adipocyte metabolism by growth hormone.........................3
1.2.1.1.1 Growth hormone and glucose transport................................................. 4
1.2.1.1.2 Growth hormone and lipogenesis............................................................ 5
1.2.1.1.3 Growth hormone and lipolysis.................................................................5
1.3 Adipose tissue development..................................................................... 6
1.3.1 Cell culture models of preadipocyte differentiation............................................7
1.3.2 The preadipocyte differentiation programme......................................................8
1.3.3 Transcriptional control of protein expression during preadipocyte 
differentiation...................................................................................................................9
1.3 .3.1 Transcriptional regulation by C/EBP and PPAR proteins......................... 10
1.3.3.2 Regulation by other transcription factors....................................................11
1.3.4 Hormonal control of preadipocyte differentiation............................................ 12
1.3 .4.1 Growth hormone and insulin-like growth factor-1......................................13
1.3.4.2 Insulin.............................................................................................................14
1.3.4.3 Epidermal growth factor............................................................................... 14
1.3.4.4 Cyclic AM P................................................................................................... 15
1.3.4.5 Agents that signal via nuclear receptors...................................................... 16
1.3.4.5.1 Triiodothyronine.....................................................................................16
1.3.4.5.2 Glucocorticoids....................................................................................... 16
1.3.4.5.3 Fatty acids and retinoids.........................................................................17
1.4 Insulin signalling......................................................................................17
1.4.1 Insulin signalling via phosphatidylinositol 3-kinase.........................................18
1.4.2 Insulin signalling via mitogen-activated protein kinases................................. 19
1.4.3 Insulin receptor substrate-1-independent signalling........................................ 20
1.5 Growth hormone signalling....................................................................20
1.5.1 Growth hormone signalling via mitogen-activated protein kinases................ 21
1.5.2 Growth hormone signalling via signal transducers and activators of 
transcription (STATs)....................................................................................................21
1.5.3 Growth hormone and additional signalling events...........................................22
1.6 The protein kinase C family...................................................................23
1.6.1 Protein kinase C structure.................................................................................. 24
1.6.2 Activation of protein kinase C ........................................................................... 26
1.6.2.1 Regulation by diacylglycerol and phorbol esters....................................... 27
1.6.2.2 Regulation by lipids..................................................................................... 28
1.6.2.3 Regulation by phosphorylation....................................................................29
1.6.2.4 Regulation by binding proteins....................................................................30
1.6.2.5 Additional mechanisms of regulation..........................................................32
1.6.3 Functions of protein kinase C isoforms............................................................. 32
1.6.3.1 Regulation of signal transduction by protein kinase C.............................. 33
1.6.3.2 Protein kinase C and cell cycle control......................................................34
1.6.3.3 Protein kinase C and differentiation........................................................... 35
1.6.3.4 Protein kinase C and growth hormone signalling..................................... 35
1.6.3.5 Protein kinase C and insulin signalling......................................................36
1.7 Aims of the project..................................................................................37
2 Materials and Methods
2.1 Materials...................................................................................................39
2.1.1 Chemicals and reagents..................................................................................... 39
2.1.2 Cell lines...............................................................................................................39
2.1.3 Antibodies.............................................................................................................39
2.1.4 Oligodeoxynucleotides....................................................................................... 40
2.1.5 Rats....................................................................................................................... 40
2.2 Methods....................................................................................................41
2.2.1 Cell culture.......................  41
2.2.1.1 Culture of 3T3-F442A preadipocytes.........................................................41
2.2.1.2 Differentiation of 3T3-F442A preadipocytes.............................................41
2.2.1.3 Culture ofNIH-3T3 cells over-expressing protein kinase C isoforms 41
2.2.1.4 Culture of 3T3-C2 cells................................................................................42
2.2.2 Preparation and treatment of cultured cells.......................................................42
2.2.2.1 Acute stimulation of 3T3-F442A cells with phorbol ester........................42
2.2.2.2 Chronic stimulation of 3T3-F442A preadipocytes with phorbol ester ....42
2.2.2.3 Chronic stimulation of 3T3-F442A adipocytes with growth hormone and 
insulin...........................................................................................................................42
2.2.2.4 Treatment of 3T3-F442A cells with protein kinase C isoform-specific- 
oligodeoxynucleotides............................................................................................... 43
2.2.2.4.1 Oligodeoxynucleotide treatment of 3T3-F442A preadipocytes 43
2.2.2.4.2 Oligodeoxynucleotide treatment of 3T3-F442A adipocytes..............44
2.2.2.5 Oil red O staining of 3T3-F442A cells........................................................44
2.2.2.6 Preparation of lysates from cultured cells.................................................. 44
2.2.2.7 Preparation of homogenates from cultured cells and sub-cellular 
fractionation.................................................................................................................45
2.2.2.8 Glycerol-3-phosphate dehydrogenase Assay..............................................46
2.2.2.9 Lipogenesis Assay.........................................................................................46
2.2.2.10 DNA Assay..................................................................................................47
2.2.3 Preparation and treatment of rat tissues............................................................. 47
2.2.3.1 Immunoneutralisation of circulating rat growth hormone.........................47
2.2.3.2 Isolation of rat adipocytes and homogenate preparation........................... 48
2.2.3.3 Determination of number of adipocytes per gram tissue........................... 48
2.2.3.4 Acute phorbol ester treatment of rat adipocytes........................................ 49
2.2.3.5 Preparation of rat brain homogenate........................................................... 49
VI
2.23.6 Preparation of serum from whole blood.....................................................50
2.2.3.7 Assay of insulin-like growth factor-1......................................................... 50
2.2.4 Immunoblotting..................................................................................................... 51
2.2.4.1 Protein Assays................................................................................................51
2.2.4.2 Standard gel electrophoresis........................................................................ 51
2.2.4.3 Mini-gels........................................................................................................ 51
2.2.4.4 Immunodetection of protein kinase C isoforms..........................................52
2.2.5 Statistical Analysis.............................................................................................. 53
3 Characterisation of protein kinase C isoforms in 3T3-F442A cells and 
rat adipocytes
3.1 Introduction............................................................................................. 54
3.2 Methods................................................................................................... 55
3.2.1 Immunoblotting.................................................................................................... 55
3.2.2 Modulation of protein kinase C isoforms by phorbol ester..............................55
3.3 Results...................................................................................................... 57
3.3.1 Protein kinase C isoform expression in 3T3-F442A cells and rat adipocytes.57
3.3.2 Modulation of 3T3-F442A cell and rat adipocyte protein kinase C isoforms by
phorbol esters.................................................................................................................. 62
3.4 Discussion.................................................................................................67
4 Investigation of the roles of individual protein kinase C isoforms in 
3T3-F442A preadipocyte differentiation
4.1 Introduction............................................................................................. 72
4.2 Methods...................................................................................................74
4.2.1 Assessment of the cellular levels of protein kinase C isoforms during 3T3- 
F442A preadipocyte differentiation..............................................................................74
4.2.1.1 Cell culture..................................................................................................... 74
4.2.1.2. Immunoblotting............................................................................................. 74
4.2.1.3 Calculating cellular levels of protein kinase C isoforms from immunoblot 
data 75
4.2.2 Effects of depletion of individual protein kinase C isoforms with antisense 
oligodeoxynucleotides on 3T3-F442A preadipocyte differentiation......................... 75
4.2.2.1 Treatment of cells with oligodeoxynucleotides..........................................75
4.2.2.2 Assessment of the effects of depletion of protein kinase C isoforms with 
antisense oligodeoxynucleotides on differentiation of 3T3-F442A cells.............. 76
4.2.3 Statistical analysis............................................................................................... 76
4.3 Results...................................................................................................... 77
4.3.1 Protein kinase C isoform expression is altered following 3T3-F442A 
preadipocyte differentiation..........................................................................................77
4.3.2 Changes in expression of protein kinase C isoforms during the differentiation 
of3T3-F442A cells....................................................................................  78
4.3.3 Effects of depletion of individual protein kinase C isoforms with antisense 
oligodeoxynucleotides on 3T3-F442A preadipocyte differentiation......................... 81
4.3.4 Protein kinase C s and protein kinase C y are required for different stages of 
3T3-F442A preadipocyte differentiation..................................................................... 84
4.4 Discussion............................................................................  86
V I1
5 Investigation of the roles of individual protein kinase C isoforms in 
growth hormone- and insulin-mediated effects on lipogenesis in 3T3- 
F442A adipocytes
5.1 Introduction...............................................................................................93
5.2 Methods.................................................................................................... 95
5.2.1 Assessment of the effects of growth hormone and insulin on protein kinase C 
isoform expression in adipocytes.................................................................................. 95
5 .2.1.1 Assessment of protein kinase C isoform expression in rats treated with
antiserum to rat growth hormone...............................................................................95
5 .2.1.1.1 Immunoneutralisation of circulating rat growth hormone.................. 95
5 .2.1.1.2 Isolation of rat adipocytes and homogenate preparation.................... 95
5.2.1.1.3. Assessment of fat pad composition.......................................................95
5 .2.1.1.4 Preparation of serum from whole blood and assay of IGF-1 .............96
5.2.1.1.5 Immunoblotting......................................................................................96
5.2.1.2 Assessment of protein kinase C isoform expression in 3T3-F442A 
adipocytes treated with growth hormone and insulin..............................................96
5.2.1.2.1 Cell culture............................................................................................. 96
5.2.1.2.2 Hormone treatment of 3T3-F442A adipocytes.................................... 96
5.2.2 Characterisation of the effects of growth hormone and insulin on the rate of 
lipid synthesis in 3T3-F442A adipocytes..................................................................... 97
5.2.2.1 Treatment of cells with kinase inhibitors...................................................97
5.2.3 Assessment of the role of protein kinase C isoforms in the growth hormone- 
and insulin-mediated effects on lipid synthesis in 3T3-F442A adipocytes..............97
5.2.4 Statistical analysis................................................................................................98
5.3 Results...................................................................................................... 99
5.3.1 The effects of growth hormone and insulin on protein kinase C isoform 
expression in adipocytes................................................................................................99
5.3.2 Characterisation of the effects of growth hormone and insulin on the rate of 
lipid synthesis in 3T3-F442A adipocytes................................................................... 101
5.3.3 The effects of depletion of individual protein kinase C isoforms with 
antisense oligodeoxynucleotides on growth hormone- and insulin-induced changes 
in the rate of lipid synthesis in 3T3-F442A adipocytes............................................ 103
5.4 Discussion............................................................................................... 108
6 General discussion..................................................................................... 117
References......................................................................................................126
V lll
List of Figures
Figure 1.1 Lipid metabolism in the adipocyte
Figure 1.2 Summary of the preadipocyte differentiation process
Figure 1.3 Temporal expression profiles of the C/EBP and PPAR transcriptional
regulatory proteins during preadipocyte differentiation
Figure 1.4 Summary of the insulin signalling pathways
Figure 1.5 Summary of the growth hormone signalling pathways
Figure 1.6 Stuctures of the protein kinase C family members
Figure 2.1 Comparing protein concentration of cellular preparations by
Coomassie Blue staining
Figure 2.2 Confirming sub-cellular fractionation by Coomassie Blue staining
Figure 3.1 Protein kinase C isoforms present in 3T3-F442A cells and rat
adipocytes
Figure 3.2 Immunoblotting for PKC p in the presence and absence of peptide
immunogen
Figure 3.3 Immunoblotting for PKC P using excess protein
Figure 3.4 Assessment of the specificity of the monoclonal PKC y antibody
Figure 3.5 Effect of peptide immunogen on detection of protein bands by a
polyclonal antiserum to PKC Ç
Figure 3.6 Immunoblotting for PKC r\ and 0
Figure 3.7 Assessment of the specificity of the PKC Q , i and X antibodies
Figure 3.8 Effects of acute phorbol ester treatment of 3T3-F442A preadipocytes
on the sub-cellular distribution of protein kinase C isoforms
IX
Figure 3.9 Effects of acute phorbol ester treatment of 3T3-F442A adipocytes on 
the sub-cellular distribution of protein kinase C isoforms
Figure 3.10 Effects of acute phorbol ester treatment of rat adipoc>4es on the sub- 
cellular distribution of protein kinase C isoforms
Figure 3.11 Effects of chronic treatment of 3T3-F442A preadipocytes with 16 pM 
phorbol ester on the cellular levels of protein kinase C isoforms
Figure 3.12 Effects of chronic treatment of 3T3-F442A preadipocytes with 500 nM 
phorbol ester on the cellular levels of protein kinase C isoforms
Figure 3.13 Densitometric analysis of the effects of chronic treatment of 3T3-
F442A preadipocytes with 500 nM phorbol ester on the cellular levels 
of protein kinase C isoforms
Figure 4.1 Protein kinase C isoform expression following differentiation of 3T3-
F442A cells
Figure 4.2 The effect of differentiation on cellular levels of protein kinase C
isoforms in 3T3-F442A cells
Figure 4.3 Protein kinase C isoforms in 3T3-C2 cells
Figure 4.4 Protein kinase C isoform expression during differentiation of 3T3-
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells
Figure 4.5 A Changes in protein kinase C a  expression during differentiation of
3T3-F442A preadipocytes and control (non-differentiating) 3T3-C2 
cells
Figure 4.5 B Changes in protein kinase C y expression during differentiation of 3T3-
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells
Figure 4.5 C Changes in protein kinase C Ô expression during differentiation of
3T3-F442A preadipocytes and control (non-differentiating) 3T3-C2 
cells
Figure 4.5 D Changes in protein kinase C 8 expression during differentiation of 3T3- 
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells
Figure 4.5 E Changes in protein kinase C Ç expression during differentiation of 
3T3-F442A preadipocytes and control (non-differentiating) 3T3-C2 
cells
Figure 4.5 F Changes in protein kinase C p. expression during differentiation of 
3T3-F442A preadipocytes and control (non-differentiating) 3T3-C2 
cells
Figure 4.6 Specific depletion of protein kinase C isoforms in 3T3-F442A 
preadipocytes by antisense oligodeoxynucleotide treatment
Figure 4.7 The effect of time on suppression of protein kinase C isoforms by 
antisense oligodeoxynucloetides
Figure 4.8 A The effect of protein kinase C a  oligodeoxynucleotides on changes in 
3T3-F442A cell morphology during differentiation
Figure 4.8 B The effect of protein kinase C y oligodeoxynucleotides on changes in 
3T3-F442A cell morphology during differentiation
Figure 4.8 C The effect of protein kinase C 5 oligodeoxynucleotides on changes in 
3T3-F442A cell morphology during differentiation
Figure 4.8 D The effect of protein kinase C 8 oligodeoxynucleotides on changes in 
3T3-F442A cell morphology during differentiation
Figure 4.8 E The effect of protein kinase C Ç, oligodeoxynucleotides on changes in 
3T3-F442A cell morphology during differentiation
Figure 4.8 F The effect of protein kinase C p oligodeoxynucleotides on changes in 
3T3-F442A cell morphology during differentiation
Figure 4.9 The effect of protein kinase C isoform-specific oligodeoxynucleotides 
on induction of glycerol-3-phosphate dehydrogenase activity during 
3T3-F442A preadipocyte differentiation
x i
Figure 4.10 The effect of protein kinase C isoform-specific oligodeoxynucleotides 
on lipid accumulation during 3T3-F442A preadipocyte differentiation
Figure 5.1 Body weight changes in rats treated with antiserum to rat growth
hormone
Figure 5.2 Protein kinase C isoform expression in rats treated with antiserum to
rat growth hormone
Figure 5.3 The effect of growth hormone and insulin on protein kinase C isoform
expression in 3T3-F442A adipocytes
Figure 5.4 The effect of growth hormone and insulin on the rate of lipogenesis in
3T3-F442A adipocytes
Figure 5.5 Specific depletion of protein kinase C isoforms in 3T3-F442A
adipocytes by antisense oligodeoxynucleotide treatment
Figure 5.6 Specific depletion of protein kinase C gamma and protein kinase C mu
in 3T3-F442A adipocytes by combined antisense oligodeoxynucleotide 
treatment
Figure 5.7 The effect of protein kinase D-specific oligodeoxynucleotides on
expression of the 112 kDa protein detected with the monoclonal 
antibody specific for protein kinase C p.
Xll
List of Tables
Table 1.1 The dual effects of growth hormone treatment on adipocyte
metabolism
Table 2.1 Protein kinase C isoform-specific oligodeoxynucleotide sequences
Table 3.1 Predicted molecular weights of PKC isoforms based on their amino
acid composition
Table 4.1 Cellular protein content and glycerol-3-phosphate dehydrogenase
activity following differentiation of 3T3-F442A cells
Table 4.2 Cellular levels of protein kinase C isoforms following 3T3-F442A
preadipocyte differentiation
Table 4.3 Cellular protein content and glycerol-3-phosphate activity during
differentiation of 3T3-F442A preadipocytes and control (non­
differentiating) 3T3-C2 cells
Table 4.4 Cellular levels of protein kinase C isoforms during differentiation of
3T3-F442A preadipocytes and control (non-differentiating) 3T3-C2 
cells
Table 4.5 The effect of protein kinase C isoform-specific oligodeoxynucleotides
on total homogenate DNA content during 3T3-F442A preadipocyte 
differentiation
Table 5.1 Fat pad composition and serum lGF-1 levels in rats treated with antiserum
to rat growth hormone
Table 5.2 Cellular levels of protein kinase C isoforms in rats treated with
antiserum to rat growth hormone
Table 5.3 The effect of growth hormone and insulin on cellular levels of protein
kinase C isoforms in 3T3-F442A adipocytes
Table 5.4 The effect of wortmannin and PD98059 on growth hormone- and
insulin- induced changes in the rate of lipogenesis in 3T3-F442A
X lll
adipocytes
Table 5.5 The effect of lipofectin on growth hormone- and insulin-induced 
changes in the rate of lipogenesis in 3T3-F442A adipocytes
Table 5.6 A The effect of protein kinase C a-speciflc oligodeoxynucleotides on 
growth hormone- and insulin-induced changes in the rate of
lipogenesis in 3T3-F442A adipocytes
Table 5.6 B The effect of protein kinase C y-specific oligodeoxynucleotides on 
growth hormone- and insulin-induced changes in the rate of
lipogenesis in 3T3-F442A adipocytes
Table 5.6 C The effect of protein kinase C ô-specific oligodeoxynucleotides on 
growth hormone- and insulin-induced changes in the rate of
lipogenesis in 3T3-F442A adipocytes
Table 5.6 D The effect of protein kinase C e-specific oligodeoxynucleotides on 
growth hormone- and insulin-induced changes in the rate of
lipogenesis in 3T3-F442A adipocytes
Table 5.6 E The effect of protein kinase C «^-specific oligodeoxynucleotides on
growth hormone- and insulin-induced changes in the rate of
lipogenesis in 3T3-F442A adipocytes
Table 5.6 F The effect of protein kinase C p-specific oligodeoxynucleotides on
growth hormone- and insulin-induced changes in the rate of
lipogenesis in 3T3-F442A adipocytes
Table 5.7 The effect of treatment with protein kinase C y- and p-specific
oligodeoxynucleotides in combination on growth hormone- and 
insulin-induced changes in the rate of lipogenesis in 3T3-F442A 
adipocytes
Table 5.8 The effect of protein kinase D-specific oligodeoxynucleotides on
growth hormone- and insulin-induced changes in the rate of
lipogenesis in 3T3-F442A adipocytes
XIV
List of Abbreviations
ACC acetyl coA carboxylase
ADDl adipocyte determination- and differentiation-dependent factor
AKAP A-kinase-anchoring protein
BSA bovine serum albumin
C/EBP CCAAT/enhancer binding protein
cdk cyclin-dependent kinase
CRE cyclic AMP response element
CREB cyclic AMP-response element binding protein
DAG diacylglycerol
DHAP dihydroxyacetone phosphate
DMEM Dulbecco's modified Eagle's medium
DMSO dimethyl sulphoxide
ECL enhanced chemiluminescence
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EGTA ethyleneglycol-bis (p-aminoethyl ether) N,N,N',N'-tetraacetic acid
FCS foetal calf serum
GH growth hormone
GPDH glycerol-3-phosphate dehydrogenase
GSK glycogen synthase kinase
XV
Hepes (N-[2-hydroxyethyl]piperazine-N'-[4-butanesulphonic acid])
HUE hormone response element
HRP horseradish peroxidase
HSL hormone sensitive lipase
EBMX 3 -isobutyl-1 -methyxanthine
IGF-I insulin-like growth factor-I
INS insulin
IP3 inositol trisphosphate
1RS insulin receptor substrate
LPL lipoprotein lipase
MAP kinase mitogen-activated protein kinase
mcv mean cell volume
MEK mitogen-activated protein kinase kinase
NADH a-nicotinamide adenine dinucleotide
ODN oligodeoxynucleotide
oGH ovine growth hormone
PA phosphatidic acid
PBS phosphate-buffered saline
PC phosphatidylcholine
PDE phosphodiesterase
PDGF platelet-derived growth factor
XVI
PDH pynivate dehydrogenase
PDK 3-phosphoinositide-dependent protein kinase
PI 3-kinase phosphatidylinositol 3-kinase
PI phosphoinositide
PICK protein interacting with C-kinase
PIP2 phosphatidylinositol bisphosphate
PIP3 phosphatidylinositol trisphosphate
PKA protein kinase A
PKB protein kinase B
PKC protein kinase C
PKD protein kinase D
PKM protein kinase M
PLA phospholipase A
PLC phospholipase C
PLD phospholipase D
PMSF phenylmethylsulphonyl fluoride
PPAR peroxisome proliferator activator receptor
PS phosphatidylserine
RACK receptor for activated C-kinase
Rb retinoblastoma protein
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
XVI1
SEM standard error of the mean
SIE sis-inducible element
STAT signal transducers and activators of transcription
T3 triiodothyronine
TBS Tris-buffered saline
TPA 12-0-tetradecanoylphorbol 13 -acetate
Tris (tris[hydroxymethyl]aminomethane)
VLDL very low density lipoprotein
a-rGH antiserum to rat growth hormone
XVI11
List o f  Publications 
Iona Millar - née FLEMING
Refereed papers
MacKenzie, S., FLEMING, L, Houslay, M.D., Anderson, N G and Kilgour, E. (1997) 
Growth hormone and phorbol esters require specific protein kinase C iso forms to 
activate mitogen-activated protein kinases in 3T3-F442A cells. Biochem. J., 324: 159- 
165.
FLEMING, I , MacKenzie, S.J., Vernon, R.G., Anderson, N.G., Houslay, M.D. and 
Kilgour, E. (1998) Protein kinase C isoforms play differential roles in the regulation 
of adipocyte differentiation. Biochem. J., 333: 719-727.
Abstracts
FLEMING, I M , MacKenzie, S.J., Houslay, M.D. and Kilgour, E. (1996) Protein 
kinase C isoform expression during differentiation of 3T3-F442A preadipocytes. 
ImmimoL, 89;S1: F\\26IBiochem. Sac. Trans., 25;2: S211.
FLEMING, I.M., MacKenzie, S.J., Houslay, M D , Vernon, R.G. and Kilgour, E. 
(1997) Antisense technology reveals distinct roles for protein kinase C isoforms 
during 3T3-F442A preadipocyte differentiation. Biochem. Soc. Trans., 25;4: S665.
Vernon, R G , Arana, A. and FLEMING, I M. (1998) Growth hormone signalling in 
ruminant adipose tissue. J. 76: "^u^f[.\U.Dairy Sci., 81: Suppl.l: 112.
XIX
Chapter 1
Introduction
1.1 General introduction
White adipose tissue depots are widely distributed throughout the body and are the 
major sites of lipid storage and metabolism. Hence, adipose tissue represents the 
body's largest energy reservoir. Vertebrate animals store excess metabolic energy in 
the form of triglycerides. Adipocyte cells in adipose tissue take up fatty acids from 
blood, or synthesise them de novo from glucose and other precursors, when the 
energy balance is positive. The fatty acids are then esterified with glycerol-3- 
phosphate and stored intracellularly as triglycerides (lipogenesis). When needed, this 
stored energy can be mobilised by the hydrolysis of triglycerides (lipolysis) and by 
the release of fatty acids into the blood stream.
Obesity is perhaps the single most important cause of morbidity in the developed 
world and is strongly linked with the state of insulin resistance (Reaven, 1988; 
DeFronzo et al, 1992). Thus, resolution of the hormonal, cellular and molecular 
processes that control adipocyte development and function may lead to a better 
understanding of these disorders and reveal possible targets for therapeutic 
intervention. Considerable commercial interest also exists in the ability to manipulate 
adipose tissue development with a view to the possibility of producing animals with a 
higher muscle to fat carcass composition.
1.2 Adipose tissue metabolism
The key features of adipocyte metabolism are the synthesis of triglycerides and their 
subsequent hydrolysis. These processes are under the control of an array of strictly 
regulated enzymes and are summarised in Figure 1.1. The synthesis of lipids requires 
a source of fatty acids. These are either liberated from the triglycerides transported in 
the blood as very low density lipoprotein (VLDL) particles or chylomicrons, by the 
action of the action of lipoprotein lipase (LPL), or synthesised from glucose, acetate 
or other precursors (Vernon, 1992). Fatty acids are synthesised from glucose in a 
series of reactions catalysed by hexokinase, the enzymes of the glycolytic pathway, 
pyruvate dehydrogenase (PDH), fatty acid synthase (FAS) and acetyl coA 
carboxylase (ACC). Lipid synthesis also requires a source of glycerol-3-phosphate 
(Vernon, 1992). This is formed mainly by the reduction of dihydroxyacetone 
phosphate (DHAP), catalysed by glycerol-3-phosphate dehydrogenase (GPDH).
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Lipids are subsequently synthesised from glycerol-3-phosphate and fatty acids in a 
further set of enzyme reactions.
The crucial step in triglyceride breakdown is the activation of the hormone-sensitive 
lipase (HSL), which is mediated via the adenylate cyclase system (Belfrage, 1984). 
This results in the generation of fatty acids and diacylglycerol, the latter being rapidly 
hydrolysed to fatty acids and glycerol. Although fatty acids can be partially re- 
esterified for triglyceride synthesis, glycerol cannot be re-utilised due to lack of 
significant glycerokinase activity and is released from the cell (Vernon, 1992).
Lipid metabolism rates are depot-specific (Budd el at, 1994). Lipogenesis and 
lipolysis are occurring continuously, therefore, the relative rates of the two processes 
determine whether there is net synthesis or deposition of lipid. Hypothalamic centres 
of the brain are thought to play an important coordinating role in this respect through 
effects on hunger and satiety, energy expenditure and the secretion of hormones that 
regulate metabolism (Hubei, 1979). The adipocyte itself is thought to play an active 
role in regulating energy homeostasis and body composition by secreting a number of 
products, including leptin (Halaas et al, 1995; Ahima et al, 1996), the product of the 
ob gene (Zhang et al, 1994b). Leptin is absent from oh oh mice, resulting in profound 
obesity, often accompanied by diabetes (Friedman and Lehel, 1992; Halaas et al, 
1995). Expression of the ob gene itself is controlled by the nutritional status of the 
animal and the anabolic hormone, insulin (Frederich et al, 1995; MacDougald et al, 
1995; Saladin et al, 1995; Kim et al, 1998). Leptin reduces adiposity by a number of 
mechanisms. Leptin lowers food intake and increases metabolism in lean and obese 
mice (Mistry et al, 1997). In vitro addition of leptin to adipocytes induces lipolysis 
(Fruhbeck et al, 1997), inhibits binding of the anti-lipolytic hormone insulin (Walder 
et al, 1997) and suppresses the expression of lipogenic enzymes and lipogenesis (Bai 
et al, 1996). The precise mechanisms of leptin action are not known, although it may 
have a direct action on the hypothalamus (Lee et al, 1996; Mistry et al, 1997).
1.2.1 Hormonal regulation o f adipocyte metabolism
Adipocyte metabolism is regulated by a number of hormones via interaction with 
specific receptors on the surface of adipocytes. It is well established that insulin is the 
most important regulator of adipocyte metabolism with regard to anabolic functions
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(increasing glucose transport and the uptake of other metabolites, stimulating 
triglyceride synthesis and inhibiting lipolysis) and that catecholamines are the major, 
acutely acting, counterparts of insulin action (Saggerson, 1984). Other hormones, 
such as growth hormone (GH), glucagon and glucocorticoids have also been reported 
to exert a variety of significant modulatory effects on adipocyte metabolism 
(reviewed in Lager, 1991).
The importance of GH in the modulation of insulin action was initially implied by 
clinical extremes of GH secretion. Insulin responses are enhanced in GH-deficient 
patients (Taylor et al, 1991) and high serum levels of GH characterise many 
pathological states in which insulin resistance occurs (Altszuler et al, 1974). In 
addition, insulin resistance is regularly seen during late pregnancy and a contributing 
reason for this may be the elevated levels of GH that are characteristic of this 
condition (Eriksson et al, 1989). Furthermore, elevated numbers of GH receptors are 
observed on the surface of diabetic adipocytes (Solomon et al, 1990). GH, therefore, 
appears to have insulin-antagonistic effects and these may be important for the 
development of the insulin-resistance that is associated with obesity and diabetes 
mellitus (Fowelin et al, 1991). Hence, there has been increasing interest in the 
modulation of adipocyte metabolism by GH The metabolic effects of insulin are well 
documented, therefore, this review will concentrate on the role of GH in the 
modulation of adipocyte metabolism.
1.2.1.1 Modulation o f  adipocyte metabolism by growth hormone 
The role of GH in the regulation of glucose and lipid metabolism in adipose tissue has 
been controversial, mainly due to discrepancies between in vivo and in vitro studies. 
Clinical observations clearly indicate that excess GH is associated with impaired 
glucose tolerance and insulin-resistance, whereas GH-deficiency enhances the 
responsiveness of adipocytes to insulin (Section 1.2.1). In addition, chronic 
administration of GH to patients with GH-deficiency increases the level of circulating 
free fatty acids and decreases the lipid content of adipose cells, probably due to 
increased lipolysis and reduced fat deposition (Bonnet et al, 1974; Van Vliet et al, 
1987). These observations are consistent with GH decreasing adiposity and 
antagonising insulin action.
hi vitro studies of the action of GH in adipose cells initially produced conflicting 
results. This is mainly due to the fact that, in vitro, GH can have transient insulin-like 
effects that are followed by the classical diabetogenic effects of the hormone if 
treatment is continued (Vernon and Flint, 1989). The physiological significance of 
these transient insulin-like effects of GH is not known since cells have to be deprived 
of GH for a significant period for the effects to manifest themselves, a situation 
unlikely to normally occur in vivo. The dual effects of GH treatment on adipocyte 
metabolism are summarised in Table 1.1.
It is now well established that, chronically, GH decreases adiposity in many species 
(Vernon and Flint, 1989). In vitro studies have demonstrated that chronic exposure of 
adipocytes to GH suppresses glucose transport and lipogenesis and promotes lipolysis 
(Ku Tai et al, 1990; Maloff et al, 1980; Boyd and Bauman, 1989; Vernon and Flint, 
1989; Goodman, 1993). Although the effects of GH on many tissues are mediated via 
insulin-like growth factor-I (IGF-I), this is not the case for adipocytes upon which GH 
exerts direct effects mediated by its cell surface receptor (Vernon and Flint, 1989). 
The fact that chronic GH treatment decreases adiposity by a mechanism that appears 
to involve changes in lipid synthesis and mobilisation is consistent with an insulin- 
antagonistic role. Chronic GH treatment suppresses the ability of fat cells to respond 
to insulin in the absence of any change in their capacity to bind the hormone (Foster et 
al, 1988). It is therefore believed that GH induces one or more post-receptor defects in 
insulin signalling cascades.
The mechanisms by which GH modulates adipocyte metabolism have not been fully 
elucidated, but undoubtedly the modulation of expression of key proteins, known to 
be involved in metabolic pathways and cross-talk with insulin and other signalling 
pathways are important. Changes in gene transcription are also likely to be involved 
(Goodman et al, 1987; Goodman, 1993). Current knowledge of the mechanisms by 
which GH modulates adipocyte metabolism is outlined below.
1.2.1.1.1 Growth hormone and glucose transport
Chronic exposure to GH restricts glucose utilisation by adipose tissue (Ku Tai et al, 
1990; Maloff etal, 1980). Glucose enters the fat cell by facilitated diffusion across the 
plasma membrane and this process is mediated by the transporter proteins GLUT 1
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Table L I The dual effects o f  growth hormone treatment on adipocyte metabolism
Effects of growth hormone treatment
Acute, insulin-like effects Chronic, insulin-antagonistic effects
Stimulation of glucose transport Suppression of glucose transport
Enhancement of lipogenesis Suppression of lipogenesis
Suppression of lipolysis Enhancement of lipolysis
and GLUT 4 (Gould and Bell, 1990). In adipocytes, the most abundant glucose 
transporter is GLUT 4, which translocates to the plasma membrane in response to 
insulin. In vitro studies have revealed that chronic GH treatment decreases GLUT 1 
protein and mRNA levels in 3T3-F442A adipocytes and that, in contrast, cellular 
levels of GLUT 4 are not affected (Ku Tai et al, 1990). This is consistent with the 
observation that GH, in vivo, down-regulates the amount of both glucose transporters 
present in rat adipocyte plasma membranes, reflecting a decrease in total cellular 
GLUT 1 levels and modification of the sub-cellular location of GLUT 4 trasporters 
(Kilgour a/, 1995).
1.2.1.1.2 Growth hormone and lipogenesis
Chronically, GH exerts a small inhibitory effect on basal lipogenesis and antagonises 
the ability of insulin to maintain or increase the basal rate (Vernon, 1982; Schwartz, 
1984; Foster et al, 1988). Lipogenesis is subject to control by changes in the 
expression and activation status of key enzymes (see Figure 1.1). The suppression of 
lipogenesis by GH has been attributed mainly to GH-induced changes in the levels 
and activation status of such enzymes. Decreases in the rates of lipogenesis, in vivo, 
have been attributed to GH suppressing the transcription of acetyl CoA carboxylase 
(Bauman and Vernon, 1993) and fatty acid synthase (Harris et al, 1993) mRNA. 
Decreases in the activities of acetyl CoA carboxylase and fatty acid synthase are also 
observed following chronic treatment of adipocytes or adipose tissue with GH (Dietz 
and Schwartz, 1991; Bauman and Vernon, 1993; Vernon et al, 1993). In addition, GH 
inhibits the activation of acetyl CoA carboxylase by insulin, possibly by inhibiting the 
synthesis of a protein required for mediation of the insulin-induced activation of the 
enzyme (Vernon et al, 1991).
/. 2.1.1.3 Growth hormone and lipolysis
The key enzyme in the lipolytic pathway is hormone sensitive lipase (HSL). Lipolytic 
agents increase cyclic AMP levels, activating cyclic AMP-dependent protein kinase 
(protein kinase A; PKA) which can phosphorylate and activate HSL (Belfrage, 1984; 
Allen, 1985). Although GH promotes lipolysis in vivo, studies done in vitro have 
failed to produce consistent effects of GH alone on lipolysis in isolated adipocytes 
(Vernon and Flint, 1989). However, in 3T3-F442A adipocytes, GH promotes lipolysis 
and increases the activity of HSL (Dietz and Schwartz, 1991). Further evidence
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suggests that chronically, GH promotes lipolysis by modulating the ability of acutely 
acting hormones, especially anti-lipolytic agents, to regulate the process (Vernon and 
Finley, 1988). This effect appears to involve a lesion in the coupling between 
receptor, the inhibitory protein Gi and adenylyl cylase (Doris et al, 1994).
Increases in cyclic AMP phosphodiesterase (PDE) activity and subsequent hydrolysis 
of cyclic AMP, lead to decreased lipolysis (Manganiello et al, 1987). Indeed, certain 
PDE isoforms play a key role in the anti-lipolytic actions of insulin in rat adipocytes 
(Eriksson et al, 1995). In vivo, GH suppresses the activity and insulin-responsiveness 
of these PDE isoforms in adipocytes (Schoenle et al, 1981). This is interesting in view 
of reports that, in vitro, chronic GH attenuates the anti-lipolytic effect of insulin in 
3T3-L1 adipocytes {GXtnnetal, 1992).
A number of studies indicate the expansion of adipose tissue and, hence, the 
development of obesity, is due to both an increase in the size and number of 
adipocytes (Greenwood and Hirsch, 1974; Hager, 1981; Bourgeois et al, 1983). An 
increase in the size of adipocytes is primarily due to the accumulation of lipid and is 
therefore closely linked to the metabolic pathways controlling lipid accumulation and 
mobilisation. The factors affecting adipocyte number are discussed below.
1.3 Adipose tissue dex^elopment
It is now generally accepted that mature, lipid-filled adipocytes do not divide and 
there is evidence for loss of various components required for mitosis during 
preadipocyte differentiation (Roncari et al, 1984). Increases in fat cell number, 
therefore, arise as the result of the proliferation and differentiation of adipose 
precursor cells. The processes involved in adipocyte development are summarised in 
Figure 1.2.
Studies to date suggest that the adipocyte lineage derives from pluripotent 
mesenchymal cells with the capacity to differentiate into adipocytes, chondrocytes 
and myocytes (Green et al, 1985; Sager and Kovac, 1982; Grigoriadis et al, 1988). 
Adipose precursor cells are thought to proliferate and differentiate under multi- 
hormonal control into preadipocytes and, subsequently, adipocytes. Studies with
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multipotent stem cells suggest that commitment to a specific lineage results from the 
activation of a small number of regulatory genes by hypomethylation (Konieczny and 
Emerson, 1984; Lassar et al, 1986; Taylor and Jones, 1979). Genes of the MyoD 
transcription factor family control myoblast differentiation in vitro (reviewed in 
Edmondson and Olson, 1993), however, attempts to identify a so-called “master 
regulatory” gene for adipocyte differentiation have, as yet, been unsuccessful. Most of 
the progress in the understanding of the molecular basis of adipose differentiation has, 
therefore, come from the study of the differentiation of preadipocytes into adipocytes. 
This is largely due to the development of immortalised preadipocyte cell-lines that 
differentiate in culture into white adipocyte-like cells.
1.3.1 Cell culture models o f preadipocyte differentiation
A number of cellular models have been developed to facilitate the study of the factors 
controlling preadipocyte differentiation in vitro. These include primary cultures of 
preadipocytes and cell-lines capable of converting to the adipocyte phenotype. 
Although cell strains that behave reproducibly in culture have been obtained from the 
stromal fraction of adipose tissue from a variety of species (Ailhaud, 1982), such 
adipose precursor cells have a limited life span in culture. Consequently, most of the 
information on preadipocyte differentiation to date has been gained from the study of 
established cell lines.
The most extensively studied cell culture models are 3T3-L1 and 3T3-F442A 
preadipocytes. These cells have undergone commitment to the adipose lineage, can 
only further differentiate into adipocytes and were originally selected from 
disaggregated mouse embryo cells for their ability to accumulate cytoplasmic lipid 
(Green and Kehinde, 1974; Green and Kehinde, 1975; Green and Kehinde, 1976). 
Other common cell lines include Ob 17 and Ob 1771, isolated from obese mice 
(Doglio et al, 1986) and TAI (Chapman et al, 1984) and 30A5 (Konieczny and 
Emerson, 1984), isolated from an established, multipotential mouse fibroblast line 
treated with a nucleotide analogue to generate cells committed to the adipose lineage 
(Taylor and Jones, 1979).
The process of adipose conversion is phenotypically similar in the various 
preadipocyte cell lines. During proliferation, cultured preadipocytes are biochemically
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and morphologically indistinguishable from fibroblasts (Hiragun et al, 1980). When 
induced to differentiate, cells convert to a spherical shape and accumulate small lipid 
droplets that later fuse into one large droplet. The shape change occurs prior to lipid 
accumulation and is due to alterations in the complement of cytoskeletal proteins 
(Spiegelman and Farmer, 1982). The mature adipocyte produced by in vitj'o 
differentiation has many characteristics of adipose cells in vivo. Cells acquire virtually 
all o f the enzymes responsible for de novo fatty acid synthesis, lipogenesis and 
lipolysis and responsiveness to the hormones that regulate these processes (Rubin et 
al, 1978; Spooner et al, 1979; Reed and Lane, 1980; Bernholer et al, 1985; Cook et 
al, 1988; Guest et al, 1990). Furthermore, subcutaneous injection of certain 
preadipocyte cell lines into nude mice gives rise to fat pads that are histologically 
indistinguishable from white adipose tissue (Green and Kehinde, 1979; Vannier et al,
1985).
1.3.2 The preadipocyte differentiation programme
Preadipocyte differentiation is a multi-step process involving a cascade of molecular 
events culminating in the terminally differentiated phenotype. The molecular events 
involved in adipocyte development have not yet been fully elucidated, but studies 
using preadipocyte cell lines have revealed a number of the factors involved.
Terminal differentiation to adipocytes involves changes in the levels of over one 
hundred proteins (Sidhu, 1979), mainly at the transcriptional level (Moustaid and Sul,
1991). The initiation of differentiation and the subsequent expression of adipocyte- 
specific genes requires exit from the mitotic cell cycle. From in vitro studies, it 
appears that growth arrest during Gl (GO entry), rather than simply cell confluence, is 
necessary to trigger initiation of the differentiation programme (Ailhaud et al, 1989). 
Cells in GO begin to express early markers of differentiation such as the mRNAs for 
the a -2  chain of type VT collagen and lipoprotein lipase (LPL) (Amri et al, 1986).
Prior to the expression of late markers, early marker-expressing cells undergo post­
confluent mitoses (Kuri-Harcuch and Marsch-Moreno, 1983; Zezulak and Green,
1986). This process of replication has been proposed to lead to the clonal expansion 
of committed cells (Pairault and Green, 1979) and is thought to allow cells to reach a
unique growth-arrested state that is permissive for subsequent differentiation (Pairault 
and Green, 1979; Scott et al, 1982; Amri et al, 1986). Clonal expansion is limited 
both in magnitude and duration (Ailhaud et al, 1989; Gamou and Shimizu, 1986; 
Kuri-Harcuch and Marsch-Moreno, 1983) and is stimulated by IGF-I and/or insulin 
(Hauner, 1990; Zezulak and Green, 1986).
Mitogens, such as PDGF, can block adipose conversion at this stage by stimulating 
cell cycle re-entry (Conn et al, 1990). Progression to the terminal stages of 
differentiation, therefore, requires the induction of an anti-mitogenic state in growth 
arrested cells. This is induced by GH, which primes cells at GO to become resistant to 
the actions of mitogens and responsive to the promoters of terminal differentiation 
(Conn et al, 1990). The mechanisms by which mitogens, such as PDGF, and anti­
mitogens, such as GH, control cell cycle entry and exit are not yet fully understood, 
but probably involve the modulation of proteins that regulate the Gl phase of the cell 
cycle (Sherr, 1994). For example, cyclin D expression is suppressed in 3T3-F442A 
preadipocytes treated with GH, which may contribute to the priming action of GH in 
these cells (Timchenko et al, 1996).
As clonal expansion slows, the expression of proteins that give rise to the adipocyte 
phenotype is initiated. The process of terminal differentiation is characterised by the 
induction of late markers, including the enzymes responsible for lipogenesis and 
triglyceride synthesis (Paulauskis and Sul, 1988; Spiegelman et al, 1983). The late 
genes also include those for hormone receptors that confer responsiveness to 
lipogenic and lipolytic hormones (de Herreros and Birnbaum, 1989; Zou et al, 1997). 
Among the first of these proteins to be expressed is the transcriptional regulatory 
protein, C/EBP a  (Christy et al, 1991). C/EBP a  is anti-mitogenic (Timchenko et al,
1996) and has been implicated in the termination of clonal expansion and 
maintenance of the terminally differentiated cell (Freytag and Geddes, 1992).
1.3.3 Transcriptional control o f  protein expression during preadipocyte 
differentiation
A number of transcriptional regulatory proteins have been implicated in the process of 
preadipocyte differentiation. In particular, isoforms of the CCAAT/enhancer binding
protein (C/EBP) family and certain members of the peroxisome proliferator activator 
receptor (PPAR) family are known to interact with the promoter elements of a number 
of adipocyte-specific genes (see Yeh and McKnight, 1995). These, and a number of 
other transcription factors (see Section 1.3.3.2), are thought to contribute critically to 
the reprogramming of gene expression that allows preadipose cells to clonally expand 
and develop into mature adipocytes. The temporal expression profiles of the C/EBP 
and PPAR proteins during in vitro preadipocyte differentiation are summarised in 
Figurel.3.
1.3,3.1 Transcriptional regulation by CÆBP and PPAR proteins
C/EBP a  is expressed in adipose tissue in vivo and in vitro (Birkenmeier et al, 1989). 
Its expression precedes that of adipocyte-specific genes during in vitro preadipocyte 
differentiation (Christy et al, 1991). C/EBP a  binds to and /ra/?5 -activates the 
promoters of a number of genes that are coordinately expressed during preadipocyte 
differentiation (Christy et al, 1989; Kaestner et al, 1990). In addition, the C/EBP a  
promoter possesses a C/EBP binding site (Christy et al, 1991). This apparently 
mediates ^ûr«5-activation by its own gene product and probably contributes to the 
maintenance of steady-state levels of C/EBP a  in the mature adipocyte (Legraverend 
et al, 1993; Lin et al, 1993). These observations suggest that C/EBP a  is an important 
regulator of adipogenesis. Several lines of evidence support this assumption. 
Antisense experiments demonstrate that C/EBP a  is required for the process of 
adipogenesis (Samuelsson et al, 1991; Lin and Lane, 1992) and ectopic expression of 
C/EBP a  has been shown to induce adipogenesis in otherwise non-differentiating 
NIH-3T3 cells (Lin and Lane, 1994; Freytag et al, 1994). In addition, lipid 
accumulation in adipose tissue is severely retarded in mice lacking functional C/EBP 
a  (Wang et al, 1995).
Although C/EBP a  can specify growth arrest and adipogenesis (Freytag and Geddes,
1992), it is not expressed during the initial stages of differentiation (Figure 1.3). Two 
additional members of the C/EBP family are, however, rapidly induced during the 
clonal expansion phase of preadipocyte differentiation, prior to the induction of 
C/EBP a  (Cao et al, 1991). C/EBP P and C/EBP ô are suggested to play an important 
transient role in early adipocyte differentiation by relaying the effects of hormonal
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stimulants such as glucocorticoids, GH, insulin and stimulators of the cAMP 
signalling pathways (Cao et al, 1991; Clarkson et al, 1995; Yeh et al, 1995). C/EBP p 
and Ô are also thought to /ra//5 -activate the C/EBP a  gene (Lane et al, 1996). It is 
therefore thought that C/EBP P and C/EBP 5 may relay the effects of adipogénie 
stimuli, culminating in the production of C/EBP a, the ultimate regulator of terminal 
adipogenesis (Cao et al, 1991).
PPARs are a subgroup of the nuclear hormone receptor subfamily of transcription 
factors (Isseman and Green, 1990, Drever et al, 1992, Gottlicher et al, 1992; Keller et 
al, 1993). The PPAR y isoforms, yl and y2, are abundantly expressed in white adipose 
tissue (Vidalpuig et al, 1996; Zhu et al, 1995). Both PPAR y isoforms are induced 
very early in several cell culture models of adipogenesis (Amri et al, 1995; Chawla et 
al, 1994) and ectopic expression of PPAR yl or PPAR y2 in fibroblasts promotes 
adipogenesis (Tontonoz et al, 1994b). These observations suggest that PPAR y 
isoforms play an important role in the process of preadipocyte differentiation. C/EBP 
P induces PPAR y expression in the preadipocyte, subsequently triggering 
differentiation (Wu et al, 1995). In addition, PPAR y synergises powerfully with 
C/EBP a  to stimulate adipogenesis (Tontonoz et al, 1994a). It has, therefore, been 
suggested that PPAR y isoforms may be important targets of C/EBP p and Ô in 
channeling the adipogénie potential of C/EBP a.
1.3.3.2 Regulation by other transcription factors
ADDl (adipocyte determination- and differentiation-dependent factor 1), a member of 
the basic helix-loop-helix family of transcription factors (Tontonoz et al, 1993), has 
also been implicated in preadipocyte differentiation. ADDl is expressed 
predominantly in adipose tissue and liver and its expression is induced at a very early 
stage of adipogenesis (Tontonoz et al, 1993; Kim and Spiegelman, 1996). Retroviral 
expression of dominant-negative ADDl significantly represses differentiation and the 
expression of adipocyte-specific genes in 3T3-L1 cells and ectopic expression of 
ADDl promotes adipocyte differentiation (Kim and Spiegelman, 1996). In addition, 
ADDl can induce expression of fatty acid synthase (FAS) and lipoprotein lipase 
(LPL), two key proteins involved in lipid synthesis (Kim and Spiegelman, 1996). The 
effects of ADDl on preadipocyte differentiation appear to be due, at least in part, to
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induction of PPAR y activity (Kim and Spiegelman, 1996).
Further transcription factors implicated in the process of adipogenesis are the so- 
called immediate early genes, c-fos, c-juu and z-myc. Transient increases in the 
expression of these genes precedes the induction of C/EBP P and Ô during the early 
stages of preadipocyte differentiation (Stone and Bernlohr, 1990; Stephens and 
Pekala, 1992). Homo- and heterodimers of z-jun and z-fos were the first proposed 
regulators of adipocyte-specific gene expression (Spiegelman et al, 1988). GH rapidly 
induces the transcription of z-fos and z-jiin in both 3T3-F442A (Gurland et al, 1990) 
and Obl771 (Barcellini-Couget et al, 1993) preadipocytes and this coincides with the 
induction of C/EBP P and 5 by GH (Clarkson et al, 1995). In 3T3-L1 preadipocytes, 
both insulin and IGF-1 induce expression of z-fos (Weiland et al, 1991). In addition, 
z-fos has been shown to play a role in the modulation of lipoprotein lipase (LPL) gene 
expression (Barcellini-Couget et al, 1993). Therefore, it appears that z-fos and z-jtm 
may relay specific temporal cues from extracellular stimuli to adipocyte-specific 
genes. Expression of z-myc is induced during clonal expansion of preadipocytes and 
decreases concomitantly with induction of the C/EBP a  gene (Christy et al, 1991). 
The C/EBP a  promoter contains a consensus c-wjc-binding site (Christy et al, 1991) 
that can bind z-myc in vitro (Legraverend et al, 1993). Therefore the induction of 
C/EBP a  during clonal expansion may involve /ra//5 -activation by z-myc.
Thus, several of the key transcriptional players in adipogenesis have now been 
identified. Adipogenesis is profoundly influenced by a variety of hormones and 
nutritional signals (Cornelius et al, 1994; Ailhaud et al, 1992; Ailhaud et al, 1994; 
Smas and Sul, 1995). A number of these hormones have been shown to affect the 
activity of adipogénie transcription factors. These observations suggest an important 
regulatory cascade in which hormonal signals first induce C/EBP P and ô and 
subsequently activate PPAR y and C/EBP a , thereby promoting and maintaining 
adipogenesis.
1.3.4 Hormonal control o f preadipocyte differentiation
The precise combination of hormones and growth factors required for the
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differentiation of preadipocytes is not known and is likely to vary amongst different 
cell-lines. Several laboratories have developed serum-free culture conditions and have 
implicated GH, IGF-I, insulin, triiodothyronine (T3), glucocorticoids and cyclic AMP- 
elevating agents as key hormonal regulators of preadipocyte differentiation (Guller et 
al, 1988; Hauner 1990; Schmidt e/a/, 1990).
1.3.4.1 Growth hormone and insulin-like growth factor-I
Depending on the cell-line, either GH or IGF-I appear to be obligatory for 
preadipocyte differentiation. Both 3T3-F442A and Ob 1771 preadipocytes require GH 
for differentiation (Nixon and Green, 1984a; Nixon and Green, 1984b; Catalioto et al, 
1992; Dani et al, 1990). GH has been shown to induce IGF-I gene expression in 
Ob 1771 preadipocytes (Doglio et al, 1987) and to increase the sensitivity of 3T3- 
F442A cells to the actions of IGF-I (Zezulak and Green, 1986). However, IGF-I 
cannot substitute for GH in the differentiation of either cell type (Nixon and Green, 
1984a; Nixon and Green, 1984b; Catalioto et al, 1992; Dani et al, 1990). At least in 
3T3-F442A preadipocytes, it appears that GH first directly stimulates adipocyte 
differentiation, then the number of young differentiated cells is increased by clonal 
expansion mediated by the mitotic actions of IGF-I (Green et al, 1985). GH does not, 
however, support the differentiation of 3T3-L1 cells. In this case, IGF-I and 
pharmacological doses of insulin are required for differentiation (Smith et al, 1988).
The effects of GH on preadipocyte differentiation appear to be differential. GH 
promotes early stages of differentiation and contributes to clonal expansion. However, 
at later stages of differentiation, GH, through its inhibitory effects on lipid metabolism 
(see Section 1.2.1.1), can reduce the proportion of newly formed adipocytes and late 
markers of differentiation (Hausman and Martin, 1989; Wabitsch et al, 1996; Fain et 
al, 1985; Goodman ûr/, 1990; Schwartz and Carter-Su, 1988; Wabitsch et al, 1996).
The exact mechanism by which GH exerts its adipogénie effects in preadipocytes is 
understood poorly. However, the transient stimulation of c-fos and/or z-jtm 
transcription by GH (Doglio etal, 1989; Sumantran et al, 1992), which coincides with 
transcriptional activation of C/EBP Ô and translational activation of C/EBP P, is likely 
to contribute to its differentiation-promoting effects (Clarkson et al, 1995).
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1.3.4.2 Insulin
Developing adipocytes become highly responsive to insulin. This has been attributed 
to increases in the number of insulin receptors (Rubin et al, 1978) and increased 
expression of metabolic proteins that are regulated by insulin (Park and Kim, 1991). 
The presence of insulin is obligatory for the differentiation of 3T3-F442A, 3T3-L1 
and Ob 17 cells (Doglio et al, 1986; Smith et al, 1988; Guller et al, 1988). Although 
insulin does not appear to be required for commitment to the differentiation process 
(Steinberg and Brownstein, 1982), it promotes the accumulation of lipid (Smith et al, 
1988) and the induction of late markers (Dani et al, 1986) in differentiating cells. To 
optimise adipose conversion in preadipocyte cell systems, insulin is often used at 
supraphysiological concentrations where its effects may be mediated via the IGF-I 
receptor (Guller et al, 1988). Therefore, there may exist subtle interplay between the 
insulin and IGF-I receptors to modulate the differentiation process.
In 3T3-F442A adipocytes, insulin has been shown to increase the expression of PPAR 
yl and y2 and regulate the transcription of C/EBPs (MacDougald et al, 1995; 
Vidalpuig et al, 1996). In addition, insulin is required for maintaining the activity of 
PPAR y2 in the adipose tissue of lean and obese mice (Vidalpuig et al, 1996). Insulin 
and IGF-I also increase the transcriptional activity of ADDl (Streicher et al, 1996). 
As ADDl has been shown to increase PPAR y activity (Kim and Spiegelman, 1996), 
this may be an additional mechanism by which insulin maintains the activity of PPAR 
y. Thus, insulin appears to modulate the activity of several critical adipogénie 
transcription factors during the differentiation process.
1.3.4.3 Epidermal growth factor
Like PDGF, EGF inhibits preadipocyte differentiation by stimulating cell cycle re­
entry (Corin et al, 1990; Serrero, 1987). However, EGF is required for the 
maintenance of 3T3-F442A and 3T3-L1 preadipocyte differentiation (Guller et al, 
1988; Schmidt et al, 1990) and elevated EGF levels are associated with adipocyte 
hypertrophy in obese mice (Kurachi et al, 1993). EGF has been shown to promote the 
insulin-stimulated accumulation of triglycerides in primed preadipocytes, possibly by 
reducing catecholamine-mediated lipolysis (Taber et al, 1993). Thus, although EGF
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can prevent initiation of the differentiation programme, it appears to be required for 
the progression of adipogenesis. The effects of EGF on the adipogénie transcriptional 
regulatory cascade are, as yet, unclear.
1.3.4.4 Cyclic AMP
The actions of many hormones are mediated at the cellular level by cyclic AMP. 
Cyclic AMP-elevating agents have been shown to promote the adipose conversion of 
a number of preadipocyte cell-lines and induce the transcription of several adipocyte- 
specific genes (Bhandari et al, 1991; Park and Kim, 1991; Yang et al, 1989). Addition 
of the cyclic AMP phosphodiesterase inhibitor, isobutylmethylxanthine (IBMX) in the 
presence of insulin and glucocorticoids, has been shown to increase the differentiation 
of 3T3-L1 (Rubin et al, 1978; Schiwek and Loffler, 1987), rat (Xu and Bjorntorp,
1990) and human preadipocytes (Hauner et al, 1989). Agents that increase cyclic 
AMP have also been shown to promote the differentiation of Ob 17 preadipocytes 
(Vassaux et al, 1992) and potentiate the GH-dependent stage of differentiation in 
3T3-F442A preadipocytes (Yarwood etal, 1998).
Increases in the expression of certain sub units of cyclic AMP-dependent protein 
kinase (PKA) precede morphological differentiation in TAI preadipocytes (Kurten et 
al, 1988). PKA phosphorylates members of the CREB (cyclic AMP-response- 
element-binding protein) family of transcription factors (Gonzalez and Montminy, 
1989; Sheng et al, 1991) that activate transcription through binding to cyclic AMP 
response elements (CREs) in target genes (Hagiwara et al, 1993). The promotion of 
adipogenesis by cyclic AMP has also been attributed to the induction of C/EBP P, 
which has been shown to be regulated by IBMX (Yeh et al, 1995). C/EBP family 
members can form heterodimers with members of the CREB family (Vallejo et al, 
1993), suggesting that ftmctional "cross talk" between CREB proteins and C/EBPs 
may contribute to the promotional effects of cyclic AMP on preadipocyte 
differentiation.
It appears that, like GH, cyclic AMP exerts differential effects on adipocyte 
development. Cyclic AMP acts both at an early stage to promote preadipocyte 
differentiation, by inducing adipocyte-specific gene expression, and during the
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terminal stages to limit fat cell size, by suppressing lipogenic gene expression (Antras 
et al, 1991) and promoting lipolysis (see Section 1.2.1.1.3).
L3.4,5 Agents that signal via nuclear receptors
In addition to those growth factors that act through membrane receptors, thyroid and 
glucocorticoid hormones, fatty acids and retinoids also influence adipocyte 
differentiation. Their mechanism of action is, as yet, understood poorly. However, in 
general, these agents diffuse into cells, interact with cognate receptors (Evans, 1988; 
Green and Chambon, 1988) and exert nuclear effects through cw-acting hormone 
response elements (HREs) in the promoter regions of target genes (Karin et al, 1984; 
Evans, 1988).
1.3.4.5.1 Triiodothyronine
Tg is essential for the differentiation of Ob 17 cells (Grimaldi et al, 1982), where it 
provokes an increase in the activity of certain lipogenic enzymes (Gharbi-Chihi et al, 
1983). It appears that T3 acts in synergy with adipogénie factors to promote 
preadipocyte differentiation (Flores-Delgado et al, 1987; Hausman and Martin, 1989). 
T3 is thought act transiently, during the early stages of terminal differentiation, to 
induce the expression of a number of proteins involved in the regulation of lipid 
metabolism (Ailhaud, 1982; Flores-Delgado et al, 1987; Hausdorf et al, 1988; 
Levacher and Picon, 1989; Moustaid and Sul, 1991).
1.3.4.5.2 Glucocorticoids
Addition of the synthetic glucocorticoid, dexamethasone, in the presence of insulin 
and the cyclic AMP-elevating agent, isobutylmethylxanthine (IBMX) has been shown 
to enhance the differentiation of preadipocytes from several species (Rubin et al, 
1978; Schiwek and Loffler, 1987; Hauner et al, 1989; Xu and Bjorntorp, 1990). This 
may be due to the induction of C/EBP p and ô which is regulated by IBMX and 
dexamethasone respectively (Cao et al, 1991; Yeh et al, 1995). Dexamethasone also 
increases the level of PPAR y expression induced by C/EBP p and 5 (Wu et al, 1996). 
In addition, a glucocorticoid response element can be found in the aP2 gene of 3T3- 
L1 preadipocytes, which may be responsible for transcriptional induction by 
dexamethasone during adipose conversion (Cook et al, 1988).
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1.3.4.5.3 Fatty acids and retinoids
When present in low concentrations, fatty acids and retinoids cooperate 
synergistically to promote the terminal differentiation of Ob 1771 preadipocytes 
(Safonova et al, 1994b) and co-regulate 3T3-L1 preadipocyte proliferation and 
differentiation (Chawla and Lasar, 1994). Both fatty acids and retinoids induce 
expression of late markers of preadipocyte differentiation, including proteins 
implicated in fatty acid metabolism (Amri et al, 1991; Abumrad et al, 1993; Safonova 
et al, 1994b). Fatty acid-activated nuclear receptors, such as PPAR yl, form 
heterodimeric complexes with retinoid receptors which can then bind corresponding 
HREs in adipocyte-specific genes (Amri et al, 1995; Tontonoz et al, 1994a).
Given the crucial roles of GH and insulin in promoting and maintaining adipogenesis, 
it is apparent that elucidation of their respective signal transduction pathways will be 
important for understanding the mechanism of action of these hormones. Although, 
the signalling mechanisms used by GH and insulin are not fully resolved, a number of 
key events have been identified and are outlined in Figures 1.4 and 1.5.
1.4 Insulin signalling
Over the past decade there has been a dramatic increase in the understanding of early 
post-receptor events involved in insulin action. The binding of insulin to the extra­
cellular a-sub unit of its receptor stimulates the tyrosine kinase activity located on the 
cytoplasmic portion of the p-sub unit. This results in autophosphorylation of the 
receptor, concomitantly enhancing kinase activity towards other protein substrates 
(White et al, 1985). A major substrate is the cytoplasmic protein termed insulin 
receptor substrate-1 (IRS-1; Sun etal, 1991). Tyrosine phosphorylated IRS-1 acts as a 
docking molecule for multiple proteins that interact via phosphotyrosyl-binding 
domains, termed SH2 (Pawson and Gish, 1992).
Proteins known to associate with IRS-1 are: the lipid kinase, phosphatidylinositol 3- 
kinase (PI 3-kinase); an adaptor protein, Grb2, which associates with the guanine 
nucleotide exchange factor Sos; a phosphotyrosine phosphatase, syp and a linker
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protein, nek (Skolnik et al, 1993; Tobe et al, 1993; Kuhne et al, 1993; Lee et al,
1993). Insulin receptor- and 1RS-1-binding proteins are being identified continuously. 
For instance, hGrblO (Dong et al, 1997), a SH2 domain-containing putative adaptor 
protein, SH2-B (Wang and Riedel, 1998) and a rho-associated kinase (Farah et al, 
1998) have recently been found to associate with the insulin receptor and may play an 
as yet unidentified role in insulin signal transduction. A number of phosphatases, in 
addition to syp, have also been proposed to modulate insulin signalling (Lammers et 
al, 1997; Lechleider et al, 1993; Kuhne et al, 1993; Hausdorff et al, 1995; Kulas et al,
1995). The exact roles of a number of these proteins with respect to insulin signal 
transduction remain to be determined.
1.4.1 Insulin signalling via phosphatidylinositol 3-kinase
The interaction of PI 3-kinase with IRS-1 results in activation of the lipid kinase 
(Backer et al, 1992). PI 3-kinase catalyses the phosphorylation of inositol lipids at the 
D3 position (Auger et al, 1989), though the exact role of such phospholipids in 
cellular signalling is uncertain. PI 3-kinase is composed of a 110 kDa catalytic sub 
unit and a regulatory sub unit. Five regulatory sub units have been identified to date; 
two 85 kDa sub units, two 55 kDa sub units and a 50 kDa sub unit which is 
alternatively spliced from the p85a gene (Inukai et al, 1997). These five sub units 
may play differential roles in the various responses induced by the numerous 
molecules that activate PI 3-kinase.
Activation of PI 3-kinase is thought to be upstream of p70^  ^ kinase activation and 
hence of mRNA translation (Cheatham et al, 1994); p70^  ^kinase phosphorylates EF-1 
and s6 , resulting in insulin stimulation of translation elongation (Chang and Traugh,
1997). Some evidence also exists for PI 3-kinase-independent activation of p70*  ^
kinase by insulin (Hara et al, 1995).
PI 3-kinase is also upstream of PKB in insulin signalling cascades (Burgering and 
Coffer, 1995). The a  and P isoforms of PKB are activated by insulin in adipocytes 
(Walker et al, 1998). PKB is activated by a kinase termed PDKl (3-PI-dependent 
protein kinase, as it is only activated in the presence of the products of PI 3-kinase; 
Alessi et al, 1997). Inhibition of glycogen synthase kinase-3 (GSK3) by serine
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phosphorylation via PKB (Cross et al, 1995) is thought to contribute to the 
stimulation of glycogen synthesis (Cross et al, 1995) and the translation of certain 
mRNAs (Welsh et al, 1994; Welsh et al, 1998) by insulin.
PI 3-kinase is required for insulin-stimulated glucose transporter translocation in rat 
(Okada et al, 1994) and 3T3-L1 (Kotani et al, 1995) adipocytes and inhibition of 
lipolysis in rat adipocytes (Okada et al, 1994). Insulin activation of the PDE 3 isoform 
in rat adipocytes, which is involved in inhibition of lipolysis, also appears to be PI 3- 
kinase-dependent (Rahn et al, 1994) and may involve PKB but does not involve p70®^  
kinase (Wijkander et al, 1998). As well as being an important transducing effector, PI 
3-kinase may exert a modulatory effect on insulin signalling via serine 
phosphorylation and attenuation of 1RS-1 (Tanti et al, 1994).
1.4.2 Insulin signalling via mitogen-activated protein kinases 
The association of Grb2-Sos with IRS-1 results in the conversion of Ras to its active 
GTP-bound form (Buday and Downward, 1993). Ras then triggers a protein kinase 
cascade, involving the sequential activation of two kinases, Raf and MEK (mitogen 
activated protein [MAP] kinase kinase; Kyriakis et al, 1992). This leads to the 
activation of the p42 and p44 MAP kinases by threonyl- and tyrosyl-phosphorylation 
(Ray and Sturgill, 1988). MAP kinases are a conserved family of serine/threonine 
kinases that are activated in all eukaryotic cells in response to a wide range of signals 
(Lenormand et al, 1993; Marshall, 1995). MAP kinases subsequently phosphorylate 
and activate p90'^ '  ^ (Haystead et al, 1990). This pathway is known to regulate gene 
transcription via phosphorylation of transcription factors by both MAP kinases and 
pp90'^ (Marshall, 1995).
Additional studies have demonstrated that MAP kinases can also mediate increased 
protein translation in response to insulin. On insulin stimulation, MAP kinase 
phosphorylates PHAS-1, a protein which interacts with the eIf-4E component of the 
translation initiation complex eIF-4F (Lin et al, 1994). Both proteins are found in 
association with mRNA cap structures prior to insulin stimulation (Merrick, 1992). 
On phosphorylation by insulin, PHAS-1 is released from eIF-4F which, also 
phosphorylated, is then free to associate with other members of the initiation complex 
and translation can occur (Lin et al, 1994).
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MAP kinases appear to be required for insulin-induced mitogenesis, however, as yet, 
little evidence has been presented to suggest a role for the MAP kinase pathway in the 
metabolic effects of insulin (Lazar et al, 1995). MAP kinases may, however, be 
required for insulin-induced stimulation of glucose transport (Inoue et al, 1993).
1.4.3 Insulin receptor substrate-l-independent signalling
Although IRS-1 undoubtedly plays an important role in mediating the actions of 
insulin, it is apparent that 1RS-1-independent signalling pathways are also involved. 
She has been termed the second major insulin receptor substrate (Pronk et al, 1993) 
and also activates the MAP kinase pathway via complex-formation with Grb2-Sos. 
Insulin activation of MAP kinase and z-fos transcription has, in fact, been shown to 
occur predominantly through Shc-Grb2 interaction (Yamauchi and Pessin, 1994) and 
it has been suggested that She and IRS-1 compete for a limited pool of Grb2 in 
mediating downstream signalling.
IRS-1 knockout studies led to the identification of a further insulin receptor substrate, 
termed IRS-2, which can activate PI 3-kinase to a lesser extent than IRS-1 (Araki et 
al, 1994). Thus, glucose transport can still occur in the absence of 1RS-1, although at 
a reduced rate due to the fact that GLUT 4 translocation is PI 3-kinase-dependent. In 
fact, IRS-2 appears to be a crucial component of the insulin signal transduction 
mechanism as disruption of the IRS-2 gene in mice results in the development of 
diabetes (Withers et al, 1998). In addition, a third potential member of the 1RS family, 
IRS-3, has recently been identified in rat adipocytes (Smith-Hall et al, 1997).
1.5 Growth hormone signalling
On binding, GH induces rapid tyrosine phosphorylation and dimérisation of its 
receptor but, unlike the insulin receptor, the GH receptor possesses no intrinsic 
tyrosine kinase activity (Leung et al, 1987). Tyrosine phosphorylation is achieved via 
recruitment of the cytosolic protein JAK 2, a member of the Janus family of tyrosine 
kinases (Argetsinger et al, 1993; Wilks et al, 1991). Members of the Janus family 
associate preferentially with the cytoplasmic domain of a number of cytokine 
receptors (see Lamb et al, 1996). Activated JAKs have been shown to phosphorylate 
both cytokine receptors themeselves and a number of downstream substrates,
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particularly members of the ST AT (signal transducers and activators of transcription) 
family of cytosolic transcription factors (see Lamb et al, 1996). Studies have 
demonstrated that GH induces the tyrosine phosphorylation of a number of 
intracellular proteins (Campbell et al, 1993; Anderson, 1992), presumably in a JAK 2- 
dependent manner (Winston and Hunter, 1995). The identification of these proteins 
has revealed two pathways that could potentially be used by GH to signal to the 
nucleus.
1.5.1 Growth hormone signalling via mitogen-activated protein kinases 
Anderson (1992) has shown that GH induces rapid and transient activation of p44 and 
p42 MAP kinases and p90"^ ^^  in 3T3-F442A preadipocytes. JAK2, Ras and Raf appear 
to be required for activation of MAP kinases by GH (Winston and Hunter, 1995). At 
least in rat liver, GH induces the translocation of MAP kinases to the nucleus where 
they can phosphorylate various transcription factors (Davis, 1993). This cascade is 
therefore a potential mechanism for the modulation of gene transcription by GH.
Recently, it has emerged that activation of the MAP kinase cascade is essential for the 
adipose conversion of 3T3-L1 preadipocytes (Sale et al, 1995). In fact, the sequential 
activation of PI 3-kinase, Ras and MAP kinase appears to be required for 
differentiation of these cells (Uehara et al, 1995). Although these signalling pathways 
are activated by both GH and insulin, the role of these events in the adipogénie 
actions of the hormones has not been defined.
1.5.2 Growth hormone signalling via signal transducers and activators o f  
transcription (STATs)
The widely expressed ST AT family of cytosolic transcription factors, which are the 
products of multiple genes and alternative splicing, are known to be phosphorylated 
by members of the JAK family of tyrosine kinases (see Lamb et al, 1996). ST AT 
proteins undergo tyrosyl phosphorylation in the cytoplasm followed by translocation 
to the nucleus where variations in the complexes formed with other transcription 
factors confer specificity of interaction with different DNA response elements (Hunter 
et al, 1993). GH phosphorylates and causes nuclear accumumlation o f ST AT l a  
(Kilgour and Anderson, 1994; Meyer et al, 1994). Phosphorylation of ST AT 1 by GH
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results in the formation of complexes that can interact with the sis-inducible element 
(SIE) of c-fos (Meyer et al, 1994). Further evidence suggests that GH can also 
activate ST AT 3 and ST AT 5, apparently in a cell-specific manner (Meyer etal, 1994; 
Gronowski and Rotwein, 1994; Cambell et al, 1995; Gouilleux et al, 1995; Thomas et 
al, 1995; Leaman etal, 1996; Yi etal, 1996).
1.5.3 Growth hormone and additional signalling e\^ents
GH has also been shown to induce a number of other signalling events. Like insulin, 
GH causes tyrosine phosphorylation of She and its association with Grb2 
(VanderKuur et al, 1995) and activates PI 3-kinase (Kilgour et al, 1996). A number of 
other proteins (Rui et al, 1997; Kim et al, 1998) have been shown to associate with 
JAK 2 upon GH stimulation, although the roles of these proteins in GH signal 
transduction remain to be determined.
Thus, by comparison of the signal transduction pathways, it can be seen that GH and 
insulin induce many of the same signalling events. Much of the data for GH has, 
however, been derived from studies using preadipocyte cell lines and awaits 
confirmation in adipocytes. In addition to the events discussed above, GH can induce 
the tyrosine phosphorylation of 1RS-1, -2 and -3 and their association with PI 3-kinase 
(Souza et al, 1994; Argetsinger et al, 1996; Yamauchi et al, 1998). Indeed, the IRS-1 
proteins are now known to be activated by a number of cytokines (Argetsinger et al, 
1996; Berlanga et al, 1997; Chen et al, 1997a). Furthermore, it now appears that the 
JAK-STAT pathway may participate in insulin signalling. In cells over-expressing the 
insulin receptor, IRS-1 and She are found in association with JAK 2 (Maegawa et al, 
1996). In addition, ST AT 5 has been identified as an insulin receptor substrate (Chen 
et al, 1997a) and insulin activates ST AT 3 in 3T3-L1 adipocytes (Ceresa and Pessin,
1996) and hepatic cells (Campos et al, 1996).
In addition to the activation of individual signal transducers, “cross talk” between 
individual signalling pathways also appears to be important in modulating the effects 
of GH. For example, PI 3-kinase is required for the signalling of GH and insulin to 
MAP kinases (Kilgour et al, 1996; Sanchez-Margalet et al, 1995). MAP kinase 
activation itself can be modulated, either positively or negatively, by regulatory "cross
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talk" with other signalling pathways, such as the cyclic AMP cascade (Malarkey et al, 
1995; Marshall, 1995). In addition, the MAP kinase pathway may regulate signalling 
via the JAK-STAT pathway (David et al, 1995; Chung et al, 1997; Purcher et al,
1997). Thus, there exists subtle interplay between individual signalling pathways in 
mediating the down-stream effects of hormones.
GH and insulin activate very similar signal transduction systems to exert very 
different effects. Thus, the timing or duration of activation of signalling proteins may 
be important in mediating down-stream effects. For example, the duration of MAP 
kinase activation has been shown to be a determining factor in the decision of cells to 
differentiate or proliferate; sustained activation provokes differentiation whereas 
transient activation stimulates cell cycle re-entry (Marshall, 1995). In addition, since a 
number of the elements of the GH and insulin signalling pathways exist in multiple 
isoforms, it may be necessary to clarify which isoforms are targeted by which 
hormone in eliciting particular cellular responses. The protein kinase C (PKC) family 
of serine/threonine kinases, exists in multiple isoforms and it is thought that 
individual isoforms may be required for distinct cellular functions. PKCs are known 
to participate in a number of the signalling pathways stimulated by GH and insulin 
(see Figures 1.4 and 1.5) and are strongly linked to the regulation of differentiation. 
Thus, these kinases may play an important role in the regulation of adipocyte 
development and function.
L 6 The protein kinase C family
PKC was initially identified as a serine/threonine kinase in brain around twenty years 
ago (Inoue et al, 1977; Takai et al, 1977). The enzyme was determined to exhibit 
reversible calcium- and phospholipid-dependent kinase activity which could be 
stimulated by the second messenger diacylglycerol (DAG) (Kishimoto et al, 1980). 
DAG is produced by phospholipid hydrolysis in response to a variety of extracellular 
stimuli, thus, the first link between receptor induced phosphoinositide (PI) breakdown 
and protein phosphorylation was discovered.
PKC is also the major receptor for tumour-promoting phorbol esters, which activate 
the kinase in vitro in a manner very similar to DAG (Gschwendt et al, 1991; Bell and
23
Burns, 1991). Phorbol esters have, therefore, been used widely as a pharmacological 
tool to investigate the Amction of PKC in the cell. By this approach it has become 
clear that PKC is involved in a variety of diverse processes. It has also been 
established that PKC is not a single entity and that many closely related PKC isoforms 
exist, perhaps providing an explanation for the range of processes in which PKC has 
been implicated.
Members of the PKC family of homologous phospholipid-dependent serine/threonine 
kinases are divided into groups according to their structural properties and kinetics of 
activation (Figurel.6 ). The conventional PKCs require DAG and calcium for maximal 
activation and consist of PKC a , p and y (Coussens et al, 1986, Knopf et al, 1986; 
Parker et al, 1986). The PKC P gene generates two iso forms, pi and pH, by 
alternative splicing (Ono et al, 1986; Coussens et al, 1987). The novel PKCs, 5, s, t] 
and 0 (Ono and Nishizuka, 1987; Ohno et al, 1988; Osada et al, 1992; Bacher et al,
1991) require DAG for maximal activation but are insensitive to calcium. The 
atypical PKCs, C^, i and X (Ono et al, 1989; Selbie et al, 1993; Akimoto et al, 1994) 
are insensitive to both DAG and calcium and are thought to be activated by 
phospholipid alone, although the regulation of atypical PKS is, as yet, understood 
poorly. In addition, there exists PKC fi (Johannes et al, 1994) and PKD (Valverde et 
al, 1994), which are thought to be human/murine homologues. PKC \i and PKD are 
structurally quite different from the other isoforms and may, thus, represent a new 
PKC sub-family.
1,6.1 Protein kinase C structure
PKC isoforms consist of a single polypeptide chain that contains an amino-terminal 
regulatory region and a carboxy-terminal kinase domain (Figurel.6 ). These domains 
can be divided further into regions that are conserved across isoforms (C l-4) and 
regions that vary between isoforms but are conserved within an isoform across species 
(Vl-5; Nishizuka etal, 1988).
The regulatory region contains an auto-inhibitory domain and one or two membrane 
targeting motifs, the Cl and C2 domains. The auto-inhibitory domain, or pseudo­
substrate site, resembles a substrate phosphorylation site but with the
24
ü ü o
0
1
u
ü
co
ü
&
C
X
CL
o
td
Z3
W)
(D
C<
CM
O
>
o
o
I
c /3
D
c /3O-O3
0>
c /3O,
X
T
? -
S.
s.
CL
C
O
î
r
CD
uT
w
U
i
è
Z
M '
S
CL
O
‘a .
O )
CO
5g
eu eu
I
5
I
«
I
%)
'S '
g
I
\ o
&
I
phosphorylatable serine replaced by an alanine residue (House and Kemp, 1987). The 
pseudo-substrate is thought to prevent activation of the enzyme by binding to the 
catalytic site (House and Kemp, 1987).
The Cl domain comprises two cysteine-rich regions and is responsible for DAG and 
phorbol ester binding (Kaibuchi et al, 1989; Ono et al, 1989). The stoichiometry of 
binding of phorbol esters to PKC is 1:1, despite the presence of two cysteine-rich 
domains in most iso forms (Mosior and Newton, 1996). The second cysteine-rich 
domain appears to be responsible for phobol ester-dependent membrane targeting 
whereas the function of the first domain remains to be determined (Szallasi et al,
1996). Although one cysteine-rich sequence is sufficient for binding of DAG/phorbol 
ester (Quest etal, 1994), the lower cooperativity and affinity of this binding leaves the 
possibility that two regions are required for efficient binding in vivo. This may explain 
the insensitivity of the atypical PKC isoforms to regulation by DAG/phorbol esters.
The C2 domain is present in conventional PKCs only and thus appears to be 
responsible for calcium binding. Calcium binding is thought to potentiate the binding 
of lipid by inducing a conformational change in the C2 domain (Newton, 1995). 
Similar sequences have been identified in the VI region of novel PKCs (Sossin and 
Schwartz, 1993). Novel PKC isoforms display calcium-independent activation as the 
key aspartates involved in calcium coordination are not present in the C2-type domain 
in these proteins. (Newton, 1995; Nalefski and Falke, 1996). The C2/C2-like domains 
in the conventional and novel PKCs also appear to be responsible for acidic 
phospholipid binding (Newton, 1997; Quest, 1996). It is, as yet, unclear which 
regions are responsible for phospholipid binding in the atypical PKCs.
The V3 region serves as a hinge that is cleaved by calpain and trypsin to separate 
PKC into a constitutively active kinase, termed PKM (Parker et al, 1986; Kishimoto 
et al, 1989). The other variable regions are highly conserved within an isoform across 
species and are therefore likely to have a functional role to separate isoforms in terms 
of substrates, localisation and regulation. The catalytic domain of PKC is similar to 
regions of other serine/threonine kinases in that it contains consensus sequences for 
ATP-binding (C3), the phosphate transfer region and the substrate binding site (C4; 
Bell and Bums, 1991; Hug and Sarre, 1993; Hanks et al, 1988). The overall homology
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in the kinase region is high between PKC isoforms, with the exception of PKC p and 
PKD which do not phosphorylate a number of putative PKC substrates (Valverde et 
al, 1994; Johannes et al, 1995; Dieterich et al, 1996).
There are a number of other discrepancies between the structures of PKC p/PKD and 
the other PKC isoforms (Valverde et al, 1994; Van Lint et al, 1995; Johannes et al, 
1995; Dieterich et al, 1996; see also Figure 1.6). The pseudo-substrate domain, that is 
present in all other PKC isoforms, is absent from PKC p and PKD. These isoforms 
possess putative leader sequences (LS) and transmembrane sequences (TMS) near the 
amino-terminus and a pleckstrin homology (PH) domain near the hinge region. In 
addition, the two cysteine-rich motifs in the Cl domains of PKC p and PKD are 
unusually far apart. However, PKC p and PKD are phospholipid-dependent 
serine/threonine kinases whose activity is stimulated by DAG and phorbol esters 
(Valverde et al, 1994; Johannes et al, 1995; Dieterich et al, 1996) and may, thus, 
represent a new PKC sub-group.
1.6.2 Activation o f protein kinase C
Classically, PKC is activated by the concerted action of calcium, phospholipids, 
particularly phosphatidylserine (PS), and DAG. Enzyme activation requires the 
removal of the auto-inhibitory pseudo-substrate domain from the active site. This 
conformational change is achieved by the highly specific binding of DAG and PS to 
the two membrane-targetting domains. Cl and C2. Binding of ligand to either domain 
is sufficient to recruit the enzyme to membranes, however, both domains must be 
membrane-bound for the high-affmity interaction that results in pseudo-substrate 
removal and maximal activation (Newton, 1995; Newton, 1997). PKC activation by 
DAG is stereo-specific since only sn-l,2-DAGs (and not 1,3- or 2,3-D AGs) are 
effective (Sharkey and Blumberg, 1985; Boni and Rando, 1985; Hannun et al, 1986). 
Calcium appears to synergise with DAG/phorbol esters since it increases the affinity 
of PKC for PS, thus, lower amounts of DAG are required for membrane binding (Luo 
etal, 1995).
In addition to the Cl and C2 domains, the pseudo-substrate domain may also be 
involved in lipid interactions. Synthetic peptides mimicking the pseudo-substrate
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region of PKC contain multiple basic residues that allow binding to acidic 
phospholipids (Mosior and McLaughlin, 1991, 1992a, 1992b). These interactions 
between the pseudo-substrate motif and acidic phospholipids may stabilise active 
PKC at the membrane.
1.6.2.1 Regulation by diacylglycerol and phorbol esters
Although phorbol esters and DAG appear to activate PKC by the same mechanism 
(Castagna et al, 1982; Sharkey and Blumberg, 1985; Hannun and Bell, 1986), phorbol 
esters are more potent and induce prolonged activation of the enzyme (Castagna et al, 
1982; Mosior and Newton, 1995). Studies with phorbol esters have revealed that 
PKCs translocate to the membrane (Kraft et al, 1982; Kraft and Anderson, 1983), 
cytoskeleton (Ito et al, 1989; Mochly-Rosen et al, 1990; Zalewski et al, 1990; Kiley 
et al, 1992) and nucleus (Kiley et al, 1995). Subsequently, down-regulation of the 
protein occurs (Solanki et al, 1981). This appears to be via proteolytic degradation in 
the hinge region, by either a calcium-dependent protease, most likely calpain 
(Pontremoli et al, 1990), or a serine protease (Chida et al, 1986) and results in the 
release of the catalytic subunit, PKM (Takai et al, 1977). Continued proteolysis 
presumably results in inactivation of the kinase and to long-term down-regulation of 
PKC activity in the cell. Whether PKM accumulates to any significant degree in the 
cell, or is involved in signal transduction, remains to be determined.
Atypical PKC isoforms do not bind DAG or, therefore, phorbol esters. However, 
species of PKC Ç which are translocationally activated and subsequently down- 
regulated in response to phorbol ester treatment have been reported (Zhou et al, 
1994a; Nishikawa et al, 1995; Borner et al, 1992). These forms of PKC Ç appear to be 
activated in response to phorbol esters by a mechanism that does not involve binding 
of the phorbol ester to the PKC. PKC p. contains a DAG-binding site and is, therefore, 
capable of binding phorbol esters (Johannes et al, 1994). However, this isoform is 
insensitive to acute and chronic modulation by phorbol ester in terms of translocation 
and subsequent down-regulation (Johannes etal, 1995; Rennecke et al, 1996). Indeed, 
PKC p was originally classified as an atypical PKC, due to lack of apparent phorbol 
ester responsiveness (Johannes et al, 1994), however, enhanced kinase activity in the 
presence of phorbol ester has since been demonstrated (Johannes et al, 1995;
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Dieterich a/, 1996).
Ill vitro experiments have shown that DAG increases the affinity of PKC for PS and 
this is likely to contribute to the redistribution of soluble PKCs to membranes upon 
activation (Newton, 1995). Thus, the classical model of activation for conventional 
and novel PKC isoforms involves translocation to cell membranes and interaction 
there with physiological activators. However, it is becoming apparent that additional 
mechanisms of regulation exist.
1.6.2.2 Regulation hy lipids
The classical regulator of PKC is DAG produced as a consequence of receptor 
mediated hydrolysis of phospholipids. Cleavage of phosphatidylinositol bisphosphate 
(PIP2), by the PIP2-specific phospholipase C (PLC) p i, results in the production of 
inositol trisphosphate (IP3) and DAG. The production of IP3 initiates a rise in 
intracellular calcium levels (Berridge, 1993) which may help in translocating 
conventional PKCs to the membrane where they can interact with DAG to become 
activated. Of course, DAG itself activates PKC by lowering its requirements for PS 
and calcium to physiological levels (Kishimoto et al, 1980). Other lipids can stimulate 
DAG-dependent activation of PKCs, presumably by mimicking PS and thus 
increasing PKCs membrane affinity.
PKC is activated by two inositol phospholipids, PIP2 itself and PIP3 
(phosphatidylinositol trisphosphate) which is a product of PI 3-kinase (Chauhan et al, 
1990; Nakanishi et al, 1993; Singh et al, 1993). PIP2 appears to act in part as a DAG 
analogue and decreases the requirements of PKC for calcium. However, PIP2 can also 
satisfy some of the phospholipid requirements of PKC (Lee and Bell, 1991). PIP2 has 
also been shown to activate PKC in the absence of PS, requiring only calcium and 
phosphatidylinositol (Kochs et al, 1993). PIP3 appears to be a potent activator of 
novel and atypical PKCs, however, the physiological relevance of this interaction has 
not been evaluated (Singh et al, 1993). Thus, products of the PI cycle may regulate 
PKC activity in the cell in a complex fashion.
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Arachidonic acid, produced by the action of PLA 2, and other c/5 -unsaturated fatty 
acids directly activate PKC in vitro (Blobe et al, 1995). Their mechanism of 
activation is distinct from that of PS/DAG as it may occur in the cytosol, allowing 
access of PKC to substrates that are not in the vicinity of the membrane. In addition, 
cleavage of phosphatidylcholine (PC) by PLA 2 also releases lysoPC (Nishizuka,
1992) which activates PKC in the presence of PS and calcium. This activation is 
synergistic with DAG and additive to fatty acid effects (Oishi et al, 1988). LysoPC 
and fatty acids are produced over long periods of time, thus, they could mediate long 
term effects of PKC (Nishizuka, 1992). Indeed, exogenous lysoPC can greatly 
potentiate the effects of DAG on processes that require prolonged activation of PKC, 
such as cellular differentiation (Asaoka et al, 1993).
PLD cleaves PC to form phosphatidic acid (PA) that can then give rise to lysoPA or to 
DAG. PA has been demonstrated to activate calcium-independent PKCs in vitro 
(Khan et al, 1994; Limatola et al, 1994). Thus, the PLD pathway may mediate its 
mitogenic effects through the PKC pathway, either directly, through activities of some 
PKC iso forms, or indirectly, through further metabolism of PA to DAG.
This diversity in the source of PKC activators allows for the activation of both 
calcium-sensitive and -insensitive isoforms and the induction of long-term activation 
of PKC. However, the co-factor regulation between each PKC sub-class is similar, 
suggesting that mechanisms additional to second messenger binding fine-tune 
isoform-specific function. These mechanisms could include regulation by 
phosphorylation and regulation by targeting proteins.
1.6.2.3 Regulation by phosphorylation
PKC is phosphorylated at three positions in the kinase core in vivo (Tsutakawa et al, 
1995; Keranen et al, 1995). Most of the PKC in resting cells is in the triple 
phosphorylated form and these phosphorylations are thought to be involved in the 
regulation of the kinase since they increase its affinity for calcium and phorbol esters 
(Huang et al, 1986) and putative substrates such as HI histone (Mochly-Rosen and 
Koshland, 1987).
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In PKC pil, the phosphorylation sites are threonine 500, in the activation loop, and 
threonine 641 and serine 660, at the carboxy-terminus. Mutation of either threonine 
residue prevents activation of the enzyme (Cazaubon et al, 1994; Orr and Newton, 
1994; Zhang et al, 1994a). PKC is unable to autophosphorylate at threonine 500 in the 
activation loop, suggesting that another kinase phosphorylates at this position 
(Keranen et al, 1995). Phosphorylation at the activation loop, by the putative PKC 
kinase, appears to trigger the subsequent phosphorylation of threonine 641 and serine 
660 at the carboxy-terminus (Keranen et al, 1995). Phosphorylation of threonine 641 
appears to occur by autophosphorylation and to lock PKC in a catalytically competent 
conformation (Keranen et al, 1995). Phosphorylation at serine 660 also appears to 
occur by autophosphorylation and correlates with release of PKC in to the cytosol 
(Keranen et al, 1995). This suggests that the role of phosphorylation at this site is to 
direct the sub-cellular location of the enzyme. The activity and stability of PKC a  are 
controlled by similar multi-site phosphorylations (Gysin and Imber, 1997). The sub- 
cellular location and function of PKC isoforms may also be modulated by 
dephosphorylation at these key positions. For example, ceramide inactivates PKC a, 
probably by activating a phosphatase (Lee et al, 1996).
Additional phosphorylation at non-conserved residues may provide a mechanism for 
iso form- and stimulus-specific regulation of PKC iso forms. For example, PKC 5 can 
be phosphorylated on tyrosine which either activates or inhibits the enzyme (Denning 
et al, 1993; Gshwendt et al, 1994; Li et al, 1994; Soltoff and Toker, 1995; Denning et 
al, 1996). The activity of PKC a  is also altered by tyrosine phosphorylation in 
response to insulin (Liu and Roth, 1994). In addition, PKC a , pi, y, ô, s and Ç are 
tyrosine phosphorylated following treatment of cos7 cells with hydrogen peroxide. 
This increases activity by a mechanism apparently unrelated to receptor-coupled 
hydrolysis of inositol phospholipids (Konishi et al, 1997).
1,6.2.4 Regulation by binding proteins
A number of proteins that interact with PKC have been identified (Blobe et al, 1996; 
Jaken, 1996; Quest, 1996; Newton, 1997). PKC-binding proteins have three potential 
functions: i) regulating the activity of the enzyme (activators and inhibitors); ii) 
mediating down-stream effects of the enzyme (substrates) and iii) localisation of the
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protein in particular sub-cellular compartments (anchoring proteins or localisers). In 
addition to the substrate-binding site in the catalytic domain, the PS-binding sites in 
the regulatory domain (pseudo-substrate. Cl and C2) appear to be important for 
interactions with PKC binding proteins (Newton, 1995). For example; deleting the 
pseudo-sub strate domain of PKC a  decreases its affinity for binding proteins (Liao et 
al, 1994), the Cl motif of PKC 8 and the hinge region of activated PKC a  are 
involved in sub-cellular localisation (Lehel et al, 1995a; Lehel et al, 1995b; 
Staudinger et al, 1995) and C2 peptides inhibit PKC translocation and binding to 
putative PKC receptors (Ron et al, 1995).
It would seem apparent that isoform-selective phosphorylation of downstream targets 
should be the basis of isoform-specific functions in vivo. However, although a large 
number of proteins are phosphorylated by PKC, in vitro phosphorylation studies have 
not indicated a large degree of substrate specificity between isoforms (Hofmann, 
1997; Kazanietz, et al, 1993; Hug and Sarre, 1993; Pearson and Kemp, 1991). Certain 
proteins are efficient substrates for the conventional isoforms but not the novel PKCs 
(Hugg and Sarre, 1993). This suggests that the substrate specificity of individual PKC 
isoforms may be quite different. Indeed, distinct optimal sequences for each PKC 
isoform have been identified (Nishikawa et al, 1997). However, as of yet, the 
physiological substrates of individual PKC isoforms remain largely unknown. 
Similarly, although a number of proteins are known to modulate the activity of PKC 
(Blobe etal, 1996; Jaken, 1996; Quest, 1996; Hofmann, 1997), known PKC activators 
and inhibitors display little specificity for individual isoforms. Therefore, it may be 
that the intracellular substrate specificity of each PKC isoform is governed by various 
factors in vivo. These may include the concentration of target proteins, regulatory 
factors and the ability, of at least certain PKC isoforms, to interact with particular 
anchoring proteins (see below).
It has been established that different PKC isoforms localise to different sub-cellular 
compartments (Kiley et al, 1995; Jaken, 1996). RACKS (receptors for activated C 
kinase), are a group of proteins found in the particulate fraction of cells that bind to 
the active conformation of PKC and are thus thought to contribute to sub-cellular 
targeting (Mochly-Rosen, 1995). In addition, PKC a  and pll bind to certain forms of
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a multi-enzyme cytoskeletal scaffolding protein family, termed AKAPs (originally 
named as A-kinase anchoring protein; Klauck et al, 1996). Furthermore, PICKl 
(protein interacting with C-kinase) is a nuclear protein that specifically interacts with 
PKC a  and may, thus, provide a potential mechanism for selective intracellular 
targeting of this iso form (Staudinger et al, 1997). PKCs are mainly soluble proteins 
that translocate to membrane, cytoskeletal and nuclear compartments upon activation, 
therefore, targeting to appropriate domains via interaction with RACKS, AKAPS, 
PICKs and other proteins, may be central to their ability to respond efficiently to 
second messengers and have ready access to substrates.
1.6.2.5 Additional mechanisms o f  regulation
Many of the cellular effects of PKC, such as those on proliferation, differentiation and 
tumourigenesis, require long term changes in PKC activity that cannot be achieved by 
the short-lived turnover of inositol phospholipids during the PI cycle. To achieve 
long-term activation of PKC, either the activators of PKC must be elevated for long 
periods, or the levels of PKC isoforms must be increased. Indeed, both sustained 
increases in cellular levels of DAG (Fleischman et al, 1986; Wolfman and Macara, 
1987; Tuominen et al, 1993) and increased expression of PKC isoforms (Dobrowsky 
and Hannun, 1992; Blobe et al, 1993 a) have been described.
Thus, another mechanism of PKC regulation involves the differential expression of 
isoforms. A number of studies suggest that differential expression can occur at the 
transcriptional (Obeid et al, 1990; McSwine-Kennick et al, 1991), translational 
(McSwine-Kennick et al, 1991; Blobe et al, 1993b) and post-translational (Isakov et 
al, 1990; Huwiler et al, 1991) level.
1.6.3 Functions o f  protein kinase C isoforms
The identification of multiple PKC species has raised important questions with 
respect to the specific functions of individual isoforms. Isoforms display distinct 
regulatory properties and tissue distributions (Borner et al, 1992; Hata et al, 1993; 
Hug and Sarre, 1993; Selbie et al, 1993; Stabel and Parker, 1993; Akimoto et al, 
1994; Hirai et al, 1994; Dieterich et al, 1996). This is consistent with the suggestion
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that individual isoforms may serve diverse functional roles. Indeed, numerous studies 
suggest that specific isoforms may control distinct transcriptional events (Kieser et al, 
1995; Spence et al, 1995; Kieser et al, 1996; Wang et al, 1997). Although the precise 
functions of different PKC isoforms have still to be elucidated, it is clear, from a wide 
range of studies, that PKCs function in the regulation of a number of cellular 
processes including growth and differentiation, apoptosis, tumourigenesis and various 
cell functions (Hug and Sarre, 1993; Kindregan et al, 1994; Li et al, 1994; Glazer, 
1994; Borner et al, 1995; Hundle et al, 1995; Blobe et al, 1996; Acs et al, 1997; 
Deacon et al, 1997). The role of PKC isoforms in the regulation of those processes 
related to adipocyte development and function are discussed further below.
1.6.3.1 Regulation o f  signal transduction by protein kinase C 
PKC modulates signalling via the MAP kinase cascade. PKC may link Ras and Raf-1 
in this pathway since interaction of PKC with Ras has been suggested in vitro and in 
vivo (Diaz-Meco et al, 1994) and PKC has been shown to directly phosphorylate and 
activate Raf-1 (Kolch et al, 1993). PKC may activate Raf-1 only when Raf-1 is bound 
to Ras-GTP (Marais et al, 1998). PKC a  and 8 function as redundant activators of 
Raf-1 in vivo (Cai et al, 1997). In an intact cell assay system, PKC 5 activates the 
MAP kinase pathway in a Ras-independent, Raf-dependent manner (Ueda et al,
1996). PKC Ô has also been linked to MAP kinase activation in CHO cells 
(Yamaguchi et al, 1995) and 3T3-F442A preadipocytes (MacKenzie et al, 1997). 
Further evidence suggests that PKC a , 8 and Ç may also be involved in the activation 
of MAP kinases (Yamaguchi et al, 1995; MacKenzie et al, 1997; Berra et al, 1995).
Products of the PI 3-kinase reaction have been shown to activate certain PKC 
iso forms in vitro (Nakanishi et al, 1993; Toker et al, 1994). In 3T3-F442A 
preadipocytes, both PI 3-kinase (Kilgour et al, 1996) and PKC (MacKenzie et al,
1997) are required for the full activation of MAP kinases by GH. This suggests that, 
in 3T3-F442A preadipocytes, PI 3-kinase may lie upstream of PKC, which is 
upstream of MAP kinases. In addition, PKCs are required for the PI 3-kinase- 
dependent stimulation of p70®^  kinase by GH in these cells (Anderson, 1992 and 
1993).
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There is also some evidence that PKC is involved in the regulation of the ST AT 
pathway. The hematopoietic Tec kinase family member, Bmx, induces activation of 
ST AT 1, 3 and 5 in both mammalian and insect cells and this is specifically inhibited 
by PKC 5 (Saharinen, 1997). Further evidence suggests that insulin signalling via 
IRS-1 (De Fea and Roth, 1997; Chin et al, 1994) and PKB (Barthel et al, 1998) is also 
modulated by PKC.
1.6.3.2 Protein kinase C and cell cycle control
During the mid to late stages of the G1 phase of the cell cycle, cyclins D and E, acting 
together with cyclin-dependent kinases (cdks), phosphorylate Rb proteins (Sherr, 
1994; Heichman and Roberts, 1994). This releases Rb from E2F transcription factors, 
allowing E2F to activate S-phase genes (ie cell cycle entry; La Thangue, 1994; 
Weinberg, 1995; Weinberg, 1996). Inhibition of Rb phosphorylation is an early event 
leading to terminal differentiation and is essential for maintaining the post-mitotic 
state of differentiated cells (Chen et al, 1989; Gu et al, 1993). Phorbol esters stimulate 
or inhibit S-phase entry in a cell type-specific manner which may be due to the 
expression of different PKC isoforms (Kaibuchi et al, 1985; Rozengurt, 1986; Huang 
et al, 1987; Ohno et al, 1994). Indeed, in rat 3Y1 fibroblasts, over-expression of PKC 
a  inhibits E2F and S-phase whereas PKC ô and s enhance E2F activity and cell 
growth (Nakaigawa et al, 1996).
Association with cyclins and subsequent phosphorylation by an activating kinase are 
both important for cdk function (Pines, 1994; Nigg, 1996). PKCs can reduce cyclin 
levels and modulate cdk activation in a number of cells (Kosaka et al, 1993; Zhou et 
al, 1993; Zhou et al, 1994b; Sasaguri et al, 1996; Hamada et al, 1996). In addition, 
PKC can enhance cellular levels of cdk inhibitors, such as p21^ ^^  ^ and p27*^ ^^  (Huang 
et al, 1987; deVente et al, 1995; de Vente et al, 1996a; Livneh et al, 1996) and p21 
induction is strongly implicated in the growth-arrest associated with terminal 
differentiation (Parker et al, 1995; Halevy et al, 1995). The importance of cell cycle 
regulation by PKC isoforms in the differentiation process is demonstrated by ectopic 
expression of PKC r\ in NIH 3T3 cells following which, the otherwise non­
differentiating cells can be induced to differentiate in response to adipogénie stimuli 
(Livneh at al, 1996). This capacity for differentiation was found to correlate with a
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blockage in cell cycle progression due to increased expression of cdk inhibitors and 
reduced cyclin activity (Livneh et al, 1996). This control of the cell cycle by PKC is, 
therefore, a potential mechanism for regulating preadipocyte differentiation.
1.6.3.3 Protein kinase C and differentiation
A number of other lines of evidence suggest a functional role for PKC isoforms in the 
regulation of cellular differentiation. Sustained PKC activation is inhibitory to 
differentiation in 3T3-L1 cells (Sahai et al, 1994). Consequently, down-regulation of 
phorbol ester-sensitive isoforms of PKC by prolonged phorbol ester treatment 
stimulates adipose conversion of these cells (Yun and Scott, 1983). Indeed, PKC 
activation is inhibitory to differentiation in a number of cell lines (Minana et al, 1989; 
Felipo et al, 1990; Taoka et al, 1990) and antisense to PKC 5 accelerates the 
chemically induced differentiation of myeloid erythroleukaemia cells (Pessino et al,
1995). In contrast, PKC activators promote differentiation in Ob 1771 preadipocytes 
(Catalioto et al, 1992). Over-expression of PKC Ô in 32 D myeloid cells allows 
differentiation in response to phorbol esters (Mischak et al, 1993) and ectopic 
expression of PKC rj in otherwise non-differentiating NIH-3T3 cells, allows cells to 
differentiate into adipocytes in response to the appropriate stimuli (Livneh et al,
1996). Although sustained PKC activation is inhibitory to differentiation in 3T3-L1 
cells, levels of PKC 8 and PKC 0 are increased during 3T3-L1 preadipocyte 
differentiation (McGowan et al, 1996). Collectively, these studies suggest differential 
roles for individual PKC isoforms at distinct phases of the preadipocyte 
differentiation process.
1.6.3.4 Protein kinase C and growth hormone signalling
Several studies have produced evidence of a role for PKC in some of the signalling 
events mediated by GH. For example, GH has been shown to increase cellular levels 
of DAG, a natural activator of PKC, in various cells (Doglio et al, 1989; Catalioto et 
al, 1992). In addition, the inhibition/down-regulation of PKC by prolonged phorbol 
ester treatment of cells has been shown to attenuate the activation of MAP kinases and 
two S6 kinases by GH in 3T3-F442A preadipocytes (Anderson, 1992 and 1993). 
Evidence suggests that in the signalling pathways utilised by GH in 3T3-F442A 
preadipocytes, PKC lies downstream of PI 3-kinase and upstream of MAP kinases
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(Kilgour et al, 1996; MacKenzie et al, 1997) and p70®^  kinase (Anderson et al, 1992 
and 1993). Studies with Ob 1771 preadipocytes suggest that GH stimulates c-fos and 
lipoprotein lipase (LPL) gene transcription and terminal differentiation in general by 
PKC-dependent mechanisms (Ailhaud et al, 1992; Catalioto et al, 1992). Similar 
studies with 3T3-F442A cells suggest that the differentiation-promoting effects of GH 
involve enhanced transcription of Q-fos and c-juti (Gurland et al, 1990) and activation 
of MAP kinases (Campbell etal, 1992) by PKC-dependent mechanisms.
With regard to adipocyte metabolism, at least in the rat adipocyte, data are consistent 
with GH exerting inhibitory and stimulatory effects on lipogenesis and lipolysis 
resectively via signal transduction which is, at least in part, mediated by the activation 
of PKC (Smal and De Meyts, 1987; Gorin et al, 1990). Thus, one or more isoforms of 
PKC are likely to be involved in the signalling pathway(s) utilised by GH to regulate 
adipocyte development and function.
1.6.3.5 Protein kinase C and insulin signalling
Activation of PKC has been associated with states of insulin resistance. PKC appears 
to counter-regulate insulin action via induction of increased serine/threonine 
phosphorylation of the insulin receptor, which has been correlated with decreased 
insulin receptor tyrosine kinase activity (see Houslay, 1991) and with decreased 
ability of the insulin receptor to promote activation of the PI 3-kinase complex (Chin, 
1993). PKC activation also results in serine phosphorylation of IRS-1, which 
contributes to inhibition of insulin signalling (De Fea and Roth, 1997). These effects 
have been largely attributed to activation of the PKC a  iso form (Chin et al, 1994; 
Danielson et al, 1995). PKC also suppresses the insulin-mediated increase in PKB 
activity in 3T3-L1 adipocytes (Barthel etal, 1998).
Insulin responses are largely unaffected in cells in which the conventional and novel 
PKC isoforms have been down-regulated by chronic phorbol ester treatment 
(reviewed in Blackshear, 1994), implying that PKCs are not involved in the signalling 
pathways used by insulin to exert its effects. Such studies do not, however, rule out a 
role for the atypical PKC isoforms in mediating insulin responses. Indeed, atypical 
PKC Ç appears to be, at least in part, required for the stimulation of glucose transport
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by insulin in 3T3-L1 adipocytes (Bandyopadhyay et al, 1997).
Although the involvement of PKC in insulin signalling remains controversial, a 
number of studies suggest a role for PKC in some of insulin's effects. IRS-1 levels are 
positively regulated by PKC ô (deVente et al, 1996), suggesting a possible role for 
this isoform in insulin signalling. In addition, insulin translocates and activates several 
PKC isoforms in a number of cell types, including adipocytes (Farese et al, 1992; 
Arnold et al, 1993; Bandyopadhyay et al, 1997). Furthermore, PKC appears to be, at 
least in part, required for the stimulation of lipogenesis by insulin in rat adipocytes 
(Smal and De Meyts, 1987). Further evidence suggests that phorbol ester-sensitive 
PKC isoforms may play some role in the stimulation of glucose transport by insulin 
(Grunberger, 1991; Standaert et al, 1990b; Yano et al, 1993; Chalfant et al, 1995). 
The controversy surrounding the role of PKC in insulin signalling appears to be, at 
least in part, due to the existence of multiple isoforms.
Thus, a number of studies indicate that PKC may be involved in the regulation of 
adipocyte development and function. Abnormal regulation or expression of PKC 
isoforms may, therefore, contribute to the development of diseased states such as 
obesity and diabetes. Support for this suggestion comes from the observation that 
altered sub-cellular location and/or expression of PKC isoforms has been observed in 
association with diabetes in a number of cell types (Babazono et al, 1998; Tang et al, 
1993; Considine et al, 1995; Schmitz-Peiffer et al, 1997), including adipocytes 
(Frevert and Khan, 1996).
1.7 Aims o f  the project
Due to the central role of the adipocyte in the diseased states of obesity and diabetes, 
there has been increasing interest in the molecular processes that control adipocyte 
development and function. Although several lines of evidence implicate the PKC 
family in adipocyte regulation and the development of obesity, the precise roles of 
PKC in these processes remain unclear. This is primarily due to the existence of 
multiple isoforms of PKC.
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The aim of this study was to determine the roles of individual PKC isoforms in the 
regulation of adipocyte development and function using 3T3-F442A cells as a model 
system. Initially, the PKC complement of 3T3-F442A cells was thoroughly 
characterised. Attempts were then made to define the roles of the individual 3T3- 
F442A cell PKC isoforms in the process of preadipocyte differentiation. The 
involvement of specific PKC isoforms in the signalling mechanisms by which two 
key hormonal regulators of adipocyte metabolism, GH and insulin, alter the rate of 
lipid synthesis in differentiated 3T3-F442A cells was then investigated.
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Chapter!
Materials and Methods
2.1 Materials
2.1.1 Chemicals and reagents
General laboratory chemicals were obtained from ICN Biomedicals Ltd., Oxon, UK 
or BDH (Merck Ltd.), Leics, UK unless stated otherwise. All other reagents were 
obtained from Sigma Chemical Co., Dorset, UK unless stated otherwise.
Tissue culture plastic was purchased from Coming Costar Corp., Bucks, UK. Tissue 
culture media, supplements and lipofectin reagent were obtained from Life 
Technologies, Paisley, UK.
Pituitary derived ovine GH was obtained from the National Hormone and Pituitary 
Program, Bethesda, MD, USA and recombinant bovine GH was a gift from 
Monsanto, St. Louis, USA.
['"‘Cj-acetate was obtained from ICN. Scintillation cocktails and vials were purchased 
from Packard, Berks, UK unless stated otherwise.
2.1.2 Cell lines
3T3-F442A and 3T3-C2 cells (Green and Kehinde, 1976) were provided generously 
by Dr Howard Green, Harvard Medical School, USA. NIH-3T3 cells which had been 
stably transfected to over-express PKC a, p, y, ô, s, Q and r\ (Goodnight ei al, 1995) 
were a generous gift from Dr Jo Anne Goodnight, NCI, Bethesda, USA.
2.1.3 Antibodies
Anti-PKC a, pi/II, y, 5, s, Ç, 0, i, X and p. mouse monoclonal antibodies were 
purchased from Affiniti Research Products Ltd., Notts, UK and were raised using 18 -
25.3 kDa fragments of rat (PKC a, 5, s and y), mouse (PKC 0 and X) or human (PKC 
p i / n .  I ,  p and Q  PKC proteins as immunogens. Polyclonal antisera to PKC a , p i / n ,  y, 
5, 8 and Ç were raised previously in-house (Tang et al, 1993). Corresponding peptide 
immunogen for PKC (amino acid sequence; GFEYINALLLSAEESV) was 
synthesised by Dr Jim Beattie, Hannah Research Institute, Ayr. Polyclonal antisera to 
PKC p i ,  T | and 0 (Marais and Parker, 1989), and corresponding peptide immunogen
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for PKC pi (amino acid sequence; SEFLKPEVKS), were supplied kindly by Dr Peter 
Parker, Imperial Cancer Research Fund, London. An additional polyclonal antiserum 
to PKC T|, raised using a short fragment of mouse PKC protein as immunogen, and 
corresponding peptide immunogen (amino acid sequence; DEFRNFSYVSPELQL), 
were purchased from Insight Biotechnologies, Middlesex, UK. HRP-conjugated sheep 
anti-mouse IgG and goat anti-rabbit IgG were obtained from Amersham International 
pic, Bucks, UK and Sigma respectively.
2.1.4 OUgodeoxynucleotides
Phosphorothioate-modified s-oligodeoxynucleotides (ODNs) were purchased from 
Genosys Biotechnologies, Cambs, UK. The antisense sequences designed to hybridise 
to the PKC isoforms of interest and the corresponding sense (control) sequences are 
shown in Table 2.1. The anti sense ODN sequences for PKC a, 8 and Ç were based on 
the start codons (ATG) plus the 15 (or 12 in the case of PKC 0  additional 
downstream bases in the murine PKC sequences. The anti sense sequence for PKC 5 
was based on nucleotides 10-27 of the coding sequence of murine PKC d. These 
antisense ODN sequences have been used successfully by others (Xu et al, 1994; 
DeCoy et al, 1995; Folgueira et al, 1996). The antisense ODN sequences for PKC y 
and |i used in this study were, therefore, derived from similar sequences; the start 
codons plus the 15 additional downstream bases the murine (Bowers et al, 1993) and 
human (Johannes et al, 1994) PKC sequences respectively. The anti sense sequence 
for PKD, corresponding to nucleotides 694-711 of the coding sequence of murine 
PKD (Valverde et al, 1994), was derived from a portion of the PKD sequence which 
is not present within the highly homologous PKC p. sequence.
2.1.5 Rats
Female Wistar rats (A Tuck and Son, Rayleigh, Essex) were fed on SDS CRM(E) 
non-irradiated diet (SDS, Essex, UK) with water freely available. Age-matched rats of 
150-180 g were used for experimental purposes.
40
Table 2.1 Protein kinase C isoform-specific oligodeoxynucleotide sequences
ODN Sequence 5' -> 3* Accession No. Nucleotides
PKC a  Antisense -CGG-GTA-AAC-GTC-AGC-CAT-
PKCy Antisense -AGG-GCC-CAG-ACC-CGC-CAT-
PKCÔ Antisense -GAA-GGA-GAT-GCG-CTG-GAA-
PKC 8 Antisense -GCC-ATT-GAA-CAC-TAC-CAT*
PKCC Antisense -GGT-CCT-GCT-GGG-CAT-
PKC p. Antisense -GAC-CGG-AGG-GGC-GCT-CAT-
PKD Antisense -AAA-GCC-AGG-GCT-CAC-AGG-
M25811
X67129
X60304
AF028009
M94632
X75756
Z34524
256-273
68-85
23-40 
10-27
24-38 
236-253 
819-836
PKC a  
PKC Y 
PKCÔ 
PKC 8 
PKCC 
PKCn 
PKD
Sense
Sense
Sense
Sense
Sense
Sense
Sense
-ATG-GCT-GAC-GTT-TAC-CCG-
-ATG-GCG-GGT-CTG-GGC-CCT-
-TTC-CAG-CGC-ATC-TCC-TTC-
-ATG-GTA-GTG-TTC-AAT-GGC-
-ATG-CCC-AGC-AGG-ACC-
-ATG-AGC-GCC-CCT-CCG-GTC-
-CCT-GTG-AGC-CCT-GGC-TTT-
2.2 Methods
2.2.1 Cell culture
2.2.1.1 Culture o f  3 T3-F442A preadipocytes
3T3-F442A preadipocytes (Green and Kehinde, 1976) were cultured in Dulbecco's 
modified Eagle's medium (DMEM) containing 2 mM glutamine (basic medium) 
supplemented with 100 units/ml penicillin, 100 //g/ml streptomycin (pen/strep) and 
10% (v/v) newborn calf serum (growth medium) in a 90% 02:10% CO2 atmosphere at 
37° C Stock cultures were passaged routinely at approximately 80 % confluence. For 
experimental purposes, preadipocytes were seeded at 10^  cells/dish and grown to 
confluence in growth medium in 100 mm diameter dishes unless stated otherwise. 
Cells were deprived of serum for 16-20 h prior to harvesting (or treatment) unless 
stated otherwise.
2.2.1.2 Differentiation o f  3T3-F442A preadipocytes
For conversion to adipocytes, 3T3-F442A preadipocytes were used at passages 6 to 
12 and grown to confluence. Two day confluent cultures were induced to differentiate 
by replacing the growth medium with basic medium supplemented with pen/strep and 
containing 10% foetal calf serum (FCS) and 1 //M insulin (Sigma Cell Culture, INS). 
The differentiation medium was replenished after 72 h and insulin removed from the 
medium on day 8. Under these conditions at least 80% of cells were converted to 
adipocytes. Adipocytes were typically harvested (or treated) ten days from induction 
of adipogenesis following a 16-20 h incubation in serum-free medium, unless stated 
otherwise.
For some experiments, parallel preadipocyte cultures were maintained in growth 
medium for twelve days. These cells, which displayed no morphological change, are 
referred to as twelve-day confluent cells (12 DC cells).
2.2.1.3 Culture o f  NIH-3T3 cells over-expressing protein kinase C isoforms 
NIH-3T3 cells which had been stably transfected to over-express PKC isoforms a , P,
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y, ô, s, (  and rj (Goodnight et al, 1995) were grown to confluence in basic medium 
supplemented with pen/strep and containing 10 % FCS. Cells were deprived of serum 
for 16-20 h prior to harvesting and preparation of lysates for use as positive controls 
on immunoblots.
2.2.1.4 Culture o f  3T3-C2 cells
3T3-C2 cells (Green and Kehinde, 1976) were treated identically to 3T3-F442A cells, 
as described in sections 2.2.1.1 and 2.2.1.2
2.2.2 Preparation and treatment o f  cultured cells
2.2.2.1 Acute stimulation o f  3T3-F442A cells with phorbol ester
Stock solutions of TP A were prepared in DMSO and stored at -20° C prior to use. 
Cells were stimulated with TP A in the absence of serum for 10 min in basic medium; 
10 nM TP A for preadipocytes and 100 nM TP A for adipocytes. Control cultures were 
incubated with diluent. Cells were washed with 10 ml of ice-cold PBS to terminate 
reactions prior to harvesting and preparation of cytosol and membrane fractions for 
immunoblotting.
2.2.2.2 Chronic stimulation o f  3T3-F442A preadipocytes with phorbol ester
Confluent 3T3-F442A preadipocytes were treated with TP A to down-regulate the 
phorbol ester-sensitive isoforms of PKC essentially as described by Blackshear et al 
(1985). Briefly, cells were washed three times with basic (serum-free) medium and 
then incubated in this medium containing 1% BSA (w/v. Sigma fraction V) in the 
presence of 16 pM or 500 nM TP A for 0-48 h prior to harvesting and preparation of 
lysates for immunoblotting. Times of initiation of TPA treatments were staggered to 
allow simultaneous harvesting of cells. Control cultures were treated identically and 
incubated with diluent.
2.2.13 Chronic stimulation o f  3T3-F442A adipocytes with growth hormone and 
insulin
Fully differentiated 3T3-F442A adipocytes were incubated for 24 h in serum-free
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basic medium in the presence or absence of 4.5 nM GH or 8.7 nM insulin, either 
alone or in combination, prior to the assessment of lipogenesis or the preparation of 
lysates for assessment of immunoreactive PKC levels by immunoblotting.
2.2.2.4 Treatment o f  3T3-F442A cells with protein kinase C isoform-specific- 
oligodeoxynucleotides
2.2.2.4.1 Oligodeoxynucleotide treatment o f  3 T3-F442A preadipocytes 
ODNs were dissolved in water and stored at -20° C until required. 3T3-F442A 
preadipocytes were cultured in 30 mm diameter wells. At typically 70-80 % 
confluence, cells were treated with antisense ODNs specific for the individual 
isoforms of PKC (Table 2.1). The appropriate isoform-specific sense ODNs were 
used as controls (Table 2.1).
Transfections were carried out in the absence of serum and antibiotics in basic 
medium which had been pre-filtered through a 0.22 pm Nalgene syringe filter (Fisher 
Scientific, Leics, UK). Prior to treatment of cells, appropriate dilutions of ODN and 
lipofectin were prepared in 100 pi volumes in filtered medium and pre-incubated at 
room temperature for 30 min with occasional mixing. The ODN and lipofectin 
mixtures were then combined and incubated for 30 min at room temperature with 
occasional mixing. Preadipocytes were washed twice with 1 ml of filtered medium 
prior to the addition of the ODN/lipofectin mixture in order to remove traces of serum 
and antibiotics from the cells. Reagents were added to give a final concentration of 10 
pM ODN and 20 pg/ml lipofectin in a total volume of 1 ml. Cells were incubated 
with the ODN/lipofectin mixture for 6 h at 37° C. Cell monolayers were then washed 
twice with 2 ml of medium prior to the addition of fresh medium containing 10 % 
heat-treated (55° C, 30 min) calf serum (pre-filtered through a 0.45 pm syringe filter) 
and the appropriate concentration of ODN but no lipofectin reagent. After a further 42 
h, cells were either assessed for immunoreactive PKC levels by immunoblotting or 
induced to differentiate by addition of medium containing 10 % heat-treated foetal 
calf serum (pre-filtered through a 0.45 pm syringe filter) and 1 pM insulin. The 
appropriate concentration of ODN was present throughout the treatment period with 
differentiation-inducing agents.
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2 2 2 4.2 OUgodeoxynucleotide treatment o f  3 T3-F442A adipocytes 
3T3-F442A cells were grown and differentiated in 30 mm diameter wells. Adipocytes 
were treated with sense or anti sense ODNs specific for the individual isoforms of 
PKC and PKD at day 8 of differentiation. Adipocytes were washed twice with 1 ml of 
filtered antibiotic- and serum-free medium prior to the addition of the ODN/lipofectin 
mixture which was prepared as described in section 2.2.2.4.1 Reagents were added to 
give a final concentration of 20 pM ODN and 40 pg/ml lipofectin in a total volume of 
1 ml. Cells were incubated with the ODN/lipofectin mixture for 6 h at 37° C and then 
washed twice with 2 ml medium prior to the addition of fresh medium containing 10 
% heat-treated foetal calf serum and the appropriate concentration of ODN but no 
lipofectin reagent. After a fiirther 42 h, cells were either assessed for immunoreactive 
PKC levels by immunoblotting or chronically incubated with hormones prior to the 
assessment of lipogenesis.
2 .2 2 5  Oil red O staining o f  3T3-F442A cells
3T3-F442A preadipocytes were pre-incubated with PKC isoform-specifc ODNs as 
described in section 2.2.2.4.1 and induced to differentiate with FCS/INS. Oil red O 
was used to stain cell lipids according to the method of Pearse (1968) at day 7 of 
differentiation. Cells were washed with 1 ml of PBS per 30 mm well and fixed for 1 h 
by incubation with 1 ml of 10 % formalin (40% formaldehyde in PBS, 1:4 [v/v]) per 
30 mm well. Stock solutions of oil red O were prepared in isopropanol, diluted 6:4 
(v/v) in H2 O and filtered through Whatman number 1 filter paper prior to use. Cells 
were overlayed with 1 ml of Oil red O filtrate for 1 h at room temperature. Stain was 
then removed and monolayers were washed with H2 O until all excess traces of stain 
were removed from the washing solution. Cells were then photographed under Phase 
Contrast Optics (x 24 magnification) using an Olympus IMT3 inverted microscope.
2.22.6 Preparation o f  lysates from  cultured cells
Cells were washed with 10 ml ice-cold PBS and harvested by scraping into lysis 
buffer (25 mM Hepes pH 7.4, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 30 mM Na 
pyrophosphate, 1% [v/v] triton X-100, 10% [v/v] glycerol, 1 mM Na orthovanadate, 1 
mM PMSF and 2 //g/ml each of aprotinin, pepstatin A and leupeptin). Lysates were
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prepared by rotation for at least 20 min at 4° C and clarified by centrifugation at 14 
000 g for 10 min at 4° C in a Camlab refrigerated microfuge. The supernatant was 
removed carefully and denatured by adding 0.25 volumes of 5 x concentrated SDS- 
sample buffer (312.5 mM Tris pH 6.7, 6.25% SDS, 62.5% glycerol, 12.5% P- 
mercaptoethanol) and boiling for 5 min. Denatured supernatants were stored at -20° C 
prior to use on immunoblots.
2.2.2.7 Preparation o f  homogenates from  cultured cells and sub-cellular 
fractionation
3T3-F442A cells were acutely stimulated with phorbol ester as described in section
2.2.2.1. Cells from ten 100 mm diameter plates (preadipocytes), or five 100 mm 
diameter plates (adipocytes), were harvested in 500 pi of homogenisation buffer (20 
mM Tris pH 7.5, 10 mM EDTA, 10 mM EGTA, 255 mM sucrose, 1 mM NaF, 1 mM 
Na pyrophosphate, 20 mM P-mercaptoethanol, 1 mM PMSF, 1 mM Na vanadate and 
20 pg/pl each of leupeptin, aprotinin, and pepstatin A) and homogenates were 
prepared on ice in a Dounce homogeniser (60 strokes). Following centrifugation at 14 
000 g for 10 min at 4° C in a Camlab refrigerated microfuge, supernatants were 
removed for further fractionation.
Supernatants were spun at 100 000 g for 30 min at 4° C in a Beckman Optima TLX 
refigerated ultrafuge fitted with a TLA rotor. The cytosolic fraction (supernatant) was 
removed carefully and boiled in 0.25 volumes of 5 x concentrated SDS-sample buffer 
for 5 min. The particulate fraction (pellet) was rinsed with 250 pi of homogenisation 
buffer, in order to minimise contamination from the cytosolic fraction, and re­
centrifuged at 100 000 g. The soluble membrane fraction was extracted from the 
pellet by resuspension of the particulate fraction in 250 pi of homogenisation buffer 
containing 1% (v/v) triton X-100, using a syringe and 26 guage needle, followed by 
an incubation on ice for 30 min. A final 100 000 g centrifugation step was used to 
remove insoluble material (the triton-insoluble cytoskeleton) from the membrane 
extract which was then boiled in 0.25 volumes of 5 x concentrated SDS-sample buffer 
for 5 min. Denatured sub-cellular fractions were snap-frozen in liquid nitrogen and 
stored at -70° C prior to use on immunoblots.
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2.2.2.8 Glycerol-3~phosphate dehydrogenase Assay
Cells were washed with ice-cold PBS and homogenates were prepared on ice in 
GPDH assay buffer (100 mM triethanolamine pH 7.5, 2.5 mM EDTA, 0.1 mM P- 
mercaptoethanol) by subjecting cell suspensions to eight passages through a 26 guage 
needle. Samples of homogenate were retained at this point for determination of 
protein or DNA content as described in sections 2.2.4.1 and 2.2.2.10 respectively, 
while remaining homogenate was centrifuged at 14000 g for 10 min at 4° C in a 
Camlab refrigerated microfuge. The resulting supernatant was removed and stored at - 
20° C prior to the determination of GPDH activity.
GPDH activity was determined by the spectrophotometric method of Wise and Green 
(1979) in assay buffer containing 0.12 mM P-NADH and 0.2 mM dihydroxyacetone 
phosphate. Absorbances at 340 nm were read in a CE 5501 double beam UV 
spectrophotometer at 30 s intervals over an appropriate time period. Enzyme activity 
was expressed as pmol NADH oxidised/min/mg protein or mg DNA.
2.2.2  9 Lipogenesis Assay
Following the chronic treatment of PKC- or PKD-depleted adipocytes with hormones, 
the rate of lipogenesis was determined by the incorporation of radiolabelled acetate 
into cell lipid by a modification of the method described by Vernon and Finley 
(1988). 3T3-F442A adipocytes, in 30 mm wells, were incubated for 4 h with basic 
medium supplemented with 2 mM acetate and 1 pCi/ml [^^C]-acetate. Adipocytes 
were lysed by the addition of GIT buffer (0.1 M EDTA pH 8.0 containing 5 M 
guanidine thiocyanate, Melford Laboratories Ltd, Suffolk, UK). Lysates were 
transferred to eppendorf tubes and lipids were extracted by addition of an equal 
volume of water-saturated chloroform followed by mixing and centrifugation at 10 
000 g for 5 min in a Camlab refrigerated microfuge. The upper aqueous layer was 
carefully removed for determination of DNA content as described in section 2.2.2.10. 
The lipid-containing chloroform layer was transferred to a glass mini-scintillation vial 
and allowed to dry overnight. Samples were then dissolved in a scintillation cocktail 
comprised of toluene-based scintillation fluid and EcoLite (ICN), 1:4, and counted in 
a Packard 1600 TR liquid scintillation analyser. The rate of lipogenesis was expressed 
as pmol acetate incorporated/h/ mg of DNA.
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2.2.2.10 DNA Assay
DNA was assayed according to the method of Labarca and Paigen (1980) using calf 
thymus DNA as a standard. Standards and samples were incubated with 1 pg/ml 
Bisbenzimide (H33342; Fluka Chemicals, Dorset, UK) for 20 min and fluorescence 
read in a Perkin-Elmer LS-5 luminescence spectrometer (excitation 360, emission 
475).
Samples of homogenate that had been retained during the preparation of extracts for 
the assay of GPDH activity were extracted with four volumes of water-saturated 
chloroform to remove cellular lipid from the samples prior to assay of DNA content.
2.2.3 Preparation and treatment o f  rat tissues
2.2.3.1 Immunoneutralisation o f  circulating rat growth hormone 
All procedures were conducted strictly according to regulations laid down by the 
Home Office under the Animals (Scientific Procedures) Act 1986. Animals were 
handled regularly prior to treatments to minimise stress.
Subcutaneous injections were administered twice daily, at 0900 and 1700 h, for 4 days. 
Rats received the following; y-globulin fraction of antiserum to rat growth hormone 
(a-rGH; 150 mg/injection, equivalent to 4.5 ml serum, reconstituted in sterile saline), 
either alone, or in combination with ovine GH (oGH; 1 mg/injection prepared in 7.5% 
bicarbonate:25% polyvinylpyrrolidone [PVP, 1:4]). Control animals received 
equivalent injections of carrier solution. Details of the preparation and characterisation 
of a-rGH, which is specific for rGH and does not recognise oGH, have been described 
previously (Madon et al, 1986). This antiserum was provided generously by Dr. David 
Flint, Hannah Research Institute, Ayr. Between 1000 and 1100 h on day 5, rats were 
anaesthetised by intraperitoneal injection with SagatafHypnorm (10:1, 0.1 ml per 
gram body weight) and samples of blood taken for extraction of serum and assessment 
of IGF-I levels as described in section 2.2.3.7. Parametrial fat pads were removed, 
weighed rapidly and placed in saline at 37° C prior to the preparation of adipocyte
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homogenates as described in section 2.2.3.2.
2.2.3.2 Isolation o f  rat adipocytes and homogenate preparation
Parametrial fat pads were removed from female Wistar rats under anaesthesia as 
described in section 2.2.3.1. Fat pads were washed in Krebs-Ringer-Hepes buffer 
(KRH; 25 mM Hepes pH 7.4, 2 mM glucose, 119 mM NaCl, 4.95 mM KH2 PO4 , 1.19 
mM MgS0 4 , 2.5 mM CaCl2 ) at 37° C and minced finely. Adipocytes were extracted 
by digestion with 1 mg collagenase per ml (Sigma type II) in KRH containing 200 nM 
adenosine. Digestion was carried out for 1 h at 37° C in stoppered flasks shaking at 80 
oscillations per min. Cell suspensions were filtered through nylon mesh to remove any 
undigested material and washed twice in KRH and twice again in TES buffer (20 mM 
Tris pH 7.4, 1 mM EDTA, 255 mM sucrose). Cells were re-suspended at room 
temperature in 500 pi TES buffer containing 2 pg/ml aprotinin, pepstatin A and 
leupeptin and 1 mM PMSF. Homogenates were prepared at room temperature by 
subjecting cell suspensions to 10 strokes with a syringe and 26 guage needle followed 
by centrifugation at 300 g for 10 min at 4° C in a Sorvall RC-5B refrigerated 
centrifuge fitted with an SS-34 rotor. The infranatant was removed carefully, boiled 
for 5 min in 0.25 volumes of 5 x concentrated SDS-sample buffer and stored at -20° C 
prior to use on immunoblots.
2.2.3.3 Determination o f  number o f  adipocytes per gram tissue
In studies involving the adipocyte preparations from rats treated with a-rGH (and the 
adipocyte preparations from the appropriate control rats), aliquots of cell suspension, 
prior to homogenisation, were placed at 37° C until transfer to a warm 
haemocytometer, where the diameter of one hundred cells was measured using a 
Projectina microscope (x 145 magnification). The mean cell volume (mcv) was 
calculated and an estimate of the number of cells per gram tissue was obtained by 
dividing total lipid content of the tissue by the average lipid content of the fat cells as 
described by Di Girolamo et ur/ (1971). Lipid content of the adipose tissue was taken to 
be equal to its dry weight and the average lipid content of the fat cells derived from the 
mcv X density of lipid (density of lipid was taken to be 0.9).
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2.2.3.4 Acute phorbol ester treatment o f  rat adipocytes
Parametrial fat pads were dissected and adipocytes extracted by collagenase digestion 
essentially as described in section 2.2.3.2 but with the addition of 3% BSA (w/v) to 
the KRH solution. Cells were then washed four times in BSA-free KRH, re-suspended 
in 20 ml of this medium plus 200 nM phenylisopropyladenosine (PIA) and allowed to 
equilibrate for 10 min at 37° C with constant shaking at 110 oscillations per min. 
Isolated adipocytes were then incubated with 100 nM TP A for 10 min at 37° C. 
Reactions were terminated by rapidly separating the cells from the incubation medium 
by centrifugation at 180 g in a Mistral 2000 centrifuge; centrifugation was terminated 
immediately at 180 g. 0.33 volumes of homogenisation buffer (20 mM Tris-HCl pH 
7.5, 10 mM EGTA, 10 mM EDTA, 255 mM sucrose, 1 mM NaF, 1 mM Na 
pyrophosphate, 20 mM p-mercaptoethanol, 1 mM PMSF, 1 mM Na vanadate and 20 
//g/pl each of leupeptin, aprotinin and pepstatin A) was then added to the cells and 
homogenates prepared by 10 strokes with a syringe and 26 guage needle performed at 
room temperature. After centrifugation at 300 g for 10 min at 4° C in a Sorvall RC-5B 
refrigerated centrifuge fitted with an SS-34 rotor, the infranatant was removed for 
further fractionation. Subcellular fractionation was carried out as described for 
cultured cells in section 2.1.11.
2.2.3.5 Preparation o f  rat brain homogenate
Rat brain homogenates were prepared essentially according to the method of Kuo et 
al (1980). Following dissection of midbrains, all procedures were carried out at 4° C. 
Brains were washed in ice-cold PBS and snap-frozen in liquid nitrogen. The tissue 
was then cryo-pulverised and homogenised in six volumes of homogenisation buffer 
(25 mM Tris pH 7.5, 2.5 mM EGTA, 250 mM sucrose, 2.5 mM MgCb, 50 mM P- 
mercaptoethanol, 1 mM Na vanadate, 1 mM PMSF and 2 pg/ml each of leupeptin, 
aprotinin and pepstatin A) using a polytron homogeniser at setting 4 for 20 sec. 
Homogenates were spun at 1000 g for 10 min at 4° C in a Sorvall RC-5B refrigerated 
centrifuge fitted with an SS-34 rotor. The supernatant was passed through buffer- 
moistened glass wool and mixed with 1% (v/v) triton X-100 for 1 h at 4° C. Following 
a second spin at 1000 g the supernatant was boiled in 0.25 volumes of 5 x 
concentrated SDS-sample buffer for 5 min and stored at -70° C prior to use as a 
positive control on immunoblots.
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2.2.3.6 Preparation o f  serum from  whole blood
Blood samples were taken from rats that had been treated with a-rGH (and the 
appropriate control rats) and allowed to clot on ice for at least 1 h. Serum was 
obtained from whole blood by centrifugation at 1800 g for 10 min at 4° C in a 
Heraeus Sepatech minifuge and stored at -20° C prior to extraction and assay of IGF- 
I.
2.2.3.7 Assay o f  insulin-like growth factor-I
Endogenous IGF-I levels were determined by radioimmunoassay using a modified 
double-antibody technique. Assays were performed in RIA buffer (60 mM NaH2P0 4  
pH 7.4, 0.9 % (w/v) NaCl, 0.5 % (w/v) BSA, 0.1 % (w/v) thimerosal). The major 
IGF-binding proteins were extracted from the serum by addition of 4 volumes of acid 
ethanol (2 M HCL:95 % ethanol [1:7 v/v]) followed by mixing and incubation at 
room temperature for 30 min. After centrifuging at 1700 g for 5 min in a Camlab 
microfuge, an equal volume of neutralisation buffer (RIA buffer containing 330 mM 
Tris) was added. Extracted serum samples were then diluted a further 10-fold (100- 
fold final dilution) in RIA buffer. Diluted sample (100 pi) was mixed with an equal 
volume of a 1/2000 dilution of anti-IGF-I first antibody (NIDDK and NHPP, 
University of Maryland School of Medicine, USA) and pre-incubated for 24 h at room 
temperature before adding 100 pi of [^^^I]-IGF-I (20,000 cpm/tube) for a further 24 h. 
Complexed IGF-I antibody was precipitated by adding 300 pi of donkey anti-rabbit 
IgG precipitating serum (Scottish Antibody Production Unit, Carluke, UK) diluted in 
RIA buffer containing 10 mM EDTA and 16 % polyethylene glycol (PEG:antibody, 
15:1). After incubating at room temperature for 4 h and centrifugation at 1700 g for 
30 min in a Heraeus Sepatech Omnifuge, the supernatant was decanted and the 
radioactivity in the pellets counted in a gamma counter (Cobra Autogamma, Packard). 
The IGF-I concentration of the serum samples was determined by interpolation from a 
standard curve (0.625-625 ng/ml IGF-I, Bachem UK, Ltd., Essex, UK). The IGF-I 
standard was iodinated as described previously (Fraker and Speck, 1978) and treated 
identically to the serum samples throughout the assay.
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2,2.4 Immunoblotting
2.2.4.1 Protein Assays
Protein content of samples was determined by the method of Bradford (1976) using 
BSA as a standard. Samples were incubated with Bio-Rad Protein Assay reagent 
(Bio-Rad Labs. Ltd., Herts, UK) and absorbances were read in a Titertek Multiskan at 
600 nm.
2.2.4.2 Standard gel electrophoresis
Protein samples were resolved by SDS-PAGE on 16 cm  ^9% gels. Gels were run at 7- 
30 mA in a Protean II x i vertical electrophoresis system (Bio-Rad). The composition 
of the running buffer was 49.5 mM Tris pH 8.3, 190 mM glycine and 3.5 mM SDS. 
Proteins were transferred to Hybond-C Super nitrocellulose membranes (Amersham) 
in a Transphor electrophoresis-transfer unit with power lid (Hoeffer UK) for 2 h at 
400 mA in ice-cold transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 20% 
methanol). Electrophoresis and transfer procedures were carried out at room 
temperature using water-fed cooling systems.
2.2.4.3 Mini-gels
For some experiments, the protein content of samples was examined by Coomassie 
Blue staining of mini-gels. 5 pg of sample was resolved by SDS-PAGE on 7.5 cm  ^
9% mini-gels using a Bio-Rad mini-gel apparatus. Gels were run at 30 mA for 
approximately 1 h, therefore no cooling system was required. Gels were then 
incubated with Coomassie Brilliant Blue (1 g/1 prepared in methanol:acetic acid:H20, 
5:1:5 [v/v], pre-filtered through Whatman number 1 filter paper) for 1 h to stain 
proteins. Excess dye was removed by overnight incubation with de-stain (7 % acetic 
acid, 5 % ethanol) and further washing with this solution until protein bands could be 
clearly visualised.
Protein concentration of samples was compared visually and protein assays repeated 
if samples did not contain equivalent protein concentrations (Figure 2.1). Coomassie 
staining of proteins was also performed following sub-cellular fractionation to 
confirm that cytosol and membrane samples had been separated (Figure 2.2).
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2.2.4.4 Immunodetection o f  protein kinase C isoforms
Nitrocellulose was stained with Ponceau S solution (1% acetic acid, 0.5% ponceau S), 
to allow the position of the non-prestained high molecular weight standards (Sigma) 
to be marked, then washed several times with distilled water. Active sites were 
blocked by incubation of membranes in Tris-buffered saline with 0.1% Tween-20 
(TBS-Tween; 19.98 mM Tris pH 7.4, 154 mM NaCl, 0.1% Tween-20) containing 3% 
BSA (w/v). TBS-Tween containing BSA was filtered through Whatman number 1 
filter paper prior to use. Membranes were blocked for at least 16 h at room 
temperature then rinsed twice with TBS-Tween followed by two 5 min washes with 
vigorous shaking.
A panel of monoclonal antibodies and anti-peptide antisera (See section 2.1.3) was 
used to screen samples for the presence of PKC isoforms. PKC a, (31/11, y, Ô, s, Ç, 0, X, 
I and p mouse monoclonal antibodies (Affmiti) were used at the dilution 
recommended by the manufacturer, namely; 1:5000 for a  and y; 1:2500 for (3; 1:1000 
for Ô and p; 1:500 for e and C and 1:250 for 0, X and i. Polyclonal antisera to PKC a, 
(3, y, Ô, sand Ç (Tang et al, 1993) were used at a dilution of 1:5000. Polyclonal 
antisera to PKC pi, r\ and 0 (Marais and Parker, 1989) were used at a dilution of 
1:2000. The commercial polyclonal antiserum to PKC r| (Insight Biotechnologies) 
was used at a dilution of 1:500. All antibodies referred to were diluted in TBS-Tween 
containing 1% BSA (filtered as before) and all washes of the nitrocellulose were with 
TBS-Tween.
Primary antibodies were incubated with the membranes for 2 h at room temperature 
with gentle shaking. Membranes were then rinsed twice followed by one 15 min and 
two 5 min washes with vigorous shaking.
For some experiments, primary antibody incubations were carried out in the presence 
of excess immunising peptide (1 mg/ml). Antibody and antigen were pre-coupled by 
incubation of serum and peptide in 100 pi TBS-Tween for 30 min at room 
temperature. Antiserum was added to give the desired concentration upon final 
dilution in TBS-Tween containing 1 % BSA. The complexed antibody solution was
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then incubated with the membranes as described above. During all peptide 
competition studies, control (uncomplexed) anti serum was treated identically and 
immunoblotting in the presence or absence of peptide was carried out simultaneously.
The corresponding secondary antibodies were HRP-conjugated sheep anti-mouse IgG 
or goat anti-rabbit-IgG and were used at a dilution of 1:5000. Secondary antibodies 
were incubated with the membranes for 1 h at room temperature with gentle shaking. 
The membranes were rinsed three times followed by one 15 min and four 5 min 
washes with vigorous shaking. Immunoreactive bands were visualised using an ECL 
detection system (Pierce and Warriner [UK] Ltd, Chester, UK). Densitometric 
analysis of immunoreactive bands was performed using a Molecular Dynamics 
Personal Densitometer and ImageQuaNT image-analysis software.
2.2.5 Statistical Analysis
Results are presented as means ± S.E.M. and, unless stated otherwise, statistical 
analysis was by Student's t-test for paired samples.
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Figure 2.1 Comparing protein concentration o f  cellular preparations by Coomassie 
Blue staining
For some experiments the protein content of different cellular preparations was 
examined, prior to immunoblotting, by Coomassie Blue staining of mini-gels. Equal 
quantities (5 pg) of cellular protein were resolved by SDS-PAGE and stained with 
Coomassie Blue as described in section 2.2.4.3. The intensity of staining of the 
different preparations was compared visually to confirm that the protein content was 
equal. Representative gels are presented containing 5 pg of lysate protein prepared 
from just confluent 3T3-F442A preadipocytes (lanes 1-3 and 7-9) and twelve day- 
confluent 3T3-F442A preadipocytes (lanes 4-6 and 10-12).
Figure 2.2 Confirming sub-cellular fractionation by Coomassie Blue staining
Sub-cellular fractions were prepared from 3T3-F442A cells and rat adipocytes as 
described in section 222.1. Equal quantities (5 pg) of cellular protein were resolved 
by SDS-PAGE and stained with Coomassie Blue as described in section 2.2.4.3. The 
protein banding patterns of samples were compared to confirm that the cytosolic and 
membrane fractions had been separated. Representative gels are presented containing 
5 pg of rat adipocyte cytosol (lane 1) and membrane (lane 2) protein preparations.
Chapter 3
Characterisation of protein kinase C isoforms in 3T3 
F442A cells and rat adipocytes
3.1 Introduction
Since the discovery that tumour-promoting phorbol esters can substitute for DAG in 
the activation of PKCs (Castagna et al, 1982; Bell and Burns, 1991; Gschwendt et al, 
1991), there has been increasing interest in the role of these kinases in the regulation 
of cell growth and differentiation. PKC is a multigene family that, to date, has been 
shown to consist of twelve members. These have been divided into groups according 
to their structural and biochemical properties. The fact that PKC isoforms display 
distinct regulatory properties and tissue distributions is consistent with the idea that 
individual isoforms serve diverse functional roles. However, although the structural 
properties of PKC subtypes have been fairly well characterised, as of yet, relatively 
little is known about the functions of the individual isoforms in any system.
The purpose of this study was to investigate the roles of individual PKC isoforms in 
adipocyte development and function using 3T3-F442A cells and rat adipocytes. Since 
the PKC isoform profile of 3T3-F442A cells has not been reported previously and 
some controversy surrounds the reported PKC profile for rat adipocytes (Farese et al, 
1992; Messina et al, 1992; Stumpo et al, 1994), a thorough characterisation of the 
PKC complement of these cell types was required initially. The complement of PKC 
isoforms in 3T3-F442A cells and rat adipocytes was, therefore, determined by 
immunoblotting using a panel of isoform-specific monoclonal and polyclonal 
antibodies. Strict criteria were applied during immunoblotting to ensure the 
appropriate identification of PKC isoforms in these cells.
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3.2 Methods
3.2.1 Immunoblotting
Cell lysates from NIH-3T3 cells which had been transfected to over-express 
individual PKC iso forms (Goodnight et al, 1995) and a rat brain homogenate (Kuo et 
al, 1980) were prepared as described in sections 2.2.2.6 and 2.2.3.5 for use as positive 
controls on immunoblots. Cell lysates were prepared from undifferentiated 3T3- 
F442A preadipocytes (Green and Kehinde, 1976), fully differentiated 3T3-F442A 
adipocytes and undifferentiated twelve-day-confluent 3T3-F442A preadipocytes and 
cell homogenates were prepared from isolated rat adipocytes as described in sections
2.2.2.6 and 2.2.3.2 respectively. 3T3-F442A cell and rat adipocyte preparations were 
analysed for PKC isoform expression, alongside the positive control preparations, by 
immunoblotting using a panel of isoform-specific monoclonal and polyclonal 
antibodies as described in section 2.2.4.4. As a further control, when immunoblotting 
was performed with polyclonal antiserum, this was carried out, where possible, in the 
presence and absence of the peptide immunogen, as described in section 2.2.4.4.
3.2.2 Modulation o f  protein kinase C isoforms by phorbol ester
Studies were done to examine the acute modulation of PKC iso forms by phorbol 
ester. In these experiments, 3T3-F442A preadipocytes were treated with 10 nM TP A, 
or vehicle alone, and both 3T3-F442A adipocytes and rat adipocytes were treated with 
100 nM TP A, or vehicle, for 10 min as described in sections 2.2.2.1 and 2.2.3.4. Cell 
homogenates were prepared from the treated cells and cytosol and membrane 
fractions separated as described in section 2.2.2.7. PKC isoform expression in cytosol 
and membrane fractions was examined, both before and after TP A treatment, by 
immunoblotting with isoform-specific monoclonal antibodies (Affmiti) to PKC, as 
described in section 2.2.4.4.
In order to assess the chronic modulation (ie: susceptibility to down-regulation) of 
PKC isoforms by phorbol esters, 3T3-F442A preadipocytes were treated with either 
16 pM or 500 nM TP A for periods of 0, 3, 6, 9 12 or 24 h, as described in section
2.2.2.2, prior to the preparation of lysates for immunoblotting. Down-regulation of 
individual isoforms during the time-course of TP A treatment was examined by
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densitometric analysis of immunoblots.
Densitometric analysis was performed using a Molecular Dynamics Personal 
Densitometer and ImageQuaNT image-analysis software.
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J.J Results
3.3.1 Protein kinase C isoform expression in 3T3-F442A cells and rat adipocytes 
The complement of PKC isoforms in 3T3-F442A preadipocytes and 3T3-F442A 
adipocytes and in rat adipocytes was examined by immunoblotting using a panel of 
isoform-specific monoclonal and polyclonal antibodies (see Section 2.1.3). Due to the 
high degree of sequence homology shared between PKC sub-species, several criteria 
were employed to ensure correct identification of PKC isoforms in 3T3-F442A cells 
and rat adipocytes. These criteria exploited the known structural and regulatory 
properties of the PKC subtypes in order to assess the specificity of the antibodies used 
for characterisation of the cells. Criteria included;
i) Precise molecular weight determination of immunoreactive species and comparison 
with the predicted molecular weight of PKC isoforms.
ii) Co-migration of immunoreactive proteins with the appropriate band from a panel 
of transfected cell-lines over-expressing individual PKC isoforms.
iii) Co-migration of immunoreactive proteins with the appropriate band from a rat 
brain homogenate.
iv) Screening of samples with more than one PKC isoform-specific antibody where 
possible.
v) Susceptibility of immunoreactive species to modulation (acute and chronic) by 
phorbol esters.
The monoclonal (Figure 3.1) and polyclonal (results not shown) anti-PKC a , ô and e 
antibodies detected a single major immunoreactive species in the NIH-3T3 cells over­
expressing these isoforms of PKC and also in rat brain homogenates. Since most PKC 
isoforms were originally identified in brain tissue, rat brain homogenate served as a 
positive control for PKC antibodies when no appropriate over-expressing cells were 
available and as an additional control for antibodies when the appropriate isoform- 
over-expressing cell lysate was available. The molecular weights of the 
immunoreactive proteins detected with the anti-PKC a , 5 and s antibodies were 
similar to the predicted molecular weights of PKC a, Ô and s (see Table 3.1). That 
both the monoclonal and polyclonal antibodies specific for these PKC isoforms 
detected the same sized immunoreactive species led to the conclusion that these
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proteins were indeed PKC a , Ô and e. A major immunoreactive band, that co-migrated 
with that seen in the rat brain homogenates and NIH-3T3 cells over-expressing the 
appropriate PKC isoform, was detected in 3T3-F442A preadipocytes and adipocytes 
and in rat adipocytes with antibodies to PKC a , ô and s. Hence, it was concluded that 
these PKC isoforms are expressed in each of these cell types.
The predicted molecular weights for PKC p i  and p l l  are 76.6 and 76.8 kDa 
respectively (Table 3.1). Both a polyclonal antiserum raised in-house to PKC p l / l l  
(Figure 3.1) and a polyclonal antiserum raised to PKC p i  (gifted by Dr Peter Parker; 
Figure 3.2) detected an immunoreactive species migrating at 75 kDa in all cell 
preparations. However, the major immunoreactive species in both rat brain 
homogenates and NIH-3T3 cells over-expressing PKC P had a molecular weight of 83 
kDa. Since co-migration with the PKC over-expresser and rat brain preparations were 
criteria used during the screening of samples for PKC isoforms, immunodetection was 
carried out in PKC P over-expressing-cell lysates and rat adipocyte homogenates in 
the presence o f the immunising peptide. Peptide competition effectively abolished the 
detection of the 83 kDa protein in the over-expressing cell lysates but had no effect on 
the 75 kDa band apparent in both the over-expressing-cell lysates and in rat adipocyte 
homogenates (Figure 3.2). This indicated that the faster migrating species of 75 kDa 
in size, seen in all blotting studies with the polyclonal PKC p  antisera (Figures 3.1 
and 3.2), was a non-specific species and that the protein detected in rat brain 
homogenates and PKC P over-expressing cells, migrating at 83 kDa, was indeed PKC 
p .  Failure to detect an 83 kDa immunoreactive species in the 3T3-F442A cell and rat 
adipocyte preparations investigated here suggested there was no PKC p  isoform 
present in these cells.
The observation that PKC P was not expressed in rat adipocytes is in contrast to 
results obtained by Farese et al (1992). Because of this discrepancy, a third antibody, 
a monoclonal antibody capable of detecting both PKC pi and pll (AffTniti), was also 
used. This antibody detected a single 83 kDa band in PKC P over-expressing-cell 
lysates and in rat brain homogenates (Figure 3.3) and, in accordance with the 
polyclonal immunoblots, this band was not apparent in 3T3-F442A cell lysates or rat 
adipocyte homogenates. This again indicated that there was no PKC P in these cells.
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In an attempt to determine whether the PKC P protein was expressed at a low level in 
the rat adipocyte, a larger quantity (400 pg as opposed to 50 pg) of homogenate 
protein was immunoblotted using the monoclonal antibody. PKC p was not detected 
even in this large quantity of rat adipocyte homogenate protein (Figure 3.3).
A monoclonal antibody to PKC y detected a major immunoreactive species in both 
3T3-F442A cells and rat adipocytes which migrated with a molecular weight of 80 
kDa, thus corresponding to the predicted molecular weight of this PKC isoform 
(Table 3.1). Furthermore, this band co-migrated with the major immunoreactive 
species in the positive antibody control preparations (Figure 3.1). The expression of 
PKC y is generally thought to be restricted to the brain and spinal chord (Nishizuka, 
1988) and, since a number of PKC isoforms have a similar predicted molecular 
weight to PKC y (see Table 3.1), lysates were prepared from NIH-3T3 cells over­
expressing either PKC a  (76.7 kDa), p (76.7 kDa), y (78.3 kDa) or 5 (77.5 kDa), and 
immunoblotted with the PKC y antibody in order to examine the cross-reactivity of 
the anti-PKC y antibody with similar PKC sub-species. Wild-type NIH-3T3 cells were 
also immunoblotted as a control. Figure 3.4 demonstrates the presence of PKC y in 
wild type NIH-3T3 cells. Thus, a co-migrating band of similar intensity was detected 
in NIH-3T3 cells which over-express PKC P and ô. A band of greater intensity was 
detected in NEH-3T3 cells over-expressing PKC a , suggesting a degree of cross­
reactivity between the PKC y antibody and the PKC a  protein. However, that a 
dramatic increase in intensity of the immunoreactive band in lysates prepared from 
NIH-3T3 cells transfected to over-express PKC y was observed, indicated that the 
PKC y antibody displayed predominant specificity for the y isoform of PKC.
Both anti-PKC Ç antibodies (monoclonal and polyclonal) detected a number of 
immunoreactive species in all samples; the major band detected with each antibody in 
both the control preparations and in 3T3-F442A cells and rat adipocytes having an 
apparent molecular weight of 83 kDa (Figures 3.1 and 3.5). From its amino acid 
sequence, the predicted molecular weight of PKC Ç is approximately 67 kDa (Table
3.1). However, that two different antibodies detected a major immunoreactive protein 
of 83 kDa suggested that this protein was authentic PKC Ç To confirm that the 83
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kDa species was indeed PKC lysates prepared from NIH-3T3 cells over-expressing 
PKC and rat adipocyte homogenates were immunoblotted with the PKC 
polyclonal antibody in the presence of immunising peptide. Peptide immunogen 
prevented binding of the PKC Ç antibody to the 83 kDa band in both cell types 
(Figure 3.5) indicating that the protein detected with the PKC C antibody, in both 
the (-over-expressing control cells and in rat adipocytes, was indeed PKC (. Thus, 
under the conditions used, PKC (  had an apparent molecular weight of 83 kDa and 
was detected in both 3T3-F442A cells and rat adipocytes (Figure 3.1).
PKC T| has a predicted molecular weight of approximately 78 kDa (Table 3.1). In 
3T3-F442A cells (results not shown) and rat adipocytes (Figure 3.6A), the major 
immunoreactive band detected with the PKC rj polyclonal antibody was 72 kDa in 
size and did not co-migrate with the major immunoreactive band of 78 kDa seen in 
N1H-3T3 cells over-expressing PKC rj. Immunising peptide effectively prevented 
binding of the PKC rj antibody to the 78 kDa species in the over-expressing cells 
indicating that this species was in fact PKC rj (Figure 3.6A). In contrast, peptide 
immunogen did not prevent binding of the PKC r\ antibody to the 72 kDa species 
detected in 3T3-F442A cells (results not shown) and rat adipocytes (Figure 3.6A). 
This indicated that the protein detected in 3T3-F442A cells and rat adipocytes was a 
non-specific species and was not PKC r\.
Both the polyclonal (Figure 3.6 B) and monoclonal (data not shown) anti-PKC 0 
antibodies detected a major immunoreactive band migrating at the predicted 
molecular weight of this isoform (82 kDa) in N1H-3T3 cells over-expressing PKC 0. 
An 82 kDa species was not apparent in preparations from either 3T3-F442A cells or 
rat adipocytes (Figure 3.6B) indicating that PKC 0 was not expressed in these cell 
types.
The monoclonal antibodies to both PKC i and X detected low levels of an 
immunoreactive protein, displaying an apparent molecular weight of 83 kDa, in both 
3T3-F442A cells (Figure 3.7) and rat adipocytes (results not shown). PKC i and X are 
thought to be mouse and human homologues of the same protein (Zhou et al, 1994)
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and have a predicted molecular weight of approximately 67 kDa (Table 3.1). These 
isoforms share 72 % homology with PKC (  (Zhou et al, 1994) which displayed an 
apparent molecular weight 83 kDa under the conditions used during this study (Figure
3.1) and cross-reactivity of anti-PKC i and X antibodies with PKC (  is a common 
problem (Zhou et al, 1994). In an attempt to establish further the specificity of the i 
and X antibodies, lysates prepared from 3T3-F442A preadipocytes and N1H-3T3 cells 
over-expressing PKC (  and homogenates prepared from rat heart and spleen were 
immunoblotted with monoclonal antibodies specific for PKC i, X and (  (Affmiti). 
Heart and spleen are reported to be rich in PKC \!X but not PKC (  (Zhou et al, 1994). 
Figure 3.7 shows that the PKC i and X antibodies detected a distinct 83 kDa band in 
the PKC (  over-expressing cells and in 3T3-F442A preadipocytes. Furthermore, the 
PKC I and X antibodies failed to detect a major immunoreactive band in heart and 
spleen samples. Although it is possible that PKC \!X was present in 3T3-F442A cells 
and rat adipocytes, it is more likely that the monoclonal antibodies to PKC i and X are 
chiefly detecting PKC (  in these cells. The PKC (  antibody cross-reacted with PKC 
\/X, which also have an apparent molecular weight of 83 kDa under the conditions 
used. This was determined by the ability of the PKC (  antibody to detect 
immunoreactive species of 83 kDa in heart and spleen homogenates (Figure 3.7). The 
cross-reactivity data indicates, however, that PKC \/X are probably not expressed in 
either 3T3-F442A cells or rat adipocytes and that the PKC (  antibody is therefore 
specific for the PKC Ç protein in these cells.
In rat brain homogenates, the PKC p. monoclonal antibody detected an 
immunoreactive protein doublet of 116 and 112 kDa (Figure 3.1). A major 
immunoreactive species was detected with the anti-PKC p antibody in 3T3-F442A 
cells and rat adipocytes that co-migrated with the 112 kDa species detected in rat 
brain homogenates. This corresponds to the predicted molecular weight of the murine 
homologue of PKC p, also known as PKD (Van Lint et al, 1995), which migrates at 
110 kDa and shares 92% sequence homology with the human form of PKC p to 
which the anti-PKC p antibody was raised (see Section 2.1.3). Thus, PKC p 
expression was detected in both 3T3-F442A cells and rat adipocytes.
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Thus, analysis of 3T3-F442A cells by immunoblotting using a panel of monoclonal 
antibodies and anti-peptide antisera, applying the defined criteria (see above) to 
ensure appropriate identification of PKC isoforms, indicated the presence of the PKC 
a , y, 5, s, (  and p isoforms. This is demonstrated in the immunoblots shown in Figure 
3.1. The same PKC species were found in undifferentiated 3T3-F442A preadipocytes, 
fully differentiated 3T3-F442A adipocytes and parallel cultures of undifferentiated 
3T3-F442A preadipocytes maintained at confluence for twelve days. In addition, the 
same major immunoreactive bands were detected in rat adipocytes (Figure 3.1).
3.3.2 Modulation o f  3T3-F442A cell and rat adipocyte protein kinase C isoforms by 
phorbol esters
To examine further the specificity and cross-reactivity of the panel of antibodies, they 
were used to probe the effects of acute and chronic treatment with phorbol esters on 
the expression of PKC isoforms. Phorbol esters, such as TP A, can substitute for DAG 
and induce the activation and translocation of conventional and novel PKC isoforms, 
but not atypical PKCs (Kraft et al, 1982; Ito et al, 1989; Kiley et al, 1995). The acute 
modulation of PKCs isoforms by phorbol esters was, therefore, assessed by 
examining PKC isoform expression in cytosol and membrane fractions both prior to 
and following TP A treatment of cells. According to the structural properties of the 
PKC isoforms (see Section 1.6; Johannes et al, 1994), conventional PKCs a  and y and 
novel PKCs ô and s would be expected to translocate from the cytosol to the 
membrane fraction following such treatment whereas atypical PKC (  and PKC 
\x would not. 3T3-F442A preadipocytes were treated with 10 nM TP A for 10 min and 
immunoreactive PKC isoform levels in both the cytosol and membrane fractions 
assessed.
The different responses of the PKC isoforms in 3T3-F442A preadipocytes to TP A are 
shown in Figure 3.8. Prior to stimulation, PKC a  was detected only in the cytosolic 
fraction. Following TP A treatment, expression of PKC a  was detected mainly in the 
membrane fraction, with very low levels of expression in the cytosol. Although TP A 
induced the translocation of a large proportion of immunoreactive PKC a  from the 
cytosol, a corresponding increase in membrane immunoreactivity was not observed.
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This may indicate that TP A induced the translocation of PKC a  to other sub-cellular 
compartments, such as the cytoskeleton and the nucleus. Alternatively, this may 
indicate that PKC a  is rapidly down-regulated following membrane association.
In resting cells, low levels of PKC y were detectable in membrane fractions, however 
this isoform was mainly detected in the cytosol prior to stimulation with TP A. TP A 
treatment induced the translocation of a large proportion of immunoreacte PKC y 
from the cytosol to the membrane.
PKC 5 was predominantly expressed in the particulate fraction prior to stimulation 
with TP A, with only low levels of expression in the cytosol. Following TP A 
treatment, expression of PKC 5 was detected exclusively in the membrane fraction.
PKC 8 was predominantly detected in the cytosol both prior to and following TP A 
treatment. However, TP A induced the translocation of a small proportion of 
immunoreactive PKC e to the membrane.
Consistent with published data (Selbie et al, 1993; Johannes et al, 1994), PKC (  and 
[I were not induced to translocate by TP A treatment and these PKC iso forms were 
detected in the cytosol both before and after stimulation of cells with TP A. 
Considering that PKC \x contains a putative membrane localisation sequence 
(Johannes et al, 1994), it was somewhat surprising that the expression of this isoform 
was found only in the cytosolic fraction of 3T3-F442A cells and rat adipocytes. 
However, this may reflect the experimental conditions used. It is possible that during 
processing of the cells the membrane association of this isoform, or its access to 
particular binding proteins, is lost.
The sensitivity of PKC isoforms in adipocytes to acute modulation by phorbol esters 
was also examined. Consistent with the observations of others (McGowan et al, 
1996), a higher concentration of TP A was found to be required for the stimulation of 
PKC isoforms in adipocytes. In 3T3-L1 cells (McGowan et al, 1996), this has been 
attributed to the selective down-regulation of phorbol ester-sensitive PKC isoforms 
during the differentiation of preadipocytes into adipocytes. Both 3T3-F442A and rat
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adipocytes were treated with 100 nM TP A for 10 min and immunoreactive PKC 
levels in the cytosol and membrane fractions assessed. The patterns of PKC isoform 
expression both prior to and following TP A treatment of 3T3-F442A adipocytes 
(Figure 3.9) and rat adipocytes (Figure 3.10) were found to be essentially identical, 
although the patterns were somewhat different from those observed for 3T3-F442A 
preadipocytes (Figure 3.8).
TP A induced the translocation of a smaller proportion of immunoreactive PKC a  and 
y from the cytosol to the membrane than was observed in preadipocytes. Thus, a large 
proportion of immunoreactive PKC a  and y remained in the cytosol following TP A 
treatment. In addition, PKC y was not detectable in adipocyte membrane fractions 
prior to treatment, as observed in preadipocytes.
PKC 5 was found only in association with membrane fractions in adipocytes. This 
was in contrast to preadipocytes, where a proportion of immunoreactive PKC Ô was 
detectable in the cytosol prior to TP A treatment. TP A treatment of 3T3-F442A and rat 
adipocytes increased the levels of immunoreactive PKC 5 in membrane fractions. 
This may be due to the translocation of PKC ô from cytoskeletal and nuclear 
compartments rather than the cytosol, as PKC 5 is not detectable in the cytosol of 
either rat adipocytes or 3T3-F442A adipocytes.
Immunoreactive PKC s was detected both in the cytosol and membrane fractions of 
adipocytes, whereas this isoform was detected only in the cytosol in preadipocytes, 
both before and after TP A treatment. TP A induced the translocation of 
immunoreactive PKC 8 from the cytosol, however, a corresponding increase in 
membrane immunoreactivity was not observed. This may indicate that TP A induced 
the translocation of PKC 8 to other sub-cellular compartments, such as the 
cytoskeleton and the nucleus, or, that PKC 8 is rapidly down-regulated following 
membrane association. '
Consistent with observations in preadipocytes, PKC (  and p were not induced to 
translocate to the membrane by acute phorbol ester treatment of adipocytes.
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Thus, the conventional and novel PKC isoforms were induced to translocate by TP A 
treatment of preadipocytes and adipocytes while atypical PKC (  and PKC p were 
unresponsive, conforming to the known structural properties of the PKC sub-families 
(see Section 1.6; Johannes et al, 1995). Due to the potency of phorbol esters, PKCs 
are thought to become irreversibly associated with the membrane fractions, resulting 
in the prolonged stimulation of their activity (Anderson et al, 1995; Nelsestuen and 
Bazzi, 1991). Such prolonged activation results in down-regulation of PKC due to 
proteolytic degradation (Nishizuka, 1988; Borner et al, 1992). The susceptibility of 
the various immunoreactive PKC species to phorbol ester-induced down-regulation 
was examined in 3T3-F442A preadipocytes. 3T3-F442A preadipocytes were 
incubated with 16 pM TP A and PKC isoform expression in cell lysates assessed over 
a 24 h period by immunoblotting.
Following chronic TP A treatment of 3T3-F442A preadipocytes PKC a , y and s were 
detected as an immunoreactive protein doublet (Figures 3.11 and 3.12). The existence 
of multiple forms of particular PKC subtypes has been reported previously (Burt et al, 
1991; Borner et al, 1992; Tang et al, 1993) in both resting and stimulated cells. 
Certain PKC isoforms have been shown to be phosphorylated or ubiquitinated in 
response to phorbol ester treatment (Borner et al, 1992; Lu et al, 1998). Thus, TPA- 
induced phosphorylation or ubiquitination of a proportion of PKC subtypes may 
account for the presence of multiple species of PKC a , y and 8 following the phorbol 
ester treatment of 3T3-F442A preadipocytes.
Chronic treatment of cells with 16 pM TP A resulted in the rapid down-regulation of 
PKC a, y, and Ô in lysates prepared from 3T3-F442A preadipocytes. PKC 8 was more 
resistant to TPA-induced down-regulation, with significant levels of this isoform still 
detectable after 24 h of treatment. (Figure 3.11). Again, PKC (  and p were unaffected 
by TP A treatment. Reduction of the TP A concentration to 500 nM slowed down the 
down-regulation of the PKC isoforms allowing the individual time-courses to be 
followed (Figure 3.12). The profiles of down-regulation for each isoform obtained 
following densitometric analysis of immunoblots (Figure 3.13) indicated that the 
order of susceptibility to phorbol ester-induced down-regulation was PKC ô > a  > y > 
8.
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Thus, assessment of the effects of acute and chronic phorbol ester treatment on the 
immunoreactive PKC species detected by the antibodies used in this study, 
demonstrated that these species conform to the known properties of the PKC sub­
families. Furthermore, that differential responses to these treatments (different relative 
sub-cellular distributions and time-courses for down-regulation) were displayed by 
each of the individual PKC isoforms raises confidence that each antibody recognises a 
distinct PKC isoform.
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Table 3,1 Predicted molecular weights o f  PKC isoforms based on their amino acid 
composition
PKC Isoform Predicted Molecular 
Weight
Reference
Alpha, a 76.7 kDa Ohno and Suzuki (1995)
Beta I, p I 76.7 kDa Ohno and Suzuki (1995)
Beta II, p II 76.8 kDa Ohno and Suzuki (1995)
Gamma, y 78.3 kDa Ohno and Suzuki (1995)
Delta, Ô 77.5 kDa Ohno and Suzuki (1995)
Epsilon, 8 83.5 kDa Ohno and Suzuki (1995)
Eta,T| 77.9 kDa Ohno and Suzuki (1995)
Theta, 0 81.5 kDa Ohno and Suzuki (1995)
Zeta, 67.6 kDa Ohno and Suzuki (1995)
Lambda, X 67.2 kDa Ohno and Suzuki (1995)
Iota, I 67.2 kDa Ohno and Suzuki (1995)
Mu, p. 115 kDa Johannes et al. (1994)
PKD 110 kDa Valverde et al. (1994)
Figure 3,1 Protein kinase C isoforms present in 3T3-F442A cells and rat 
adipocytes
Cell lysates (75 pg of protein) prepared from “just-confluent” 3T3-F442A 
preadipocytes (lane 3), twelve-day-confluent 3T3-F442A preadipocytes (lane 
4) and fully differentiated 3T3-F442A adipocytes (lane 5) and cell 
homogenates prepared from rat adipocytes (lane 6) were subjected to SDS- 
PAGE alongside 50 pg of lysate prepared from NIH-3T3 cells over-expressing 
the appropriate PKC isoform (lane 1; except for PKC p) and 50 pg of rat brain 
homogente (lane 2). PKC isoform expression was assessed by immunoblotting 
with monoclonal antibodies (Affiniti) to PKC a , y, 6,8, and p and a 
polyclonal antibody capable of detecting PKC pi as described in section 
2.2.4.4. Molecular weights (kDa) of the major immunoreactive bands are 
indicated. Immunoblots are representative of results obtained in at least six 
separate experiments.
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Figure 3.2 Immunoblotting fo r  PKC p  in the presence and absence o f  peptide 
immunogen
Equal quantities (50 pg of protein) of cell homogenate prepared from isolated rat 
adipocytes (lane 1) and cell lysate prepared from NIH-3T3 cells over-expressing PKC 
P (lane 2) were subjected to immunoblotting with polyclonal antiserum raised to PKC 
pi in the presence (+ peptide) or absence (- peptide) of peptide immunogen. 
Molecular weights (kDa) of the immunoreactive bands are indicated. Immunoblots 
are representative of results obtained in at least four separate experiments.
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Figure 3.3 Immunoblotting fo r  PKC /3 using excess protein
50 pg (lane 3) and 400 pg (lane 4) of homogenate protein prepared from isolated rat 
adipocytes were subjected to SDS-PAGE alongside 50 pg of cell lysate protein 
prepared from NIH-3T3 cells over-expressing PKC p (lane 1) and 50 pg of rat brain 
homogenate protein (lane 2). Immunoblotting was carried out using a monoclonal 
antibody capable of recognising both PKC pi and PKC pll. The position of 
immunoreactive PKC p is indicated by an arrow. The immunoblot is representative of 
results obtained in at least three separate experiments.
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Figure 3,4 Assessment o f  the specificity o f the monoclonal PKC y  antibody
Equal quantities of cell lysate (50 pg of protein) prepared from wild type NIH-3T3 
cells (lane 5) or from NIH-3T3 cells transfected to over-express either PKC p (lane 1), 
Ô (lane 2), a  (lane 3) or y (lane 4) were subjected to immunoblotting with a 
monoclonal antibody to PKC y. The immunoblot is representative of results obtained 
in at least three separate experiments.
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Figure 3.5 Effect o f  peptide immunogen on detection o f  protein bands by a 
polyclonal antiserum to PKC Ç
Equal quantities (50 pg of protein) of cell lysate prepared from NIH-3T3 cells over­
expressing PKC (lane 1 ) and cell homogenate prepared from isolated rat adipocytes 
(lane 2) were subjected to immunoblotting with polyclonal antiserum raised to PKC 
in the presence (+ peptide) or absence (- peptide) of peptide immunogen. The 
molecular weight of PKC is indicated. Immunoblots are representative of results 
obtained in at least four separate experiments.
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Figure 3.6 Immunoblotting fo r  PKC rf and 0
A Equal quantities (50 pg of protein) of a cell lysate prepared from NIH-3T3 cells 
over-expressing PKC q (lane 1) and of a cell homogenate prepared from isolated rat 
adipocytes (lane 2) were subjected to immunoblotting with polyclonal antiserum 
raised to PKC r\ in the presence (+ peptide) or absence (- peptide) of peptide 
immunogen. The position of immunoreactive PKC q is indicated. Immunoblots are 
representative of results obtained in at least three separate experiments.
B Equal quantities (50 pg of protein) of cell lysate prepared from 3T3-F442A 
preadipocytes (lane 2) or 3T3-F442A adipocytes (lane 3) and cell homogenates 
prepared from isolated rat adipocytes (lane 4) and rat brain (lane 1) were subjected to 
immunoblotting with polyclonal antiserum raised to PKC 0. The position of 
immunoreactive PKC 0 is indicated. The immunoblot is representative of results 
obtained in at least three separate experiments.
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Figure 3.7 Assessment o f  the specificity o f the PKC Ç, i and X antibodies
Equal quantities (50 pg of protein) of cell lysate prepared from NIH-3T3 cells over­
expressing PKC (lane 1) or from 3T3-F442A preadipocytes (lane 2) and cell 
homogenate prepared from rat heart (lane 3) and spleen (lane 4) were subjected to 
immunoblotting with isoform-specific monoclonal antibodies (AtTiniti) to PKC C, 
I and X as indicated. The molecular weight (kDa) of the major immunoreactive 
species is indicated. Immunoblots are representative of results obtained in at least four 
separate experiments.
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Figure 3.8 Effects o f acute phorbol ester treatment o f 3T3-F442A preadipocytes on 
the sub-cellular distribution o f  protein kinase C isoforms
3T3-F442A preadipocytes were incubated in the presence (lanes 3 and 5) or absence 
(lanes 2 and 4) of 10 nM TPA for 10 min prior to the preparation of cytosol (lanes 2 
and 3) and membrane fractions (lanes 4 and 5) as described in section 222.1. Equal 
quantities (50 pg) of cytosol and membrane protein were resolved by SDS-PAGE 
alongside 50 pg of a rat brain homogenate (lane 1) and analysed by immunoblotting 
with isoform-specific monoclonal antibodies to PKC as indicated. Immunoblots are 
representative of results obtained in at least four separate experiments.
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Figure 3.9 Effects o f acute phorbol ester treatment o f  3T3-F442A adipocytes 
on the sub-cellular distribution o f protein kinase C isoforms
3T3-F442A adipocytes were incubated in the presence (lanes 3 and 5) or absence 
(lanes 2 and 4) of 100 nM TPA for 10 min prior to the preparation of cytosol 
(lanes 2 and 3) and membrane fractions. Equal quantities (50 pg) of cytosol and 
membrane protein were resolved by SDS-PAGE alongside 50 pg of rat brain 
homogenate (lane 1) and analysed by immunoblotting with isoform-specific 
monoclonal antibodies to PKC as indicated. Immunoblots are representative of 
results obtained in at least four separate experiments.
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Figure 3.10 Effects o f  acute phorbol ester treatment o f  rat adipocytes on the sub- 
cellular distribution o f  protein kinase C isoforms
Isolated rat adipocytes were incubated in the presence (lanes 2 and 4) or absence 
(lanes 1 and 3) of 100 nM TPA for 10 min prior to the preparation of cytosol (lanes 2 
and 3) and membrane fractions. Equal quantities (50 pg) of cytosol and membrane 
protein were resolved by SDS-PAGE and analysed by immunoblotting with isoform- 
specific monoclonal antibodies to PKC as indicated. Immunoblots are representative 
of results obtained in at least four separate experiments.
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Figure 3.11 Effects o f chronic treatment o f  3T3-F442A preadipocytes with 16 pM  
phorbol ester on the cellular levels o f  protein kinase C isoforms
3T3-F442A preadipocytes were treated with vehicle for 24 h (DMSO, lane 2) or 16 
pM TPA for 3 h (lane 3), 6 h (lane 4), 9 h (lane 5), 12 h (lane 6) or 24 h (lane 7) prior 
to the preparation of cell lysates. Equal quantities (50 pg) of lysate protein were 
resolved by SDS-PAGE alongside 50 pg of rat brain homogenate (lane 1) and 
analysed by immunoblotting with isoform-specific monoclonal antibodies to PKC as 
indicated. Immunoblots are representative of results obtained in at least three separate 
experiments.
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Figure 3.12 Effects o f  chronic treatment o f  3T3-F442A preadipocytes with 500 nM  
phorbol ester on the cellular levels o f protein kinase C isoforms
3T3-F442A preadipocytes were treated with vehicle for 24 h (DMSO, lane 2) or 500 
nM TPA for 3 h (lane 3), 6 h (lane 4), 9 h (lane 5), 12 h (lane 6) or 24 h (lane 7) prior 
to the preparation of cell lysates. Equal quantities (50 pg) of lysate protein were 
resolved by SDS-PAGE alongside 50 pg of rat brain homogenate (lane 1) and 
analysed by immunoblotting with isoform-specific monoclonal antibodies to PKC as 
indicated. Immunoblots are representative of results obtained in at least four separate 
experiments.
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Figure 3.13 Densitometric analysis o f effects o f chronic treatment o f 3T3-F442A 
preadipocytes with 500 nM phorbol ester on the cellular levels o f  protein kinase C 
isoforms
3T3-F442A preadipocytes were treated with vehicle (DMSO) for 24 h (TPA pre­
treatment = 0 h) or 500 nM TPA for 3-24 h prior to the preparation of cell lysates for 
immunoblotting with isoform-specific monoclonal antibodies to PKC. Immunoblots were 
subjected to densitometric analysis and the level of PKC isoform expression in cell 
lysates which had been pretreated with TPA expressed as a percentage of the level in 
cells treated with vehicle alone (control = 100 %). Results are the means ± S.E.M. of four 
separate observations carried out on different cell preparations.
3,4 Discussion
In this study, the presence of conventional PKCs a  and y, novel PKCs 5 and s, 
atypical PKC (  and PKC p was demonstrated in both undifferentiated 3T3-F442A 
preadipocytes and differentiated 3T3-F442A adipocytes and in rat adipocytes. Using 
the antibodies available, expression of the PKC pi/II, r|, 0, i and X isoforms was not 
detectable in 3T3-F442A cells or rat adipocytes, despite the fact that the antibodies 
detected expression of these proteins in the appropriate positive control preparations.
The apparent molecular weight of the PKC C, isoform detected in 3T3-F442A cells 
and rat adipocytes differed slightly from the predicted molecular weight of this 
isoform shown in Table 3.1. This isoform, which has a predicted molecular weight of 
67 kDa, was detected as an 83 kDa protein following immunoblotting. Previous 
studies (see for example Borner et al, 1992; Nishikawa et al, 1995; Ducher et al, 
1995; Frevert and Kahn, 1996; Standaert et al, 1996a; Gschwendt et al, 1992; Ways et 
al, 1992; Tang et al, 1993; Nishikawa et al, 1995) have indicated, however, that the 
molecular mass of PKC isoforms deduced from SDS-PAGE may differ somewhat 
from that calculated from their amino acid composition. Thus, PKC a , y and 5 
generally display an apparent molecular weight of -80 kDa, PKC e an apparent 
molecular weight of -90 kDa and PKC an apparent molecular weight within the 
range of -65 to -85 kDa, with multiple forms of PKC within this weight range often 
being found within the same cell type (Gschwendt et al, 1992; Ways el al, 1992; Tang 
et al, 1993; Nishikawa et al, 1995). Indeed, the species of PKC Ç expressed in rat 
adipocytes has been reported previously to display an apparent molecular weight of 
85 kDa (Farese et al, 1992).
Although expression of PKC P has been reported in rat adipocytes (Farese et al, 
1992), the three different antibodies used in the present study were unable to detect 
expression of PKC pi or pll in these cells, even following overloading of gels and 
over-exposure of autoradiographs. Such anomalies have been reported previously 
with respect to characterisation of rat H4IIE cells by Farese and co-workers, where 
the cells were reported to express PKC P (Messina et al, 1992) although this result 
could not be reproduced by Stumpo et al (1994). It seems that PKC P is not expressed 
in the rat adipocytes used during the present study. The rat adipocytes used during this
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study were isolated from the parametrial fat pads of female Wistar rats, whereas the 
rat adipocytes characterised previously were isolated from the epididymal fat pads of 
male Sprague-Dawley rats (Farese et al, 1992). The discrepancy with regard to the 
PKC complement of rat adipocytes between the two studies may, therefore, simply 
reflect variation between species, sex or fat depot. Detection of the a , y, 5, s and 
isoforms of PKC in rat adipocytes is in agreement with the findings of Farese et al 
(1992). In this study, expression of PKC p. was also demonstrated in rat adipocytes. 
The presence of PKC p., a recently identified member of the PKC family (Johannes et 
al, 1994), in the rat adipocyte has not been reported previously.
Expression of PKC a, 5, s and C has been reported previously for the related Swiss 
3T3 cell-line (Olivier and Parker, 1992) and R6 rat embryo fibroblasts (Borner et al, 
1992). Indeed, expression of these PKC isoforms appears to be fairly ubiquitous. 
Preadipocytes from the 3T3-L1 cell line, however, which is closely related to 3T3- 
F442A cells, have been reported to express the a, s and Ç isoforms of PKC but not 
PKC 5 (McGowan et al, 1996; Frevert and Kahn, 1996). 3T3-L1 cells were also 
found to express PKC 0 following differentiation into adipocytes (McGowan et al, 
1996), whereas this isoform was not detectable in 3T3-F442A adipocytes (or 
preadipocytes). In addition, 3T3-F442A cells were found to express the same 
isoforms of PKC in both the undifferentiated and fully differentiated state, therefore, 
no such phenotype-specific expression of iso forms was observed. Thus, from the 
studies performed so far, it would appear that 3T3-F442A and 3T3-L1 cells, two 
closely related cell-lines, display somewhat different complements of PKC isoforms.
Murine adipocytes have been reported to express the novel PKC isoforms Ô, e and r| 
and atypical PKC Ç (Frevert and Kahn, 1996). Expression of other PKC isoforms in 
murine adipocytes has not been investigated. In the present study, PKC q could not be 
detected in 3T3-F442A cells, which are a murine cell-line. Thus, although the present 
study indicated that 3T3-F442A adipocytes express an identical complement of PKC 
isoforms to that of rat adipocytes, this cell-line may differ, at least with respect to 
expression of PKC q, from murine adipocytes.
Expression of PKC y in preadipocyte cell-lines has not been reported previously.
68
Indeed, expression of this isoform is traditionally thought to be restricted to tissues of 
the brain and spinal chord (Nishizuka, 1988). Immunoreactive proteins were, 
however, detected with the anti-PKC y monoclonal antibody used during this study in 
both 3T3-F442A cells and rat adipocytes. Affiniti Research Products have indicated 
that the anti-PKC y monoclonal antibody cross-reacts with the PKC a  protein 
(personal communication). However, the immunoblotting studies carried out (Figures
3.1 and 3.4), together with the observation that PKC a  and y displayed different 
susceptibilities to phorbol ester-induced down-regulation (Figure 3.13), indicate that 
the immunoreactivity of the PKC y antibody cannot simply be explained by cross­
reactivity with PKC a .  In addition, expression of PKC y has been demonstrated 
previously in the rat adipocyte (Farese ei al, 1992). Expression of this PKC isoform 
may, therefore, be more widespread than originally thought.
Having established which PKC isoforms were present in 3T3-F442A cells and rat 
adipocytes, the panel of antibodies used to characterise the cells were then used to 
investigate the acute and chronic modulation of these isoforms by phorbol ester. 
Conforming to their known structural properties (see Section 1.6), the DAG- 
responsive conventional PKC a  and y and novel PKC ô and 8 isoforms were observed 
to translocate from the cytosol to the membrane and be subsequently down-regulated 
by treatment of cells with TPA. Conforming to previous reports (Selbie et al, 1993; 
Johannes et al, 1994), atypical PKC and PKC \x were not translocated or down- 
regulated by TPA treatment. The fact that isoforms responded to phorbol ester 
treatment according to their known structural properties and that the conventional and 
novel isoforms displayed different susceptibilities to phorbol ester-induced down- 
regulation, increased confidence regarding the specificty of the antibodies used for 
characterisation of the cells. The conventional and novel isoforms of PKC have been 
reported previously (Olivier and Parker, 1992) to display differential sensitivity to 
treatment with phorbol esters. In Swiss 3T3 cells (Olivier and Parker, 1992), for 
example, the susceptibility of PKC isoforms to down-regulation following chronic 
phorbol ester treatment was found to be ô > a  > s > C, with PKC e being fairly 
resistant and PKC Ç showing no response to such treatment. Essentially identical 
results were observed in 3T3-F442A cells during the present study. In addition, the
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susceptibility of PKC y to TPA-induced down-regulation was found to be between 
that observed for PKC a  and 8. Thus, the order of susceptibility to TPA-induced 
down regulation in 3T3-F442A cells was found t o b e ô > a > y > 8 > ( ^  = |i.
During the acute phorbol ester treatment studies, it was established whether specific 
isoforms were found in the cytosolic or particulate fractions of the cells. This revealed 
some differences in the sub-cellular distribution of isoforms following differentiation 
of 3T3-F442A cells. Thus, following differentiation, there was a shift in 
immunoreactive PKC y towards the cytosol and PKC Ô and 8 towards the membrane 
fraction. In contrast, the relative sub-cellular distribution of PKC a, Ç and p. was 
unchanged following differentiation. Selective redistribution of PKC isoforms has 
been observed by others during the differentiation and transformation of various cells 
as well as in response to different stimuli (reviewed in Kiley et al, 1995; Taken, 1996). 
Such targeting of PKCs to discrete sub-cellular compartments restricts access to 
substrates and may contribute to isoform-specific responses. Although the sub-cellular 
distribution and phorbol ester-responsiveness of PKC isoforms in 3T3-F442A 
adipocytes was somewhat different from that of 3T3-F442A preadipocytes, it was 
found to be essentially identical to that found for rat adipocytes. It is, therefore, 
possible that the altered sub-cellular location of PKC isoforms in differentiated 3T3- 
F442A adipocytes occurs as a result of the differentiation process.
In summary, both undifferentiated 3T3-F442A preadipocytes and fully differentiated 
3T3-F442A adipocytes were found to express PKC a , y, 5, 8, (  and p. These PKC 
isoforms displayed differential sensitivities to modulation by phorbol esters, which 
conformed to the results of others. The PKC complement of 3T3-F442A cells was 
found to be identical to that of rat adipocytes. In addition, the sub-cellular distribution 
and phorbol ester-responsiveness of 3T3-F442A adipocyte PKC isoforms was found 
to be similar to that of rat adipocyte PKC isoforms. Together, these results support the 
suitability of using 3T3-F442A cells as a model system of adipocyte development and 
function.
It is generally thought that the PKC heterogeneity within cells indicates that
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individual isoforms serve diverse functional roles in the regulation of cell growth and 
differentiation. Knowledge of the PKC isoforms in 3T3-F442A cells and rat 
adipocytes enabled subsequent evaluation of the roles of these individual isoforms in 
adipocyte development and function.
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Chapter 4
Investigation of the roles of individual protein kinase 
C isoforms in 3T3-F442A preadipocyte differentiation
4.1 Introduction
The differentiation of preadipocytes is a complex process dependent upon the strict 
temporal regulation of multiple and interacting signalling events, ultimately leading to 
the modulation of expression of an array of genes necessary for the attainment of the 
adipocyte phenotype (Mandrup and Lane, 1997; Smas and Sul, 1995). 3T3-F442A 
cells have the capacity to undergo differentiation, both in vitro (Green and Kehinde, 
1976) and in vivo (Green and Kehinde, 1979), into cells which exhibit most of the 
morphological and biochemical characteristics of normal adipocytes and, therefore, 
provide a good model system of cellular differentiation. As a result of extensive 
studies using such preadipocyte cell lines, many of the key regulators of the 
differentiation process have now been identified (see Sections 1.3.2 - 1.3.4). 
However, the exact intracellular molecular events which regulate the adipocyte 
differentiation process and which are required to maintain the adipocyte phenotype 
remain largely unknown.
Although the precise functions of different PKC isoforms remain elusive, it is clear 
from a wide range of studies that PKCs have an important role in the regulation of cell 
growth and differentiation (Hug and Sarre, 1993; Kindregan et al, 1994; Li et al, 
1994; Borner et al, 1995; Hundle et al, 1995; Acs et al, 1997). Indeed, a number of 
lines of evidence implicate this family of kinases in preadipocyte differentiation. For 
example, PKCs are involved in a number of signalling pathways, including those of 
MAP kinase (Cobb and Goldsmith, 1995), p70^  ^kinase (Anderson, 1993) and PI 3- 
kinase (Nakanishi et al, 1993; Toker etal, 1994), all of which have been implicated in 
adipocyte differentiation (Sale et al, 1995; Uehara et al, 1995; Yeh et al, 1995). In 
addition, phorbol esters, which can activate the diacylglycerol-reponsive PKC 
isoforms, have been shown to modulate adipogenesis in a number of preadipocyte cell 
lines (Shimizu et al, 1983; Serrero, 1987; Navre and Ringold, 1989; Serrero and 
Mills, 1991; Hauner et al, 1995; Hu et al, 1996). Finally, more direct evidence for a 
role of PKCs in adipocyte development has emerged from studies demonstrating 
differential changes in the expression of PKC isoforms during the differentiation of 
3T3-L1 preadipocytes (Frevert and Kahn, 1996; McGowan et al, 1996). These 
observations suggest distinct functional roles for individual PKC isoforms during 
preadipocyte differentiation.
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In this study, the roles of individual PKC isoforms in preadipocyte differentiation 
were investigated using the 3T3-F442A cell-model. Initially, in order to gain an 
indication of the functional roles of PKC iso forms in the differentiation process, the 
temporal expression patterns of the conventional, novel and atypical PKCs and of the 
recently identified PKC p were examined during adipocyte development. 
Furthermore, by selective depletion of individual PKC subtypes with antisense ODNs 
prior to the initiation of differentiation, the dependence of the differentiation process 
on individual PKC isoforms was determined.
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4.2 Methods
4.2.1 Assessment o f  the cellular 1e\^els o f  protein kinase C isoforms during 3T3- 
F442A preadipocyte differentiation
4.2.1.1 Cell culture
3T3-F442A preadipocytes (Green and Kehinde, 1976) were grown to confluence in 
100 mm diameter dishes. Two-day confluent cultures of preadipocytes (subsequently 
referred to as just-confluent cells) were either harvested or induced to differentiate 
with foetal calf serum and insulin as described in section 2.2.1.2. Adipocytes were 
harvested ten days from the induction of differentiation. For some experiments, 
parallel cultures of 3T3-F442A preadipocytes were maintained in growth medium for 
twelve days. These cells, which are subsequently referred to as twelve-day confluent 
cells, displayed no morphological change. As an additional control, cultures of non­
differentiating 3T3-C2 cells (Green and Kehinde, 1976) were treated with 
differentiation medium as described for 3T3-F442A cells in section 2.2.1.2.
4.2.1.2. Immunoblotting
Cell lysates were prepared from 3T3-F442A and 3T3-C2 cells at confluence (day -2), 
two days post-confluence (just prior to treatment with differentiation-inducing agents; 
day 0) and at days 2, 5 and 10 of treatment with differentiation-inducing medium. Cell 
lysates were also prepared from 3T3-F442A preadipocytes that had been maintained 
at confluence in growth medium for twelve days. The protein content of cell lysates 
was determined as described in section 2.2.4.1 and confirmed by Coomassie staining 
of mini-gels as described in section 2.2.4.3. Equal quantities of lysate protein were 
subjected to SDS-PAGE alongside a homogenate prepared from rat brain (Kuo et al, 
1980) that served as a positive control for the PKC antibodies. Changes in PKC 
isoform expression were examined by immunoblotting with isoform-specific 
monoclonal antibodies to PKC (Affiniti) as described in section 2.2.4.4. PKC isoform 
expression was quantified by densitometric analysis of immunoblots.
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4.2,1.3 Calculating cellular levels o f  protein kinase C isoforms front immunoblot 
data
When carrying out direct comparisons of immunoreactive PKC levels in cells at 
different stages of the differentiation process, cellular lysates were loaded onto gels 
on the basis of equal protein. To analyse cellular levels of PKC isoforms, values 
obtained from the densitometric analysis of immunoblots had to be adjusted to reflect 
the protein content of the cells. This was achieved by setting up parallel cultures for 
determination of the number of cells per plate. Cell monolayers weri^ washed with 10 
ml of PBS and scraped into 1 ml of PBS per 100 mm diameter dish. Aliquots of cell 
suspension were then counted using a Nebauer Haemocytometer to obtain the number 
of cells per plate and, hence, the number of cells per lysate. These values, together 
with the protein content of the cellular lysates, permitted the calculation of the amount 
of protein per cell that was then used to convert immunoreactive PKC levels, assessed 
by densitometry of gels, into PKC level per cell.
Parallel cultures were also set up for assay of the adipocyte marker enzyme GPDH, as 
described in section 2.2.2.8, as a means of assessing adipocyte development following 
treatment with differentiation-inducing agents.
4.2.2 Effects o f  depletion o f  individual protein kinase C isoforms with antisense 
oligodeoxynucleotides on 3T3-F442A preadipocyte differentiation
4.2.2.1 Treatment o f  cells with oligodeoxynucleotides
3T3-F442A preadipocytes were grown in 60 mm diameter wells. Typically at around 
70-80 % confluence, cells were treated with sense or antisense ODNs to specific PKC 
isoforms as described in section 2.2.2.4.I. For the first 6 h of treatment, cells were 
incubated with the appropriate ODN in combination with lipofectin reagent. The 
lipofectin was subsequently removed from the culture medium and incubations 
continued in the presence of ODN alone. After a further 42 h, cells were either used 
immediately for the preparation of lysates for assessment of immunoreactive PKC 
levels by immunoblotting or, alternatively, cells were induced to differentiate with 
foetal calf serum and insulin.
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4.2.2.2 Assessment o f  the effects o f  depletion o f  protein kinase C isoforms with 
antisense oligodeoxynucleotides on differentiation o f  3T3-F442A cells
3T3-F442A preadipocytes were treated for 48 h with antisense or sense ODNs 
specific for individual isoforms of PKC, as described in section 4.2.2.1 above, then 
induced to differentiate with foetal calf serum and insulin. Differentiation medium 
was replenished every 72 h and the appropriate concentration of ODN was present 
throughout the entire differentiation treatment period. Following the induction of 
differentiation, changes in cell morphology were examined on a daily basis, from day 
1 to day 7 of treatment with differentiation medium, by photographing the cells under 
Phase Contrast Optics (x 24 magnification) using an Olympus 1MT3 inverted 
microscope. After 4 and 7 days of treatment with differentiation medium, 
homogenates were prepared for assay of the adipocyte marker enzyme GPDH as 
described in section 2.2.2.8. The DNA content of cell homogentaes was determined 
fluorimetrically, as described in section 2.2.2.10. In addition, at day 7 of treatment, 
cells were fixed with formalin and stained with Oil Red O, as described in section 
2.2.2.5, for assessment of lipid accumulation.
4.2.3 Statistical analysis
Results are presented as means ± S.E.M. and, unless stated otherwise, statistical 
analysis was by Student’s t-test for paired samples.
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4.3 Results
4.3.1 Protein kinase C isoform expression is altered following 3T3-F442A 
preadipocyte differentiation
The results presented in Chapter 3 demonstrate that 3T3-F442A preadipocytes and 
adipocytes express the same complement of PKC isoforms. To investigate whether 
PKC isoform expression alters as a result of the differentiation process, cellular levels 
of PKC isoforms in 3T3-F442A preadipocytes and adipocytes were compared by 
immunoblot analysis (Figure 4.1). 3T3-F442A preadipocytes maintained in growth 
medium at confluence for twelve days were used as a control to isolate changes in the 
expression of PKC isoforms that were specific to differentiation (Figure 4.1).
The protein content of 3T3-F442A preadipocytes is known to increase as a result of 
differentiation (Lai et al, 1981; Kilgour and Anderson, 1993). Therefore, the cellular 
protein content of lysates was examined during 3T3-F442A preadipocyte 
differentiation (Table 4.1). In accordance with others (Lai et al, 1981), the amount of 
protein per cell in fully differentiated 3T3-F442A adipocytes was found to be 
approximately 2.5 times that of preadipocytes (Table 4.1). The twelve day confluent 
control cells displayed no signs of adipocyte development, either in terms of cell 
morphology (data not shown) or development of activity of the adipocyte enzyme 
marker, GPDH (Table 4.1). The cellular protein content of cells maintained at 
confluence for twelve days, however, was found to be approximately 1.4 fold of that 
of just-confluent preadipocytes (Table 4.1). These values were used to convert the 
data obtained from the densitometric analysis of immunoblots, loaded on an equal 
protein basis (Figure 4.1), to a per cell basis, as described in section 4.2.1.3. (Table
4.2).
Cellular levels of PKC a, y and ô were decreased significantly (p < 0.001, 0.001 and 
0.02 respectively) in 3T3-F442A adipocytes as compared to preadipocytes, by 84 ± 3 
%, 89 ± 2% and 59 ± 13 % respectively (Figure 4.2, hatched bars). In contrast, cellular 
levels of PKC s were increased significantly (p < 0.001) in adipocytes by 298 ± 54 % 
(Figure 4.2, hatched bars). That cellular levels of PKC a , y, Ô and s were unchanged 
in twelve-day confluent 3T3-F442A cells (Figure 4.2, plain bars), which displayed no 
morphological change and did not develop GPDH activity (Table 4.1), suggested that
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changes in expression of PKC a , y, ô and s were specific to the process of 
differentiation.
PKC Ç levels were unchanged by differentiation (Figure 4.2, hatched bars) but an 
elevation (p < 0.02) of 160 ± 3 % in expression of this isoform was observed in the 
twelve-day confluent control cells (Figure 4.2, plain bars). This suggested that PKC Ç 
levels were unchanged by differentiation of 3T3-F442A cells but increased as a result 
of the prolonged confluence of growth-arrested preadipocytes.
Cellular levels of PKC \x were increased (p < 0.01) by 220 ± 30 % in 3T3-F442A 
adipocytes as compared to preadipocytes (Figure 4.2, hatched bars), however, a 
similar increase (p < 0.02) occurred in the control cells which were maintained at 
confluence for twelve days (Figure 4.2, plain bars). That the increase in expression of 
PKC p in differentiated cells was matched in cells maintained at confluence for the 
same period suggested that alterations in expression of PKC p were not specific to the 
differentiation process and may be due to prolonged confluence of growth-arrested 
cells.
4.3.2 Changes in expression o f  protein kinase C isoforms during the differentiation 
o f  3T3-F442A cells
Comparison of the cellular levels of PKC isoforms in 3T3-F442A preadipocytes and 
adipocytes suggested that decreased expression of PKC a , y and Ô and increased 
expression of PKC s were specific to the differentiation process. To examine the 
changes in PKC isoform expression more fully, cellular levels of PKC isoforms were 
examined throughout the time-course of differentiation of 3T3-F442A preadipocytes. 
The patterns of isoform expression that were observed during differentiation of 3T3- 
F442A cells were compared to patterns observed for 3T3-C2 cells that had been 
treated identically with differentiation medium. 3T3-C2 cells are related to 3T3- 
F442A cells but do not differentiate in response to adipogénie stimuli (Green and 
Kehinde, 1976) and were therefore employed to separate differentiation-specific 
effects from other effects of treatment.
Immunoblot analysis of 3T3-C2 cells revealed expression of the same complement of
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PKC isoforms as found in 3T3-F442A cells, namely PKC a , y, 5, e, and |i (Figure
4.3). Similarly, expression of PKC P I/E, r\, 0, 7. or i was not detectable in 3T3-C2 
cells (Figure 4.3). Cellular lysates were prepared from 3T3-F442A and 3T3-C2 cells 
at confluence (day -2), just prior to treatment with differentiation-inducing medium 
(day 0) and at days 2, 5, and 10 of treatment with differentiation-inducing agents and 
subjected to immunoblotting with isoform-specific monoclonal antibodies to PKC 
a , y, 5, s, Ç and p. (Figure 4.4). In addition, immunoblotting was performed using 
polyclonal anti serum raised to PKC P I/II. As reported in Chapter 3, PKC p is not 
detectable in either 3T3-F442A preadipocytes or adipocytes. Similarly, it has been 
reported that PKC p is not expressed in either 3T3-L1 preadipocytes or adipocytes 
(McGowan et al, 1996). However, transient expression of this isoform was reported to 
occur between day 2 and day 5 of treatment of 3T3-L1 cells with differentiation 
medium (McGowan et al, 1996). In the present study, no such temporal expression of 
PKC P was observed during the differentiation of 3T3-F442A preadipocytes (Figure
4.4).
The protein content of 3T3-F442A and 3T3-C2 cell lysates was examined during 
treatment with differentiation medium (Table 4.3) to allow levels of PKC isoforms to 
be expressed on a per cell basis (Table 4.4). By day 2 of treatment, the number of 
3T3-F442A cells per plate had increased approximately 2 fold (Table 4.3), reflecting 
the initial round of cell division found to be necessary for differentiation of the cells 
(Mandrup and Lane, 1997; Smas and Sul, 1995). The protein content of cell lysates 
was found to be approximately 1.4 fold that of untreated cells at this time (Table 4.3). 
At day 5 of treatment, the cellular protein content of the differentiating cells was 
approximately 2 fold that of preadipocytes and reached 2.5 fold that of preadipocytes 
when cells were fully differentiated at day 10 of treatment (Table 4.3). GPDH activity 
was induced between days 2 and 5 of treatment with differentiation-inducing agents in 
3T3-F442A cells and increased as differentiation progressed (Table 4.3). No change 
in either total cell number, cellular protein content, GPDH activity (Table 4.3) nor cell 
morphology (data not shown) was observed in 3T3-C2 cells treated under identical 
differentiation-inducing conditions to the 3T3-F442A cells. Values obtained from the 
densitometric analysis of immunoblots (Figure 4.4) were adjusted accordingly to 
reflect the levels of PKC isoforms in preparations containing an equal number of cells
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(Table 4.4). The changes in cellular levels of PKC isoforms during differentiation of 
3T3-F442A cells were then compared to those of 3T3-C2 cells treated identically 
(Figures 4.5A-F).
Prior to treatment with differentiation-inducing agents, confluent 3T3-F442A 
preadipocytes were allowed to enter a state of growth arrest (day -2 to day 0). During 
this period, cellular levels of PKC y, ô and e decreased (p< 0.05, p< 0.001 and p< 0.05 
respectively) whereas levels of PKC a , (  and |i were unchanged (Figure 4.5A-F). In 
3T3-C2 cells, cellular levels of PKC a , y, ô, and |i were all unchanged during this 
period (Figure 4.5A-F), and, in contrast to observations in 3T3-F442A cells, levels of 
PKC s were increased (p< 0.001; Figure 4.5D).
During the differentiation of 3T3-F442A cells (day 0 - day 10), three distinct patterns 
of change in PKC isoform expression were observed (Figures 4.5A-F ). Prior to 
decreasing to the levels observed in differentiated adipocytes (Figure 4.2), cellular 
levels of PKC a , y and 6 increased (p < 0.001) between day 0 and day 2 of treatment 
with differentiation medium (Figures 4.5A-C). Between days 2 and 10 of 
differentiation, levels of these isoforms fell sharply to values below those observed in 
day 0 preadipocytes (p < 0.001, p < 0.001 and p < 0.01 respectively; Figures 4.5A-C). 
Levels of PKC a  and y fell to values below those observed in day 0 preadipocytes (p< 
0.02 and p< 0.001 respectively) between days 2 and 5 of differentiation (Figures 4.5 
A&B). PKC Ô levels decreased less rapidly after the peak at day 2 of differentiation, 
but were reduced to values below those of undifferentiated preadipocytes (p< 0.01) 
between days 5 and 10 of treatment (Figure 4.5C). The expression of PKC a , y and 5 
followed a similar pattern in identically treated 3T3-C2 cells (Figure 4.5A-C). 
However, the proportional increases in PKC a  and y between days 0 and 2 of 
treatment were much larger (Figures 4.5 A&B) and cellular levels of PKC a , y and 5 
were not reduced between days 2 and 5 of treatment, as observed in 3T3-F442A cells. 
In addition, cellular levels of PKC a, y and 5 were not reduced below the levels 
observed in untreated cells (day 0 preadipocytes) at any time during the treatment of 
3T3-C2 cells (Figures 4.5A-C). This suggested that, following the transient peak in 
expression between day 0 and day 2, decreases in expression of PKC a , y and ô may 
be important for progression of 3T3-F442A preadipocyte differentiation.
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In 3T3-F442A cells, levels of PKC e increased steadily following the induction of 
differentiation, peaking at around day 5 of treatment (Figure 4.5D). Although 
expression of PKC e followed a similar pattern in 3T3-C2 cells treated identically, the 
proportional increase (1.92 ± 0.14 fold versus 2.86 ± 0.09 fold at day 5 of 
differentiation) in expression of PKC s was much smaller (p< 0.01; Figure 4.5D). 
This fact, coupled to the observation that no significant increase in expression of PKC 
8 was observed in 3T3-F442A cells held at confluence for twelve days, (Figure 4.2) 
implied that the proportional increase in expression of PKC s in 3T3-F442A cells may 
be important for preadipocyte differentiation to occur.
Cellular levels of PKC p. increased throughout the course of differentiation of 3T3- 
F442A cells, with the maximal increase observed at day 10 (Figure 4.5F). No 
significant alteration in PKC p expression occurred in 3T3-C2 cells over the same 
period (Figure 4.5F), which suggested that increased expression of PKC p was an 
integral part of the differentiation process. However, the increase in expression of 
PKC p in differentiating cells was matched in 3T3-F442A cells maintained at 
confluence for the same period (Figure 4.2) suggesting that PKC p expression 
increases in 3T3-F442A cells due to prolonged confluency rather than differentiation 
per se.
Finally, the expression of PKC C, was unchanged during treatment of either 3T3- 
F442A or 3T3-C2 cells with differentiation-inducing agents (Figure 4.5E). This 
implied that PKC Ç was not involved in the regulation of 3T3-F442A preadipocyte 
differentiation.
4.3.3 Effects o f  depletion o f  individual protein kinase C isoforms with antisense 
oligodeoxynucleotides on 3T3-F442A preadipocyte differentiation 
The differential changes in the expression of PKC isoforms during 3T3-F442A 
preadipocyte differentiation implied distinct roles for PKC isoforms in the regulation 
of the differentiation process. To investigate further the role of PKC isoforms in 
adipocyte development, antisense ODNs were used to deplete selectively individual 
isoforms from 3T3-F442A preadipocytes prior to the initiation of differentiation.
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3T3-F442A preadipocytes were treated with the appropriate antisense or sense ODNs 
for 48 h prior to the induction of differentiation with medium containing foetal calf 
serum and insulin, as described in section 4.2.2.1. In order to achieve the successful 
depletion of PKC isoforms, it was necessary for lipofectin reagent, which can form 
liposomes that complex with nucleic acids and facilitate cellular uptake (Feigner et al, 
1987), to be present for the first 6 h of the 48 h treatment with ODNs (data not 
shown). However, treatment with lipofectin alone had no effect on the expression of 
PKC isoforms (data not shown). Immunoblot analysis of cells that had been 
preincubated with the specific antisense ODNs revealed that over 90 % of the 
appropriate PKC isoform was depleted at the initiation of differentiation (Figure 4.6). 
In contrast, there was no detectable effect following the identical treatment of cells 
with the appropriate sense ODN (Figure 4.6). Importantly, each antisense ODN was 
specific for the appropriate PKC subtype and had no effect on cellular levels of other 
PKC subtypes (Figure 4.6).
Cells were treated with the individual antisense ODNs for 48 h prior to the induction 
of differentiation. This ensured that the depletion of the relevant PKC subtype was 
complete at the initiation of differentiation. Further immunoblot analysis, of lysates at 
days 0, 3, 4 and 7 of treatment with differentiation medium, revealed that maximal 
depletion of PKC isoforms persisted for at least the first three days of differentiation 
(Figure 4.7). Between days 3 and 4 of differentiation, however, all PKC proteins 
recovered from the effects of antisense suppression (Figure 4.7). The rate of recovery, 
as judged by comparison of levels of expression in cells at day 4 of differentiation to 
those of cells at day 0, did, however, vary between individual isoforms (PKC isoform 
expression as a percentage of that observed in untreated cells = 43 ± 8 % for PKC a, 
62 ± 3  % for PKC y, 51 ± 4 % for PKC ô, 25 ± 9 % for PKC s, 110 ±11 % for PKC 
Ç and 116 ± 10 % for PKC p). The fact that ODN suppression of PKC isoforms was 
transient indicated that the various ODNs were not toxic to the cells and that the 
suppression of PKC isoform expression was reversible. This allowed the impact of 
depletion of PKC isoforms during the early stages of differentiation on the attainment 
of the adipocyte phenotype to be addressed. The effects of preincubation of cells with 
ODNs on subsequent differentiation were assessed qualitatively, by both examination
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of changes in cell morphology and lipid accumulation by staining with Oil Red 0 , and 
also quantitatively, by assaying the activity of the adipocyte marker enzyme GPDH.
Antisense treatment of preadipocytes had three main effects on preadipocyte 
differentiation which were not observed when cells were treated with the appropriate 
sense ODNs or lipofectin alone (Figures 4.8 - 4.10). From morphological examination 
of cells, it appeared consistently that depletion of PKC a , Ô and [i, enhanced the rate 
of adipocyte development during the early stages of treatment with differentiation 
medium (days 2 - 4 )  compared to cells treated with lipofectin alone (Figures 4.8A, C 
and F). However, this effect was no longer detectable at the later stages of the 
differentiation process. This suggested that depletion of PKC a , 5 and p enhanced the 
rate of adipocyte development. Consistent with these observations, at day 4 of 
differentiation the specific activity of the adipocyte enzyme marker GPDH was 
elevated significantly (p < 0.001) in cells depleted of PKC a , 5 or p., by 127 ±2.5 %, 
162.9 ± 8.0 % and 153.2 ± 4.0 % respectively, compared to control cells treated with 
lipofectin alone (Figure 4.9A). However, by day 7 there was no longer any significant 
difference between GPDH activity in cells depleted of PKC a  as compared to control 
cells and only small increases in GPDH activity, of 108.9 ± 0.5 % and 108.5 ± 1.2 % 
respectively, were detected in cells depleted of PKC 5 and p. (Figure 4.9B).
In contrast, depletion of PKC 8 or y clearly inhibited the differentiation process. Cell 
rounding was delayed until day 4 of differentiation following suppression of PKC 8 
and until day 7 following suppression of PKC y (Figures 4.8B and D). GPDH activity 
was significantly decreased (p< 0.001), by 12.8 ± 1.3 % and 15.3 ± 1.42 % 
respectively, at day 4 of differentiation in cells depleted of these isoforms (Figure 
4.9A). At day 7 of differentiation, the activity of this adipocyte marker enzyme was 
reduced to 34.8 ± 0.3 % of control in cells depleted of PKC 8 (Figure 4.9B) and lipid 
filling of the cells was retarded compared to control cells treated with lipofectin alone 
(Figure 4.10). Lipid filling of cells at day 7 of differentiation was completely absent 
following depletion of PKC y (Figure 4.10) and GPDH activity was merely 17.3 ± 8.0 
% of control (Figure 4.9B); a level of activity comparable to that observed in 
undifferentiated preadipocytes (results not shown).
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Depletion of PKC had no detectable effect upon preadipocyte differentiation 
assessed either qualitatively or quantitatively by measurement of GPDH activity 
(Figures 4.8 - 4.10). Thus, it appears that PKC Ç is not essential during the early 
stages of differentiation in 3T3-F442A cells, PKC a , 5 and |i each appear to exert an 
inhibitory influence while PKC e and y are necessary for the differentiation process.
4.3.4 Protein kinase C sa n d  protein kinase C y are required fo r  different stages o f  
3T3-F442A preadipocyte differentiation
Immunoblotting studies revealed that PKC proteins were being expressed by day 4 of 
differentiation (Figure 4.7). Following depletion of PKC s, morphological signs of 
adipocyte development became apparent only when antisense suppression of the PKC 
8 protein was lost at day 4 of differentiation. Following depletion of PKC y, however, 
morphological signs of differentiation were delayed until day 7 of differentiation. 
That a delay occurred between expression of PKC y and morphological signs of 
differentiation suggested a possible role for this isoform in the clonal expansion phase 
of the differentiation process.
To investigate this possibility, the DNA content of cultures was examined at days 0, 
2, 4 and 7 of treatment with differentiation-inducing agents. The clonal expansion that 
is necessary for terminal differentiation to occur in 3T3-F442A cells (Mandrup and 
Lane, 1997; Smas and Sul, 1995) is reflected by an approximate doubling of the 
number of cells per plate that can be observed some two days after exposure to 
differentiation medium (Table 4.3). This increase in cell number, as observed by a 
doubling of the DNA content of cell homogenates, was no longer apparent if cells 
were depleted of PKC y prior to exposure to differentiation medium (Table 4.5). 
Indeed, in cultures depleted of PKC y the increase in DNA content did not occur until 
between day 4 and day 7 of differentiation (Table 4.5). In contrast, treatment of cells 
with the corresponding PKC y sense ODN, or antisense depletion of PKC 8, had no 
effect upon clonal expansion (Table 4.5). Similarly no effect upon clonal expansion 
was detected, as measured by an increase in the DNA content of cultures, following 
depletion of the a , 5, Ç or p isoforms of PKC (Table 4.5). These results suggest that 
differential mechanisms account for the differentiative effects of PKC y and 8. Thus, 
PKC y appears to be required for the clonal expansion of differentiating preadipocytes
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whereas PKC s is not and is likely, therefore, to influence another aspect of the 
differentiation process.
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Figure 4.1 Protein kinase C isoform expression following 
differentiation o f  3T3-F442A cells
Equal quantities (75 pg of protein) of lysate protein prepared from just- 
confluent 3T3-F442A preadipocytes (lanes 1-4), twelve-day-confluent 
3T3-F442A preadipocytes (lanes 5-8) and fully differentiated 3T3- 
F442A adipocytes (lanes 9-12) and homogenate protein prepared from 
rat brain (lane 13) were subjected to immunoblotting with isoform- 
specific monoclonal antibodies to PKC. Results are representative of 
eight separate experiments carried out on different cell preparations.
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Table 4.2 Cellular levels ofprotein kinase C isoforms following 3T3-F442A preadipocyte 
differentiation
Equal quantities (75 pg) of lysate protein prepared from just-confluent 3T3-F442A 
preadipocytes (JC), twelve-day confluent 3T3-F442A preadipocytes (12 DC) and fully 
differentiated 3T3-F442A adipocytes (AD) were subjected to immunoblotting with isoform- 
specific monoclonal antibodies to PKC (Figure 4.1). PKC isoform expression was quantified 
by densitometric analysis and the cellular protein content of lysates (Table 4.1) used to convert 
the values obtained from densitometric analysis of immunoblots into PKC level per cell. Data 
are means ± S.E.M. from eight separate experiments carried out on different cell preparations. 
% ** and *** indicate the value differs significantly from that for just-confluent preadipocytes, 
p < 0.02, 0.01 and 0.001 respectively. Statistical analysis was by Student's t-test for paired 
samples.
Isoform
PKC Expression (arbitrary units)
JC cells 12 DC cells Adipocytes
per unit 
protein
per cell per unit 
protein
per cell per unit 
protein
per cell
a 1285± 102 1285± 102 679± 126 951± 175 83 ±19 208 ± 48***
Y 1667± 153 1667± 153 750 ± 14 1050 ±20 71± 5 177 ± 13***
Ô 1305 ± 48 1305 ± 48 932 ±106 1292± 148 218±71 545 ± 173**
e 1017± 23 1017 ± 23 1013±215 1403 ±302 1213 ±225 3033 ± 563***
c 257 ± 25 257 ± 25 296 ± 25 411 ±36* 109 ± 25 287 ± 62
288± 17 288± 17 419 ±77 587± 107* 249 ± 21 633 ± 52**
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Figure 4.2 The effect o f  differentiation on cellular le\'els o f protein kinase C 
isoforms in 3T3-F442A cells
Cellular lysates were prepared from just-confluent 3T3-F442A preadipocytes, 12-day- 
confluent 3T3-F442A preadipocytes and fully differentiated 3T3-F442A adipocytes 
and subjected to immunoblotting with isoform-specific monoclonal antibodies to PKC 
(Figure 4.1). PKC isoform expression was quantified by densitometric analysis o f  
immunoblots and expressed as PKC level per cell (Table 4.2). The changes in cellular 
levels o f  isoforms following differentiation (hatched bars) or maintenance o f  cells at 
confluence for twelve days (plain bars) are showm as a percentage o f  expression in 
just-confluent preadipocytes (control = 100 %). Data are means ± S.E.M. from eight 
separate experiments carried out on different cell preparations. , * and *** indicates 
the value differs significantly from that for just-confluent preadipocytes, p < 0.02, 
0.01 and 0.001 respectively. Statistical analysis was by Student's t-test for paired 
samples.
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Figure 4.3 Protein kinase C isoforms in 3T3-C2 cells
Equal quantities (75 jug) o f  lysate protein prepared from continent 3T3-C2 cells (lane 
2) and homogenate protein prepared from rat brain (lane 1) were subjected to 
immunoblotting with isoform-specific antibodies to PKC as indicated. Results are 
representative o f  four separate experiments carried out on different cell preparations.
Figure 4.4 Protein kinase C isoform expression during 
differentiation o f  3T3-F442A preadipocytes and control (non­
differentiating) 3T3-C2 cells
Cellular lysates were prepared from 3T3-F442A (lanes 2-6) and 3T3- 
C2 (lanes 7-11) cells at conflence (day -2; lanes 2 and 7) just prior to 
treatment with differentiation medium (day 0; lanes 3 and 8) and at 
days 2 (lanes 4 and 9), 5 (lanes 5 and 10) and 10 (days 6 and 11) of 
treatment with differentiation-inducing agents. Equal quantities (75 
|ig) of lysate protein and protein prepared from a rat brain homogenate 
(lanel) were subjected to immunoblotting with isoform-specific 
antibodies to PKC as indicated. The molecular weights (kDa) of the 
species detected with the polyclonal PKC p antibody are indicated. 
Immunoblots are representative of results obtained from six separate 
experiments carried out on different cell preparations.
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Table 4,4 Cellular levels o f  protein kinase C isoforms during 
differentiation o f  3T3-F442A preadipocytes and control (non­
differentiating) 3T3-C2 cells
Equal quantities (75 pg) of lysate protein prepared from 3T3-F442A 
and 3T3-C2 cells at confluence (day -2) just prior to treatment with 
differentiation medium (day 0) and at days 2, 5 and 10 of treatment 
with differentiation-inducing agents were subjected to immunoblotting 
with isoform-specific monoclonal antibodies to PKC (Figure 4.4). PKC 
isoform expression was quantified by densitometric analysis and the 
cellular fffotein content of lysates (Table 4.3) used to convert the 
values obtained from densitometric analysis of immunoblots into PKC 
level per cell. Data are means ± S.E.M. from six separate experiments 
carried out on different cell preparations. Values for individual PKC 
isoforms that differ significantly (p< 0.05) carry different superscripts. 
Statistical analysis was by ANOVA.
Isoform
Day of 
differentiation
PKC Expression (arbitrary units)
F442A cells C2 Cells
Per unit 
protein Per cell
Per unit 
protein/Per cell S.E.M.
a -2 817.0 817.0* 344.7* 72.08
0 649.3 649.3* 203.0***
2 938.0 1313.0’’ 392.0*
5 183.0 365.3* 606.0“*
10 36.3 91.0** 285.7*
Y -2 241.3 241.3* 110.3’’** 23.65
0 158.3 158.3’’ 48.7***
2 207.3 290.0* 170.3’’*
5 43.0 86.0**’ 234.7“*
10 8.5 21.3* 89.0***
5 -2 356.7 356.7* 168.3*’^ 18.49
0 214.3 214.3’’ 147.0*^
2 399.1 558.7* 318.7“
5 206.7 413.3** 422.7**
10 38.6 96.4* 210.7*’
e -2 503.7 503.7* 154.0^ 22.90
0 424.7 424.7’’ 354.0»
2 570.7 798.7* 612.3*'
5 607.3 1214.7** 680.7’
10 428.3 1070.7* 540.0“
Ç -2 177.7 177.7*’’ 184.0*’ 3.80
0 170.7 170.7“ 186.7*’
2 128.6 180.0*’’ 183.3*’
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Figure 4.5A Changes in protein kinase C a  expression during differentiation o f  
3T3-F442A preadipocytes and control (non-differentiating) 3T3-C2 cells 
Cellular lysates were prepared from 3T3-F442A (■ )  and 3T3-C2 (A) cells at 
confluence (day -2), just prior to treatment with differentiation medium (day 0) and at 
days 2, 5 and 10 o f  treatment with differentiation-inducing agents for assessment o f  
PKC a  levels by immunoblotting (Figure 4.4). Expression o f  PKC a  was quantified by 
densitometric analysis o f  immunoblots and expressed on a per cell basis (Table 4.3). 
The changes in expression o f  PKC a  during treatment with differentiation medium are 
shown both on a per cell basis and as a percentage o f  expression in day 0 preadipocytes 
(control =  100 %). Data represent means ± S.E.M. from six separate experiments 
carried out on different cell preparations. *, **, *** and **** indicate the value differs 
significantly from that for day 0 cells, p < 0.05, 0.02, 0.01, 0.001 respectively. 
Statistical analysis was by ANOVA.
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Figure 4. SB Changes in protein kinase C y  expression during differentiation o f 3T3- 
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells
Cellular lysates were prepared from 3T3-F442A (■) and 3T3-C2 (A)  cells at 
confluence (day -2), just prior to treatment with differentiation medium (day 0) and at 
days 2, 5 and 10 of treatment with differentiation-inducing agents for assessment of 
PKC Y levels by immunoblotting (Figure 4.4). Expression of PKC y was quantified by 
densitometric analysis of immunoblots and expressed on a per cell basis (Table 4.3). 
The changes in expression of PKC y during treatment with differentiation medium are 
shown both on a per cell basis and as a percentage of expression in day 0 preadipocytes 
(control = 100 %). Data represent means ± S.E.M. from six separate experiments 
carried out on different cell preparations. % *** and **** indicate the value differs
significantly from that for day 0 cells, p < 0.05, 0.02, 0.01, 0.001 respectively. 
Statistical analysis was by ANOVA.
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Figure 4.5C Changes in protein kinase C Ô expression during differentiation o f 3T3- 
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells
Cellular lysates were prepared from 3T3-F442A (■ )  and 3T3-C2 (A)  cells at 
confluence (day -2), just prior to treatment with differentiation medium (day 0) and at 
days 2, 5 and 10 o f  treatment with differentiation-inducing agents for assessment o f  
PKC 5 levels by immunoblotting (Figure 4.4). Expression o f  PKC 8 was quantified by 
densitometric analysis o f  immunoblots and expressed on a per cell basis (Table 4.3). 
The changes in expression o f  PKC Ô during treatment with differentiation medium are 
shown both on a per cell basis and as a percentage o f  expression in day 0 preadipocytes 
(control = 100 %). Data represent means ± S.E.M. from six separate experiments 
carried out on different cell preparations. *, **, *** and **** indicate the value differs 
significantly from that for day 0 cells, p < 0.05, 0.02, 0.01, 0.001 respectively. 
Statistical analysis was by ANOVA.
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Figure 4.5D Changes in protein kinase C e expression during differentiation o f  3T3- 
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells 
Cellular lysates were prepared from 3T3-F442A (■) and 3T3-C2 (A)  cells at 
confluence (day -2), just prior to treatment with differentiation medium (day 0) and at 
days 2, 5 and 10 of treatment with differentiation-inducing agents for assessment of 
PKC 8 levels by immunoblotting (Figure 4.4). Expression of PKC 8 was quantified by 
densitometric analysis of immunoblots and expressed on a per cell basis (Table 4.3). 
The changes in expression of PKC 8 during treatment with differentiation medium are 
shown both on a per cell basis and as a percentage of expression in day 0 preadipocytes 
(control = 100 %). Data represent means ± S.E.M. from six separate experiments 
carried out on different cell preparations. % **, *** and **** indicate the value differs
significantly from that for day 0 cells, p < 0.05, 0.02, 0.01, 0.001 respectively.
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Statistical analysis was by ANOVA. (
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Figure 4.5E Changes in protein kinase C f  expression during differentiation o f  3T3- 
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells
Cellular lysates were prepared from 3T3-F442A (■) and 3T3-C2 (A) cells at 
confluence (day -2), just prior to treatment with differentiation medium (day 0) and at 
days 2, 5 and 10 of treatment with differentiation-inducing agents for assessment of 
PKC C, levels by immunoblotting (Figure 4.4). Expression of PKC C, was quantified by 
densitometric analysis of immunoblots and expressed on a per cell basis (Table 4.3). 
The changes in expression of PKC during treatment with differentiation medium are 
shown both on a per cell basis and as a percentage of expression in day 0 preadipocytes 
(control = 100 %). Data represent means ± S.E.M. from six separate experiments 
carried out on different cell preparations. % **, *** and **** indicate the value differs 
significantly from that for day 0 cells, p < 0.05, 0.02, 0.01, 0.001 respectively. 
Statistical analysis was by ANOVA.
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Figure 4.5F  Changes in protein kinase C p  expression during differentiation o f  3T3- 
F442A preadipocytes and control (non-differentiating) 3T3-C2 cells 
Cellular lysates were prepared from 3T3-F442A (■) and 3T3-C2 (A) cells at 
confluence (day -2), just prior to treatment with differentiation medium (day 0) and at 
days 2, 5 and 10 of treatment with differentiation-inducing agents for assessment of 
PKC p levels by immunoblotting (Figure 4.4). Expression of PKC p was quantified by 
densitometric analysis of immunoblots and expressed on a per cell basis (Table 4.3). 
The changes in expression of PKC p during treatment with differentiation medium are 
shown both on a per cell basis and as a percentage of expression in day 0 preadipoc>4es 
(control = 100 %). Data represent means ± S.E.M. from six separate experiments 
carried out on different cell preparations. *, **, *** and **** indicate the value differs 
significantly from that for day 0 cells, p < 0.05, 0.02, 0.01, 0.001 respectively. 
Statistical analysis was by ANOVA.
Figure 4,6 Specific depletion o f  protein kinase C isoforms in 3T3- 
F442A preadipocytes by antisense oligodeoxynucleotide treatment 
3T3-F442A preadipocytes were preincubated with ODNs for 48 h prior 
to the preparation of lysates for assessment of PKC levels by 
immunoblotting. Immunoblots show the amount of each indicated 
isoform in 25 pg of lysate prepared from NIH-3T3 cells over­
expressing the appropriate PKC subtype (OE), control 3T3-F442A 
preadipocytes treated with lipofectin alone (C), 3T3-F442A 
preadipocytes treated with the appropriate sense ODN (S) and 3T3- 
F442A preadipocytes treated with antisense ODN to the PKC isoform 
indicated. Immunoblots are representative of experiments performed 
on at least four occasions for each PKC isoform.
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Figure 4.7 The effect o f time on suppression o f  protein kinase C isoforms by 
antisense oligodeoxynucloetides
3T3-F442A preadipocytes were preincubated with anti sense ODNs to the PKC 
isofonns indicated for 48 h prior to induction of differentiation. Equal quantities (25 
pg) of lysate protein prepared from cells at days 0 (lane 4), 3 (lane 5), 4 (lane 6) and 7 
(lane 7) of differentiation were subjected to immunoblotting with isoform-specific 
monoclonal antibodies to PKC. Immunoblots also show the amounts of each indicated 
PKC isoform in 25 pg of lysate protein prepared from NIH-3T3 cells over-expressing 
the appropriate PKC isoform (lane 1 ), control 3T3-F442A preadipocyles treated with 
lipofectin alone (lane 2) and 3T3-F442A preadipocytes treated with the appropriate 
sense ODN (lane 3). Immunoblots are representative of results obtained on at least 
four occasions for each PKC isoform.
Figure 4,8 A The effect o f  protein kinase C a  oligodeoxynucleotides 
on changes in 3T3-F442A cell morphology during differentiation 
3T3-F442A preadipocytes were preincubated with sense or anti sense 
ODNs to PKC a , or lipofectin alone, for 48 h prior to the induction of 
differentiation. Changes in cell morphology following induction of 
differentiation were examined by photographing cells daily over the 
next seven days. Results are representative of experiments performed 
on at least six occasions.
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Figure 4.8 B  The effect o f  protein kinase C y  oligodeoxynucleotides 
on changes in 3T3-F442A cell morphology during differentiation 
3T3-F442A preadipocytes were preincubated with sense or anti sense 
ODNs to PKC y, or lipofectin alone, for 48 h prior to the induction of 
differentiation. Changes in cell morphology following induction of 
differentiation were examined by photographing eells daily over the 
next seven days. Results are representative of experiments performed 
on at least six occasions.
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Figure 4,8 C The effect o f  protein kinase C 5 oligodeoxynucleotides 
on changes in 3T3-F442A cell morphology during differentiation 
3T3-F442A preadipocytes were preincubated with sense or antisense 
ODNs to PKC 6, or lipofectin alone, for 48 h prior to the induction of 
differentiation. Changes in cell morphology following induction of 
differentiation were examined by photographing cells daily over the 
next seven days. Results are representative of experiments performed 
on at least six occasions.
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Figure 4,8 D The effect o f  protein kinase C e oligodeoxynucleotides 
on changes in 3T3-F442A cell morphology during differentiation 
3T3-F442A preadipocytes were preincubated with sense or antisense 
ODNs to PKC e, or lipofectin alone, for 48 h prior to the induction of 
differentiation. Changes in cell morphology following induction of 
differentiation were examined by photographing cells daily over the 
next seven days. Results are representative of experiments performed 
on at least six occasions.
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Figure 4,8 E  The effect o f  protein kinase C f  oligodeoxynucleotides 
on changes in 3T3-F442A cell morphology during differentiation 
3T3-F442A preadipocytes were preincubated with sense or antisense 
ODNs to PKC or lipofectin alone, for 48 h prior to the induction of 
differentiation. Changes in cell morphology following induction of 
differentiation were examined by photographing cells daily over the 
next seven days. Results are representative of experiments performed 
on at least six occasions.
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Figure 4,8 F  The effect o f  protein kinase C p  oligodeoxynucleotides 
on changes in 3T3-F442A cell morphology during differentiation 
3T3-F442A preadipocytes were preincubated with sense or antisense 
ODNs to PKC p, or lipofectin alone, for 48 h prior to the induction of 
differentiation. Changes in cell morphology following induction of 
differentiation were examined by photographing cells daily over the 
next seven days. Results are representative of experiments performed 
on at least six occasions.
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Figure 4.9 The effect o f  protein kincise C isoform-specific oligodeoxynucleotides on 
induction o f  glycerol-3-phosphate dehydrogenase activity during 3T3-F442A 
preadipocyte differentiation
3T3-F442A cells were preincubated with sense or antisense ODNs to the PKC 
isoform indicated, or lipofectin alone, prior to the induction of differentiation. 
Homogenates were prepared from cells at day 4 (A) and day 7 (B) of differentiation 
for determination of GPDH activit}  ^as described in section 2.2.2.8. GPDH activity of 
homogenates pretreated with sense and antisense ODNs is expressed as a percentage 
of the activity in homogenates prepared from control cultures differentiated following 
pretreatment with lipofectin alone (control = 100 %). Data are means ± S.E.M. of six 
separate experiments carried out on different cell preparations. * indicates the value 
differs significantly from that for cells treated with lipofectin alone, p < 0.001. 
Statistical analysis was by Student's t-test for paired samples.
Figure 4,10 The effect o f  protein kinase C isoform-specific 
oligodeoxynucleotides on lipid accumulation during 3T3-F442A 
preadipocyte differentiation
3T3-F442A preadipocytes were preincubated with sense or antisense 
ODNs to the PKC isoform indicated, or lipofectin alone, for 48 h prior 
to the induction of differentiation. At day 7 of differentiation, cells 
were fixed with formalin and stained for lipid with Oil red O as 
described in section 2.2.2.5.
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Table 4.5 The effect o f  protein kinase C isoform-specific oligodeoxynucleotides on 
total homogenate DNA content during 3T3-F442A preadipocyte differentiation
3T3-F442A preadipocytes were pretreated with sense or antisense ODNs to the PKC 
subtype indicated, or lipofectin alone (control), prior to the induction of differentiation. 
Cellular homogenates were prepared either just prior to (day 0) or 2,4 or 7 days after the 
induction of differentiation for determination of DNA content as described in section 
2.2.2.10. Data are means ± S.E.M. of six separate experiments carried out on different 
cell preparations. * indicates the value differs significantly from that for cells treated with 
lipofectin alone, p < 0.001. Statistical analysis was by Student's t-test for paired samples.
Total DNA per plate (pg/ml of extract)
Day of differentiation
ODN Treatment 0 2 4 7
None 7.4 ±0.41 14.9 ± 1.44 14.9 ±1.35 15.0 ± 1.51
Sense a 7.4 ±0.39 15.0 ± 1.90 15.1 ± 1.47 15.1 ± 1.62
Antisense a 7.6 ±0.50 15.1 ± 1.72 15.1 ± 1.44 15.2 ± 1.65
Sense y 7.5 ± 0.49 14.9 ± 1.61 15.2 ± 1.56 15.1 ± 1.61
Antisense y 7.3 ± 0.29 7.4 ± 0.52* 7.2 ± 0.49* 14.7 ±1.43
Sense ô 7.3 ±0.35 14.8 ± 1.83 15.5 ± 1.82 15.5 ± 1.62
Antisense 5 7.7 ±0.69 15.2±2.11 16.0 ± 1.98 16.1 ±2.10
Sense 8 7.4 ± 0.42 14.7 ± 1.20 15.0 ± 1.39 15.3 ± 1.71
Antisense 8 7.4 ±0.30 14.4 ± 1.71 14.7 ± 1.52 15.0± 1.11
Sense Ç 7.5 ±0.61 14.9 ± 1.51 15.4 ± 1.61 15.6 ± 1.66
Antisense ( 7.3 ± 0.40 15.1 ± 1.79 15.5 ± 1.64 15.5 ± 1.56
Sense |Ll 7.0 ± 0.22 15.0 ± 1.61 15.3 ± 1.71 15.3 ±1.64
Antisense |l 7.4 ±0.51 15.4 ± 1.73 15.5 ± 1.81 16.0 ±2.01
4.4 Discussion
There is now mounting evidence to show that the multiple members of the PKC 
family assume distinct functional roles in the regulation of cellular growth and 
differentiation (see Section 1.6.3). PKC is inhibitory to differentiation in a number of 
cell-lines (Minana et al, 1989; Felipo et al, 1990; Taoka et al, 1990; Sahai et al,
1994). However, in contrast, selective over-expression or up-regulation of PKC 
isoforms has been shown to promote differentiation (Catalioto et al, 1992; Mischak et 
al, 1993; Livneh et al, 1996; McGowan et al, 1996). These studies suggest differential 
roles for individual PKC isoforms at distinct phases of the differentiation process. In 
this study, the 3T3-F442A preadipocyte cell-model was used to investigate the roles 
of individual PKC isoforms in the regulation of adipocyte development.
Initially, in order to gain an indication of the functional roles of PKC isoforms in 3T3- 
F442A preadipocyte differentiation, changes in the expression of individual isoforms 
during the differentiation of 3T3-F442A cells were examined. Two control systems 
were employed to distinguish between changes in cellular levels of PKC isoforms 
induced by the differentiation process per se and changes attributable to cell growth 
or treatment. Initially, cellular levels of PKC isoforms in 3T3-F442A adipocytes were 
compared to those of both just-confluent 3T3-F442A preadipocytes and cells 
maintained at confluence in growth medium for twelve days which did not undergo 
adipose conversion. This gave an indication of whether changes in cellular levels of 
PKC isoforms in adipocytes were specific to differentiation. Secondly, temporal 
patterns of PKC isoform expression during the differentiation of 3T3-F442A cells 
were compared to those observed in 3T3-C2 cells treated identically. 3T3-C2 cells are 
related to 3T3-F442A cells but do not differentiate in response to adipogénie stimuli 
(Green and Kehinde, 1976). Immunoblot analysis of 3T3-C2 cells revealed that they 
expressed the same PKC isoforms as 3T3-F442A cells. That both cell lines had a 
similar PKC complement suggested that differences in the patterns of change of 
cellular levels of PKC isoforms following treatment with differentiation-inducing 
agents may be important in regulating the differentiation process. Comparison of the 
changes in cellular levels of PKC isoforms during the differentiation of 3T3-F442A 
cells with those of 3T3-C2 cells treated identically gave an indication of changes in 
PKC isoforms that were important for the initiation and progression of differentiation.
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Cellular levels of PKC Ç were unchanged both during the differentiation of 3T3- 
F442A cells and during the identical treatment of 3T3-C2 cells. This suggested that 
PKC Ç assumed no obligatory role in the regulation of the differentiation process.
Cellular levels of PKC p increased throughout the differentiation of 3T3-F442A cells 
but were unaltered during the identical treatment of 3T3-C2 cells. This suggested that 
increases in the expression of PKC p were important for the differentiation of 3T3- 
F442A cells. The fact that cellular levels of PKC p were also elevated in 3T3-F442A 
preadipocytes maintained at confluence for twelve days, however, suggested that 
elevated PKC p expression was not specific to the process of differentiation. Thus, 
following temporal studies, the role of PKC p in 3T3-F442A preadipocyte 
differentiation remained unclear.
Following the induction of differentiation in 3T3-F442A preadipocytes, cellular levels 
of PKC a , Y and 5 increased rapidly, peaking at around day 2, correlating with the 
time-point at which clonal expansion of the differentiating cells was observed. 
Subsequently cellular levels of the a , y and 5 isoforms decreased, such that a 
significant reduction in their expression was observed as cells attained the adipocyte 
phenotype. Although expression of PKC a , y and ô followed a similar pattern of 
expression in 3T3-C2 cells treated with differentiation medium, the observation that 
levels of PKC a, y and 5 were reduced during 3T3-F442A preadipocyte 
differentiation prior to the reduction in 3T3-C2 cells supported a possible role for the 
reduction of these isoforms in the differentiation process. This hypothesis was 
strengthened by the fact that cellular levels of PKC a , y and ô were not reduced below 
the levels observed in untreated 3T3-C2 cells at any point during treatment with 
differentiation medium. Thus, following the clonal expansion stage, these isoforms 
may exert an inhibitory influence on the differentiation process.
Cellular levels of PKC s increased throughout the first five days of differentiation and 
were elevated significantly in 3T3-F442A adipocytes compared to preadipocytes. The 
expression profile of PKC was similar in 3T3-C2 cells treated identically. However, 
the proportional increase in expression was much larger in 3T3-F442A cells
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suggesting that the level of PKC expression in 3T3-F442A cells may be important for 
differentiation to progress.
Consistent with the present observations in 3T3-F442A cells, preadipocyte 
differentiation was found to have no effect on cellular levels of PKC Ç in the related 
3T3-L1 cell-line, but was accompanied by an increase in expression of PKC s and a 
reduction in expression of PKC a  (Frevert and Kahn, 1996; McGowan et al, 1996). It 
was also reported that, although PKC P is not expressed in 3T3-L1 preadipocytes or 
adipocytes, brief, transient expression of this iso form occurs during differentiation of 
the cells (McGowan et al, 1996). However, in the present study, expression of PKC P 
could not be detected at any point during the differentiation of 3T3-F442A cells.
3T3-F442A and 3T3-C2 cells also displayed differences in PKC isoform expression 
prior to the induction of differentiation (between day -2 and day 0), during the period 
in which confluent cells become quiescent. Cellular levels of PKC a , y, Ô, C and \i 
were unaltered during this period in 3T3-C2 cells whereas cellular levels of PKC y, Ô 
and s decreased as 3T3-F442A cells entered growth arrest. In contrast to the decrease 
in cellular levels of PKC e observed in growth-arrested 3T3-F442A cells, cellular 
levels of PKC e in 3T3-C2 cells were elevated compared to those in just-confluent 
cells. The differences in PKC expression profiles of quiescent 3T3-F442A and 3T3- 
C2 cells may have important implications for the differentiation process. For example, 
growth-arrested 3T3-F442A cells can be induced to enter a unique state in which they 
become insensitive to mitogens that can induce cell cycle re-entry and sensitive to the 
differentiating activity of hormones that induce expression of the adipose phenotype 
(Guller et al, 1988; Conn et al, 1990). Growth-arrested 3T3-C2 cells cannot be 
induced to reach this anti-mitogenic state (Conn et al, 1990), suggesting that it is an 
integral part of the differentiation process. A number of studies indicate that PKCs 
can contribute to the induction of growth arrest, cell cycle exit and, hence, 
differentiation by a number of mechanisms, including the suppression of cyclins and 
the induction of cyclin-dependent kinase inhibitors (reviewed in Livneh and Fishman, 
1997; see also Section 1.6.3.2). Thus, the differential expression of PKC isoforms in 
3T3-F442A cells and 3T3-C2 cells at growth arrest may be important for the 
induction of the differentiation process.
88
Thus, temporal studies suggested that several isoforms of PKC might have roles at 
different stages in the differentiation of 3T3-F442A preadipocytes. To define the 
dependence of 3T3-F442A preadipocyte differentiation on PKC isoforms, antisense 
ODNs were used to achieve the selective depletion of individual isoforms prior to 
differentiation. Immunoblotiing studies revealed that complete depletion of PKCs 
could be achieved by using the sequence-specific antisense ODNs designed to 
hybridise with the isoform of interest. Importantly, none of the anti sense treatments 
significantly affected the expression of other PKC subtypes. In addition, the effects of 
antisense treatment were fully reversible, indicating that the ODNs were not toxic to 
the cells. Maximal depletion of PKC isoforms also persisted for at least the first three 
days of differentiation. Thus, the role of individual PKC isoforms during the early 
stages of differentiation could be assessed.
Using the antisense approach it was demonstrated that, in agreement with the 
expression data, depletion of PKC C had no detectable effect upon adipocyte 
differentiation assessed either qualitatively, by examining changes in cell morphology 
and accumulation of cell lipid, or quantitatively, by assay of the adipocyte marker 
enzyme GPDH. Thus, it appears that PKC C plays no obligatory role in the process of 
3T3-F442A preadipocyte differentiation.
In contrast, depletion of either PKC a , 5 or p. significantly accelerated the 
differentiation of preadipocytes into adipocytes. Hence, these three isoforms each 
appear to exert an inhibitory influence upon adipocyte differentiation. Therefore, the 
decrease in expression of the a  and 5 isoforms, which occurs following the clonal 
expansion phase of differentiation, may be required for the attainment and 
maintenance of the adipocyte phenotype.
As suppression of PKC a  or PKC 5 accelerated the differentiation of 3T3-F442A 
preadipocytes, the reason for the initial increase in these isoforms at the onset of 
differentiation is unclear. Although levels of PKC a  and Ô are elevated around the 
time of clonal expansion, antisense studies indicate that neither of these isoforms is
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essential for this increase in cell number to occur. It is therefore possible that PKC a  
and Ô play a modulatory role in the clonal expansion phase of differentiation. It is also 
possible that these isoforms can functionally substitute for each other during the 
differentiation of 3T3-F442A cells and that clonal expansion would not occur in the 
simultaneous absence of both isoforms.
Cellular levels of PKC p increase throughout the process of adipocyte development, 
although antisense studies demonstrated that this isoform is not required for 
differentiation to occur. This may point to a functional role for PKC p in the 
adipocyte. That preadipocyte differentiation is actually accelerated in the absence of 
PKC p may indicate that, like PKC a  and 5, PKC p plays a modulatory role during 
the early stages of the differentiation process. Antisense depletion of PKC a , ô and p 
also appeared to increase the growth rate of 3T3-F442A preadipocytes (as assessed by 
morphological examination of cells; I. Fleming, S. MacKenzie and E. Kilgour, 
unpublished observation). Thus, PKC a , 5 and p may play a modulatory role in the 
regulation of growth and the early stages of differentiation in 3T3-F442A cells.
Depletion of PKC y, which displayed a similar temporal pattern of expression to the 
a  and Ô PKC isoforms, severely inhibited adipocyte differentiation. Further antisense 
studies revealed that PKC y was essential for the process of clonal expansion, which 
occurs early during differentiation. Antisense experiments also demonstrated that 
neither PKC a  nor PKC Ô, whose expression levels follow a similar temporal pattern 
to those of PKC y and thus are elevated during the clonal expansion phase, are able to 
functionally substitute for PKC y. From the expression studies, it appeared that, 
following clonal expansion, decreases in PKC y, like PKC a  and Ô, may be important 
for the progression of differentiation.
Depletion of PKC 8 also severely attenuated adipocyte differentiation, thus 
demonstrating that other PKC isoforms are unable to assume the essential functional 
role that this isoform plays in adipocyte development. Further studies revealed that 
PKC 8 is not required for clonal expansion of differentiating cells, but is likely to be 
necessary in the later stages of differentiation, when its expression is markedly 
elevated, for attainment and maintenance of the adipocyte phenotype.
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Preadipocyte differentiation is a complex process, requiring the strict ordering of a 
cascade of multiple and interacting molecular events, leading to the expression of 
multiple genes required for maintenance of the adipocyte phenotype. PKCs are 
involved in a number of the signalling pathways that are known to modulate the 
process of preadipocyte differentiation (Anderson, 1993; Nakanishi et al, 1993; Toker 
et al, 1994; Cobb and Goldsmith, 1995; Sale et al, 1995; Uehara et al, 1995; Yeh et 
al, 1995) and there is considerable evidence that the PKC family of isoforms play an 
important part in the "cross talk" which occurs between different signalling pathways 
(Houslay, 1991; Hata et al, 1993; Stabel and Parker, 1993; Chin, et al, 1994; Houslay,
1995). Thus, the fluctuations in cellular levels of PKC isoforms that occur throughout 
adipocyte development are likely to be important for the modulation and integration 
of the variety of signals that regulate the differentiation process.
At present, the mechanisms by which the PKC family regulate adipocyte development 
are uncertain. However, the results of this study indicate that PKC isoforms assume 
distinct functional roles during 3T3-F442A preadipocyte differentiation and are, thus, 
likely to target different cellular substrates. Members of the C/EBP and the PPAR 
family of transcription factors, which are especially prominent in the control of 
adipogenesis (see Yeh and McKnight, 1995), display similar temporal expression 
profiles to individual PKC isoforms during preadipocyte differentiation (see Figure 
1.3). In particular, C/EBP p and C/EBP 5, which are induced during the early stages 
of differentiation, peak during the clonal expansion phase and subsequently decline as 
cells attain the adipocyte phenotype, follow a similar temporal pattern of expression 
to PKC a , y and ô. In addition, PPAR y, which is induced during the clonal expansion 
phase of differentiation and continues to increase as cells attain the adipocyte 
phenotype, follows a similar temporal pattern of expression to PKC 8 and p. This 
implies that the C/EBP and PPAR proteins may be plausible candidiates as the 
ultimate down-stream targets of individual PKC isoforms during preadipocyte 
differentiation. Indeed, a role for PKCs in the regulation of PPAR y has already been 
implied by studies demonstrating that suppression of adipogenesis by TP A involves 
the MAP kinase-mediated phosphorylation of PPAR y and attenuation of its
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transcriptional activity (Hu et al, 1996).
In summary, selective changes in PKC isoform expression accompany the 
differentiation process in 3T3-F442A cells, implying distinct functional roles for PKC 
isoforms in the regulation of adipocyte development and function. Anti sense 
depletion of PKC isoforms revealed that PKC Ç is not essential for any stage of the 
differentiation process. PKC a , 5 and p each exert an inhibitory influence upon the 
early stages of adipocyte development and are therefore likely to modulate this stage 
of the differentiation process. PKC s is required for the attainment of the adipocyte 
phenotype and PKC y is essential for the clonal expansion of differentiating 
preadipocytes. These results clearly demonstrate that PKC subtypes assume distinct 
functional roles in 3T3-F442A cells and are therefore likely to target different cellular 
substrates.
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Chapter 5
Investigation of the roles of individual protein kinase 
C isoforms in growth hormone- and insulin- mediated 
effects on lipogenesis in 3T3-F442A adipocytes
5.7 Introduction
The key features of adipose tissue metabolism are the synthesis and subsequent 
hydrolysis of fat. The enzymes involved in lipid metabolism in the adipocyte are 
subject to strict regulation by a number of hormones. Two important hormonal 
regulators of adipocyte metabolism are insulin, which promotes fat deposition, and 
growth hormone (GH), which reduces adiposity (see Sections 1.2.1 and 1.2.1.1).
Several studies have produced evidence of a role for PKC in some of the signalling 
events mediated by GH (see Section 1.6.3.4). GH increases levels of DAG, a natural 
activator of PKC, in various cells (Doglio et al, 1989; Catalioto et al, 1992). In 
addition, studies with phorbol esters suggest that, in preadipocytes, activation of MAP 
kinases, and s6 kinases (Anderson 1992 and 1993) and promotion of terminal 
differentiation (Gurland et al, 1990; Campbell et al, 1992) by GH occur by PKC- 
dependent mechanisms. Furthermore, at least in the rat adipocyte, data are consistent 
with GH exerting inhibitory effects on lipogenesis (Smal and De Meyts, 1987) and 
stimulatory effects on lipolysis (Gorin et al, 1990) via signal transduction which is, at 
least in part, mediated by the activation of PKC. Thus, one or more isoforms of PKC 
are likely to be involved in the signalling pathway(s) by which GH regulates 
adipocyte metabolism.
The role of PKC in mediating the effects of insulin remains more controversial (see 
Section 1.6.3.5). PKC has been associated with attenuation of the insulin response and 
the induction of insulin resistance (see Houslay, 1991; Chin et al, 1993). However, 
insulin has been noted to activate a number of PKC isoforms in adipocytes (Farese et 
al, 1992; Bandyopadhyay et al, 1997). In addition, PKC appears to be, at least in part, 
required to mediate insulin-stimulated lipogenesis (Smal and De Meyts, 1987) and 
glucose transport (Standaert et al, 1990; Grunberger, 1991; Yano et al, 1993; Chalfant 
et al, 1995) in the adipocyte. Therefore, the role of PKC isoforms in mediating the 
metabolic effects of insulin appears to be complex. This may be due, in part, to 
interactions of a range of PKC isoforms.
In this study, the involvement of specific PKC isoforms in the signalling mechanisms 
by which GH and insulin alter the rate of lipogenesis in the adipocyte was
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investigated. Initially, the effects of GH in vivo on the expression of PKC isoforms in 
the rat adipocyte were examined. The effects of GH and insulin on the expression of 
PKC isoforms in vitro were then examined in 3T3-F442A adipocytes. Finally, the 
selective depletion of individual PKC isoforms from 3T3-F442A adipocytes was 
carried out using specific antisense ODNs, in an attempt to define the roles of 
individual PKC isoforms in the GH- and insulin-mediated effects on lipid synthesis in 
the adipocyte.
94
5,2 Methods
5.2.1 Assessment o f  the effects o f  growth hormone and insulin on protein kinase C 
isoform expression in adipocytes
5.2.1.1 Assessment o f  protein kinase C isoform expression in rats treated with 
antiserum to rat growth hormone
5.2.1.1.1 Immu noneutralisation o f  circulating rat growth hormone
Female Wistar rats of 150-180g were treated twice daily with antiserum to rat GH, 
either alone, or in combination with ovine GH, for four days as described in section
2.2.3.1. Control animals received equivalent injections of carrier solutions. Rat body 
weights were taken prior to the commencement of treatments and following their 
completion to assess the effectiveness of treatments in changing serum GH 
concentrations. On day 5, rats were anaesthetised as described in section 2.2.3.1 prior 
to the extraction of parametrial fat pads and blood samples. Upon removal, the 
parametrial fat pads were weighed rapidly and placed in saline at 37° C prior to the 
isolation of adipocytes.
5.2.1.1.2 Isolation o f  rat adipocytes and homogenate preparation
Parametrial fat pads, removed from rats treated as described above in section
5.2.1.1.1, were washed in Krebs-Ringer-Hepes buffer and minced finely as described 
in section 2.2.3.2. Adipocytes were subsequently extracted by collagenase digestion 
as described in section 2.2.3.2. Undigested material was removed by filtration and 
adipocyte homogenates were prepared at room temperature as described in section
2.2.3.2.
5.2.1.1.3. Assessment o f  fa t pad composition
Prior to homogenisation, aliquots of adipocyte suspension were retained and placed at 
37° C until transfer to a warm haemocytometer where the diameter of one hundred 
cells was measured to allow calculation of the mean cell volume as described in 
section 2.2.3.3. Further aliquots of adipocyte suspension were oven dried at 100° C. 
An estimate of the number of cells per gram tissue was obtained by dividing the total
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lipid content of the tissue by the average lipid content of the fat cells as described by 
Di Girolamo et a / (1971). Lipid content of the adipose tissue was taken to be equal to 
its dry weight and the average lipid content of the fat cells derived from the mean cell 
volume X density of lipid (= 0.9).
5.2.1.1.4 Preparation o f  serum from  whole blood and assay o f  IGF-1
Blood samples, taken from rats treated as described above in section 5.2.1.1.1, were 
allowed to clot on ice prior to the extraction of serum by centrifugation as described 
in section 2.2.3.6. Endogenous serum lGF-1 levels were determined by 
radioimmunoassay as described in section 2.2.3.7.
5.2.1.1.5 Immunoblotting
Cellular homogenates were prepared from the isolated adipocytes of rats treated as 
described above in section 5.2.1.1.1. The protein content of cell homogenates was 
determined as described in section 2.2.4.1 and confirmed by Coomassie staining of 
mini-gels as described in section 2.2.4.3. Equal quantities of homogenate protein were 
subjected to SDS-PAGE alongside a homogenate prepared from rat brain that served 
as a positive control for the PKC antibodies. PKC isoform expression was examined 
by immunoblotting with isoform-specific monoclonal antibodies to PKC as described 
in section 2.2.4.4. PKC isoform expression was quantified by densitometric analysis 
of immunoblots.
5.2.1.2 Assessment o f  protein kinase C isoform expression in 3T3-F442A 
adipocytes treated with growth hormone and insulin
5.2.1.2.1 Cell culture
3T3-F442A preadipocytes were grown to confluence in 100 mm diameter dishes. Two 
day confluent cultures were induced to differentiate with foetal calf serum and insulin 
as described in section 2.2.1.2. Insulin was removed from the medium on day 8 of 
differentiation and adipocytes were treated as required at day 10 of differentiation 
following a 16-18 h incubation in the absence of serum.
5.2.1.2.2 Hormone treatment o f  3 T3-F442A adipocytes
Fully differentiated 3T3-F442A adipocytes were incubated for 16-18 h in the absence
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of exogenous hormones and then incubated for 24 h in the presence or absence of 4.5 
nM GH or 8.7 nM insulin, either alone, or in combination. Subsequently, cellular 
lysates were prepared as described in section 2.2.2.6. The protein content of cell 
lysates was determined as described in section 2.2.4.1 and confirmed by Coomassie 
staining of mini-gels as described in section 2.2.4.3. PKC isoform expression in 
adipocyte lysates was examined and quantified as descibed above in section 5.2.1.1.5.
5.2.2 Characterisation o f  the effects o f  growth hormone and insulin on the rate o f  
lipid synthesis in 3T3-F442A adipocytes
3T3-F442A preadipocytes were grown to confluence in 30 mm diameter wells. Two- 
day confluent cultures were induced to differentiate as described above in section
5.2.1.2.1. Fully differentiated adipocytes were incubated with hormones as described 
above in section 5.2.1.2.2, except that incubations were carried out for 24 and 48 h. 
Hormones were replenished every 24 h and the rate of lipogenesis subsequently 
determined as described in section 2.2.2.9.
5.2.2.1 Treatment o f  cells with kinase inhibitors
For some experiments, the effects of GH and insulin on the rate of lipid synthesis in 
3T3-F442A adipocytes were determined in the presence of wortmannin, an inhibitor 
of Pi 3-kinase (Arcaro and Wymann, 1993; Powis et al, 1994), and PD98059, an 
inhibitor of MAP kinase kinase and, hence, MAP kinase (Alessi et al, 1995). Stock 
solutions of wortmannin and PD98059 were prepared in DMSO and stored at -20° C 
until use. Solutions of wortmannin were kept dark until required.
3T3-F442A adipocytes were incubated with hormones as described above in section
5.2.1.2.2. Wortmannin (100 nM) and PD98059 (50 p.M) were added immediately 
following hormones and wortmannin was replenished every 8 h. The rate of 
lipogenesis was subsequently determined as described in section 2.2.2.9.
5.2.3 Assessment o f  the role o f  protein kinase C isoforms in the growth hormone- 
and insulin-mediated effects on lipid synthesis in 3T3-F442A adipocytes 
3T3-F442A preadipocytes were grown and differentiated in 30 mm diameter wells. 
Adipocytes were treated with sense or antisense ODNs (20 pM) specific for
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individual isoforms of PKC or PKD at day 8 of differentiation as described in section
2.2.2.4.2. (Insulin was effectively removed from the culture medium at this stage). For 
the first 6 h of treatment, adipocytes were incubated with appropriate ODN in 
combination with lipofectin reagent (40 pg/ml). The lipofectin was subsequently 
removed from the culture medium and incubations continued in the presence of ODN 
alone. After a further 42 h, cells were either used immediately for the preparation of 
lysates for assessment of immunoreactive PKC levels by immunoblotting or, 
alternatively, cells were incubated with hormones as desribed above in section
5.2.1.2.2 prior to the assessment of lipogenesis as described in section 2.2.2.9.
5.2.4 Statistical analysis
Results are presented as means ± S.E.M. and, unless stated otherwise, statistical 
analysis was by Student's t-test for paired samples.
98
5.3 Results
5.3.1 The effects o f  growth hormone and insulin on protein kinase C isoform 
expression in adipocytes
In order to gain an indication of the possible functional roles of PKC isoforms in fat 
cells, the involvement of individual isoforms in the signalling pathways utilised by 
GH and insulin in adipocytes was investigated. Initially, it was established whether 
GH and insulin affected the expression of adipocyte PKC isoforms.
To establish whether GH affected the expression of PKC isoforms in vivo, rats were 
treated with antiserum to rat GH to neutralise circulating levels of the hormone. In 
addition to the antiserum, some animals also received ovine GH. The purpose of these 
animals was to serve as a control against the non-specific effects of the antiserum. 
The effectiveness of treatments in changing serum GH concentrations was assessed 
by measuring changes in rat growth rate (Figure 5.1) and serum IGF-I concentration 
(Table 5.1). In addition, the effect of treatments on fat pad composition was examined 
(Table 5.1).
The total changes in body weight following treatments indicated that significant 
changes in serum GH levels were being achieved (Figure 5.1). Anti serum treated 
animals exhibited significant weight loss (p < 0.001) compared to control animals 
indicating that neutralisation of circulating GH was being achieved (Figure 5.1). This 
was confirmed by determination of serum IGF-I levels (Table 5.1). Antiserum-treated 
animals displayed significantly reduced (p < 0.01) levels of IGF-I compared to control 
animals and those treated with antiserum to rat GH in combination with oGH (Table 
5.1). In accordance with others (Kilgour et al, 1995), it was found that neutralisation 
of circulating GH had no significant effect on the size or number of parametrial 
adipocytes (Table 5.1).
Simultaneous administration of oGH reversed the effect of antiserum treatment on rat 
growth rate (Figure 5.1), resulting in a weight gain greater that that of control animals 
(p < 0.001). This suggested that the oGH replacement regime achieved serum GH 
levels greater than those in control rats. Thus, PKC isoform expression could be
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examined both in the absence of GH and in the presence of excess GH. Isolated 
adipocytes prepared from treated rats were subjected to immunoblotting with isoform- 
specific antibodies to PKC (Figure 5.2) and PKC isoform expression was quantified 
by densitometric analysis of immunoblots (Table 5.2).
Removal of circulating GH had no effect on the level of expression of PKC a , y or 5 
in homogenates prepared from isolated rat adipocytes (Table 5.2). However, addition 
of excess GH suppressed significantly (p < 0.05) the levels of expression of these 
isoforms (Table 5.2), suggesting a possible threshold serum GH concentration, above 
which GH suppresses levels of PKC a , y and Ô in rat adipocytes.
On removal of circulating GH, levels of PKC Ç and p were suppressed significantly (p 
< 0.05; Table 5.2), suggesting that GH enhances the expression of these PKC 
isoforms. In agreement with this, administration of excess GH reversed the effect of 
antiserum treatment on cellular levels of PKC ^ and p (Table 5.2).
The situation with PKC 8 was more complicated in that levels of expression were 
enhanced significantly (p < 0.002) in both the absence of GH and upon addition of 
excess GH (Table 5.2). Collectively, these results suggested that GH differentially 
regulates the expression of PKC isoforms in rat adipocytes.
The effects of GH on PKC isoform expression were further assessed in vitro. In 
addition, the effects of insulin on PKC iso form expression were examined in vitro. 
3T3-F442A adipocytes were incubated in the absence of exogenous hormones for 16- 
18 h and then incubated in the presence or absence of 4.5 nM GH or 8.7 nM insulin 
for a period of 24 h. PKC isoform expression in adipocyte lysates was subsequently 
examined by immunoblotting (Figure 5.3) and quantified by densitometric analysis of 
immunoblots (Table 5.3). PKC isoform expression in adipocytes treated with GH or 
insulin did not differ significantly from that obser\^ed in control adipocytes incubated 
in the absence of hormones (Table 5.3). Thus, direct in viti^o addition of GH or insulin 
to 3T3-F442A adipocytes did not effect significantly the expression of PKC isoforms. 
This suggested that GH and insulin did not exert their chronic effects in adipocytes 
via changes in the expression of PKC isoforms.
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5.3.2 Characterisation o f  the effects o f  growth hormone and insulin on the rate o f  
lipid synthesis in 3T3-F442A adipocytes
It is well established that chronic incubation with insulin increases the rate of lipid 
synthesis in the adipocyte whereas chronic incubation with GH both suppresses the 
basal rate of lipid synthesis and antagonises the ability of insulin to maintain or 
increase the basal rate (Vernon, 1982; Vernon and Flint, 1989; see Section 1.2.1.1.2). 
The involvement of PKC isoforms in the signalling pathway(s) utilised by GH and 
insulin to exert these effects on the rate of lipogenesis was investigated in 3T3-F442A 
adipocytes.
The effects of treatment with hormones on the rate of lipid synthesis were initially 
characterised. 3T3-F442A adipocytes were incubated with GH and insulin, either 
alone, or in combination, for 24 or 48 h and the rate of lipid synthesis determined by 
incorporation of radiolabelled acetate into cell lipid. Incubation with GH for 24 h 
reduced significantly (p < 0.001) the rate of lipogenesis to approximately 40 % of that 
observed in cells incubated in the absence of hormones (Figure 5.4). Incubation with 
insulin for 24 h increased significantly (p < 0.001) the rate of lipogenesis to 
approximately 160 % of control (Figure 5.4). Following incubation with GH and 
insulin in combination, no significant alteration in the rate of lipogenesis was 
observed (Figure 5.4), indicating that GH was antagonising the ability of insulin to 
stimulate lipogenesis. The effects of both GH and insulin on the rate of lipid synthesis 
were not enhanced further by treatment with hormones for 48 h (Figure 5.4). Hence, 
in all subsequent experiments, hormone incubations were carried out for a period of 
24 h.
GH and insulin are known to stimulate the signalling pathways of MAP kinase and PI 
3-kinase (Anderson, 1992; Kilgour et al, 1996; Denton and Tavare, 1995; Moule et al, 
1995), both of which have been shown to involve isoforms of PKC (Cobb and 
Goldsmith, 1995; Nakanishi et al, 1993; Toker et al, 1994). It is, however, unclear 
whether these pathways are involved in the signalling mechanisms by which GH and 
insulin alter the rate of lipid synthesis in 3T3-F442A adipocytes. The involvement of 
the MAP kinase and PI 3-kinase pathways in the GH- and insulin-mediated effects on 
lipid synthesis in 3T3-F442A adipocytes was, therefore, investigated by making use
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of the kinase inhibitors wortmannin and PD98059. When used at appropriate 
concentrations, wortmannin is a potent and relatively specific inhibitor of PI 3-kinase 
(Arcaro and Wymann, 1993; Powis et al, 1994). PD98059 has been shown to prevent 
the activation of MAP kinase by its activating kinase, MEK (Alessi et al, 1995). 3T3- 
F442A adipocytes were incubated in the absence of exogenous hormones for 16-18 h 
and then incubated with GH or insulin for 24 h in the presence of 100 nM wortmannin 
or 50 |iM PD98059.
Following treatment with GH, the rate of lipogenesis in control adipocytes was 
reduced significantly (p < 0.001) to 37.1 ± 6.2 % of that observed in cells incubated in 
the absence of hormones (Table 5.4). Following treatment with insulin, the rate of 
lipogenesis was enhanced significantly (p < 0.001) to 165.5 ± 9.8 % of that observed 
in cells incubated in the absence of hormones (Table 5.4).
In the presence of wortmannin, the basal rate of lipogenesis was reduced significantly 
(p < 0.001) to 41.3 ± 4.5 % of that observed in control adipocytes (Table 5.4). Hence, 
the rate of lipogenesis following treatment with GH was reduced significantly (p < 
0.001) in wortmannin-treated cells compared to control adipocytes (Table 5.4). 
However, treatment with wortmannin had no significant effect on the ability of GH to 
suppress the rate of lipogenesis. GH reduced the rate of lipogenesis to 52.7 ± 6.7 % 
and 41.3 ± 4.5 % of that observed in adipocytes incubated in the absence of hormones 
in wortmannin-treated cells and control adipocytes respectively (Table 5.4). This 
suggested that, although PI 3-kinase was required to maintain the basal rate of 
lipogenesis, this kinase was not required for the suppression of lipogenesis by GH.
Similarly, the rate of lipogenesis following treatment of adipocytes with insulin was 
reduced significantly (p < 0.001) in wortmannin-treated cells compared to control 
adipocytes incubated in the absence of inhibitors (Table 5.4). Insulin stimulated 
significantly (p < 0.01) the rate of lipogenesis in wortmannin-treated cells (Table 5.4). 
However, the stimulation by insulin was reduced slightly, but significantly (p < 0.05), 
to 80.4 ±5.1  % of that observed in control adipocytes (Table 5.3). Thus, it would 
appear that insulin affects lipogenesis through multiple routes, one of which involves 
the PI 3-kinase pathway.
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Incubation of cells with the MEK inhibitor PD98059 was found to have no effect on 
the basal rate of lipogenesis or on the ability of GH and insulin to suppress or 
stimulate the rate of lipogenesis respectively (Table 5.4). This suggested that MAP 
kinases are not involved in the signalling pathways utilised by GH or insulin to exert 
their effects on the rate of lipid synthesis in 3T3-F442A adipocytes.
5.3.3 The effects o f  depletion o f  individual protein kinase C isoforms with antisense 
oligodeoxynucleotides on growth hormone- and insulin-induced changes in the rate 
o f  lipid synthesis in 3T3-F442A adipocytes
To define whether PKC isoforms were required for the GH and insulin-mediated 
effects on the rate of lipid synthesis in 3T3-F442A adipocytes, antisense ODNs were 
used to deplete individual isoforms of PKC selectively from 3T3-F442A adipocytes 
prior to stimulation with hormones. 3T3-F442A adipocytes were treated with sense or 
antisense ODNs in combination with lipofectin reagent, or lipofectin was used alone 
as a control, for 6 h at day 8 of differentiation. Immunoblot analysis of adipocytes 
after 48 h revealed that over 90 % of the appropriate PKC isoform was depleted 
following treatment with the appropriate antisense ODN (Figure 5.5). PKC-depleted 
adipocytes were treated with GH or insulin, either alone, or in combination, for 24 h 
and the rate of lipid synthesis determined.
Treatment of cells with lipofectin alone had no significant effect on the stimulation of 
lipogenesis by insulin, the direct suppression of lipogenesis by GH or the ability of 
GH to antagonise the insulin-mediated stimulation of lipogenesis (Table 5.5). 
Similarly, incubation of 3T3-F442A adipocytes with the appropriate sense ODNs had 
no significant effect on the GH- and insulin-mediated effects on the rate of 
lipogenesis (Tables 5.6 A-F).
Following depletion of PKC a , 5 or Ç, there was no significant effect on the 
suppression of lipogenesis by GH, the stimulation of lipogenesis by insulin or the 
ability of GH to antagonise the insulin-stimulated increase in the rate of lipogenesis 
(Tables 5.6 A, C and E). This suggested that these isoforms of PKC were not essential 
for GH or insulin to exert their effects on lipogenesis in 3T3-F442A adipocytes.
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Following depletion of PKC y, the rate of lipogenesis following treatment with either 
GH or insulin did not differ significantly from that observed in control adipocytes 
incubated with lipofectin alone (Table 5.6 B). In the absence of PKC y, however, the 
rate of lipogenesis in cells incubated with GH and insulin in combination did not 
differ significantly from that observed when cells were incubated with insulin alone 
(Table 5.6 B). Thus, in the absence of PKC y, GH did not antagonise the insulin- 
mediated increase in lipid synthesis. Therefore, in 3T3-F442A adipocytes, PKC y 
does not appear to be required for the insulin-stimulated increase in lipogenesis or the 
inhibition of basal lipogenesis by GH. PKC y appears to be essential, however, for the 
inhibition of insulin-stimulated lipogenesis by GH
Following depletion of PKC 8, the rate of lipogenesis following treatment with GH, 
either alone, or in combination with insulin, did not differ significantly from that 
observed in control adipocytes incubated with lipofectin alone (Table 5.6 D). This 
suggested that PKC 8 is not essential for the inhibition of basal or insulin-stimulated 
lipogenesis by GH in 3T3-F442A adipocytes. In the absence of PKC 8, treatment with 
insulin stimulated significantly (p < 0.05) the rate of lipogenesis (Table 5.6 D). 
However, the rate of lipogenesis in insulin-stimulated cells depleted of PKC 8 did not 
differ significantly from the basal rate of lipogenesis in cells treated with lipofectin 
alone (Table 5.6 D). This was due to a small, but significant (p < 0.05) reduction in 
the insulin response; the insulin-induced stimulation of lipogenesis in adipocytes 
depleted of PKC 8 was reduced to 81.3 ± 3.4 % of that observed in control adipocytes 
treated with lipofectin alone (Table 5.6 D). Thus, in 3T3-F442A adipocytes, PKC 8 
appears to be one of the multiple components required for the stimulation of 
lipogenesis by insulin.
Following depletion of PKC (i, treatment with GH reduced significantly (p < 0.05) the 
rate of lipogenesis compared to that observed in adipocytes incubated in the absence 
of hormones (Table 5.6 F). However, the rate of lipogenesis in PKC ^.-depleted cells 
following treatment with GH did not differ significantly from the basal rate of 
lipogenesis observed in control cells treated with lipofectin alone (Table 5.6 F). The 
suppression of lipogenesis by GH was, thus, reduced significantly to 51.1 ±9.1 % of
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that observed in control cells incubated with lipofectin alone (Table 5.6 F). That the 
suppression of lipogenesis by GH was reduced significantly in adipocytes depleted of 
PKC indicated that PKC fx is a component of the signalling mechanism by which 
GH suppresses the basal rate of lipogenesis in 3T3-F442A adipocytes and that other, 
PKC ^-independent pathways are also required.
More strikingly, the rate of lipogenesis in PKC |i-depleted adipocytes treated with 
insulin did not differ from that observed in cells incubated in the absence of hormones 
(Table 5.6 F). Thus, in the absence of PKC p., insulin did not stimulate lipogenesis. 
This suggested that PKC p. is an essential component of the signalling mechanism by 
which insulin increases the rate of lipogenesis in 3T3-F442A adipocytes.
When PKC |i-depleted adipocytes were incubated with GH and insulin in 
combination, the rate of lipogenesis did not differ significantly from that observed 
following incubation of cells with insulin alone or following incubation in the absence 
of hormones (Table 5.6 F). Thus, GH did not alter the rate of lipogenesis in the 
presence of insulin. Since insulin does not alter the rate of lipogenesis in the absence 
of PKC there is no insulin response for GH to antagonise. Thus, these results are 
likely to reflect the fact that the suppression of basal lipogenesis by GH requires PKC 
ft
Antisense depletion of PKC \i reduced the direct suppression of lipogenesis by GH to 
approximately 50 % of that observed in control adipocytes (Table 5.6 F). In the 
absence of PKC y, the direct suppression of lipogenesis by GH was reduced to 
approximately 60 % of that observed in control adipocytes. However, the effect of 
depletion of PKC y on the suppression of lipogenesis by GH was found not to be 
significant. To investigate further the involvement of PKC y in the signalling 
mechanism by which GH suppresses the basal rate of lipid synthesis, lipogenesis was 
examined in the absence of both PKC y and PKC |i. 3T3-F442A adipocytes were 
incubated with anti sense ODNs to PKC y and PKC p. in combination and the rate of 
lipogenesis following hormone stimulation subsequently determined. Immunoblotting 
studies revealed that incubation of cells with PKC y and PKC p antisense ODNs in
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combination resulted in complete depletion of the appropriate PKC isoforms (Figure 
5.6). The rate of lipogenesis in PKC y/p-depleted adipocytes following GH-treatment, 
however, did not differ significantly from that observed in adipocytes depleted of 
PKC p alone (Table 5.7 and Table 5.6 F). That the GH-response was not reduced 
further following depletion of PKC y in addition to PKC p indicated that PKC p was 
important for the suppression of basal lipogenesis by GH and that PKC y was not 
essential, as earlier studies had suggested
Thus, in 3T3-F442A adipocytes, PKC p appears to be, at least in part required for the 
suppression of basal lipogenesis by GH and essential for the stimulation of 
lipogenesis by insulin. Given the importance of the results obtained using the 
antisense ODN to PKC p, 3T3-F442A adipocytes were also treated with an antisense 
ODN to PKD, which is thought to be the murine homologue of this protein (Van Lint 
et al, 1995). PKC p was originally identified in cells of human origin (Johannes et al, 
1994). Thus, the ODN used to deplete PKC p from murine 3T3-F442A adipocytes 
was derived from the human gene sequence. The PKD ODN was designed to 
hybridise specifically with bases within the murine (PKD) coding sequence which 
were not present within the human (PKC p) coding sequence (see Section 2.1.4). 
Immunoblotting studies revealed that treatment of adipocytes with the PKD antisense 
ODN resulted in the complete depletion of the 112 kDa protein detected with the 
monoclonal antibody to PKC p (Figure 5.7). Thus, treatment with either the PKC p 
antisense ODN or the PKD antisense ODN resulted in depletion of the same 112 kDa 
protein from 3T3-F442A adipocytes. PKD-depleted cells were incubated with GH and 
insulin either alone, or in combination, and the rate of lipogenesis determined.
The rates of lipogenesis following treatment of PKD-depleted adipocytes with GH 
and insulin were found to be essentially identical to those observed following 
hormone treatment of PKC p-depleted adipocytes (Table 5.8 and Table 5.6 F). Thus, 
the suppression of lipogenesis by GH was reduced to 48 ± 10.9 % of that observed in 
control cells incubated with lipofectin alone (Table 5.8), suggesting a role for PKD in 
the GH-mediated suppression of lipogenesis in 3T3-F442A adipocytes. In the absence 
of PKD, insulin was unable to stimulate lipogenesis (Table 5.8) suggesting that PKD 
is essential for the insulin-mediated stimulation of lipogenesis in 3T3-F442A
106
adipocytes. That the rate of lipogenesis in cells incubated with GH and insulin in 
combination did not differ significantly from that observed in cells incubated with 
insulin alone (Table 5.8), is likely to reflect the reduced GH response in these cells 
since insulin has no effect on lipogenesis in the absence of PKD.
Thus, the PKD antisense studies confirmed that the murine PKC p/PKD protein was, 
at least in part, required for the direct suppression of lipogenesis by GH and essential 
for the stimulation of lipogenesis by insulin. In addition, the results of these studies 
suggest that PKC p and PKD are indeed homologues of the same protein.
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Figure 5.1 Body weight changes in rats treated with antiserum to rat growth hormone 
Rats were treated with antiserum to rat GH (anti-rGH), either alone, or in combination 
with ovine GH (oGH) twice daily for four days as described in section 5.2.1.1.1. Control 
animals received carrier solutions. Body weights were taken prior to the commencement 
of treatments and following their completion and the difference calculated. Results are 
means ± SEM from eight rats. * indicates the value is significantly different from that for 
control animals, p < 0.001. Statistical analysis was by Student's t-test for unpaired 
samples.
Table 5.1 Fat pad composition and sérum IGF-1 levels in rats treated with antiserum to 
rat growth hormone
Rats were treated with antiserum to rat GH (Anti-rGH), either alone, or in combination with 
ovine GH (+ oGH) twice daily for four days as described in section 5.2.1.1.1, Control 
animals received carrier solutions. Subsequently, parametrial fat pads were removed and the 
fat pad composition determined as described in section 5.2.1.1.3. Samples of blood were also 
taken for the determination of serum lGF-1 levels as described in section 5.2.1.1.4. Results 
are means ± S.E.M from four rats. * indicates the value differs significantly from that 
observed for control animals, p < 0.001. Statistical analysis was by Student's t-test for 
unpaired samples.
Treatment Serum IGF-1 
(ng/ml)
Mean cell 
volume (pi)
Fat pad composition
Fat pad 
weight (g)
Adipocytes per 
fat pad (x 10 )^
Control 
Anti-rGH 
Anti-rGH + oGH
167.8 ± 14.9
54.4 ± 4.7*
198.9 ± 17.1
165.4 ± 9
222.1 ±30 
171.6 ±20
2.01 ± 0.2 
1.97±0.1 
2.33 ±0.2
4.40 ± 0.34 
2.70 ± 0.64 
4.95 ± 1.43
Figure 5,2 Protein kinase C isoform expression in rats treated with 
antiserum to rat growth hormone
Homogenates were prepared from the isolated adipocytes of rats that 
had been treated with antiserum to rat GH alone (Anti-rGH; lanes 5-8), 
or antiserum to rat GH in combination with ovine GH (+ oGH; lanes 9- 
12) and control rats which had been treated with carrier solutions 
(lanes 1-4). Equal quantities (50 ug) of homogenate protein were 
subjected to immunoblotting with isoform-specific monoclonal 
antibodies to PKC alongside 50 pg of homogenate protein prepared 
from rat brain (RB; lane 13) that served as a positive antibody control. 
Results are representative of four separate experiments carried out on 
different cell preparations.
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Table 5,2 Cellular levels o f  protein kinase C isoforms in rats treated with antiserum to 
rat growth hormone
Rats were treated with antiserum to rat GH (Anti-rat GH), either alone, or in combination 
with ovine GH (+ oGH) twice daily for four days as described in section 5.2.1.1.1. 
Control animals received carrier solutions. Homogenates were prepared from isolated 
adipocytes and subjected to immunoblotting with isoform-specific monoclonal antibodies 
to PKC. Data are expressed as arbitrary units following densitometric analysis of 
immunoblots. Results are means ± S.E.M. of four observations. * and ** indicate the value 
is significantly different from that for control animals, p < 0.05 and p < 0.002 
respectively. Statistical analysis was by analysis of variance.
Isoform
PKC isofomi expression (arbitrary units)
Treatment
Control Anti-rat GH Anti-rat GH + oGH S.E.M
a 203.51 139.75 5 7 .3 f 26.86
7 723.90 583.00 354.20* 112.4
5 702.50 516.60 277.60* 126.8
e 89.22 232.98" 195.38** 16.15
Ç 104.26 65.97* 128.61 12.00
(I 418.80 159.10* 305.90 69.82
Figure 5.3 The effect o f growth hormone and insuiin on protein 
kinase C isoform expression in 3T3-F442A adipocytes 
3T3-F442A adipocytes were incubated for 16-18 h in the absence of 
exogenous hormones and for a further 24 h in the absence of hormones 
(No Additions; lanes 2-5) or in the presence of 4.5 nM GH (lanes 6-9) 
or 8.7 nM insulin (INS; lanes 10-13). Cellular lysates were 
subsequently prepared and equal quantités (50 ug) of lysate protein 
were subjected to immunoblotting with isoform-specific monoclonal 
antibodies to PKC alongside 50 pg of homogenate protein prepared 
from rat brain (RB; lane 1) that served as a positive antibody control. 
Immunoblots are representative of results obtained on at least six 
occasions with different cell preparations.
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Table 5.3 The effect o f  growth hormone and insulin on cellular levels o f  protein kinase C 
isoforms in 3T3-F442A adipocytes
3T3-F442A adipocytes were incubated for 16-18 h in the absence of exogenous hormones and 
for a further 24 h in the absence of hormones or in the presence of 4.5 nM GH or 8.7 nM 
insulin. Cellular lysates were subsequently prepared and subjected to immunoblotting with 
isoform-specific monoclonal antibodies to PKC. Following densitometric analysis of 
immunoblots, changes in expression of PKC isoforms are shown as a percentage of the 
expression level in control adipocytes incubated in the absence of hormones (100 %). Results 
are means ± S.E.M. of six separate experiments carried out on different cell preparations.
Isoform
PKC isoform expression [% of control (= untreated adipocytes; 100 %)]
Hormone treatment
Growth hormone Insulin
a 109.7 ± 4.8 129.6 ± 14.2
Y 149.8 ±28.8 116.1 ±23.85
5 98.9 ± 2.2 74.5± 12.1
e 179.4 ±65.9 132.3 ±21.4
Ç 91.1 ± 7.8 77.4 ± 19.6
125.3 ±14.7 103.9 ± 5.6
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Figure 5.4 The effect o f growth hormone and insulin on the rate o f lipogenesis in 3T3- 
F442A adipocytes
3T3-F442A adipoc>les were incubated for 16-18 h in the absence o f  exogenous 
hormones and for 24 or 48 h in the absence o f  hormones (■) or in the presence o f  4.5 nM 
GH ( • )  or 8.7 nM insulin ( ♦ ) ,  either alone, or in combination (A). Subsequently the rate 
o f  lipogenesis was determined as described in section 2.2.2.9. Results are means ± S.E.M. 
o f  SIX separate observations carried out on different cell preparations, indicates the value 
differs significantly from that for control adipocytes incubated in the absence o f  
hormones, p < 0.001. Statistical analysis was by Student's t-test for paired samples.
Table 5,4 The effect o f  wortmannin and PD98059 on growth hormone- and insulin- 
induced changes in the rate o f  lipogenesis in 3T3-F442A adipocytes 
3T3-F442A adipocytes were incubated for 16-18 h in the absence of exogenous 
hormones and for 24 h in the absence of hormones (No additions) or in the presence of
4.5 nM GH or 8.7 nM insulin (INS). Incubations were carried out in the absence of 
inhibitors (control), or in the presence of 100 nM wortmannin or 50 pM PD98059. 
Subsequently, the rate of lipogenesis was determined as described in section 2.2.2.9. 
Results are means ± S.E.M. of six separate observations carried out on different cell 
preparations. The rate of lipogenesis following hormone treatment as a percentage of 
the rate of lipogenesis in control adipocytes incubated in the absence of hormones (100 
%) is indicated in parenthesis. * indicates the rate of lipogenesis differs significantly 
from that for control adipocytes incubated in the absence of inhibitors, p < 0.001. * 
indicates the effect of hormone treatment differs significantly from that observed for 
control adipocytes incubated in the absence of inhibitors, p < 0.05. Statistical analysis 
was by Student's t-test for paired samples.
Rate of Lipogenesis (pmol acetate.h' .mg DNA" )
Inhibitor
Hormone treatment Control Wortmannin PD98059
No Additions 2.22 ± 0.29
(100 %)
0.91 ±0.23'
(100 %)
2.01 ±0.34 
( 100%)
GH 0.78 ± 0.05 
(41.3+4.5% )
0.48 ±0.12'
(52.7 ± 6.7 %)
0.74 ±0.11 
(39.2 ± 5.2 %)
INS 3.76 ±0.33 
(169.1 ± 10.2%)
1.27 ±0.25' 
(139.4 ± 3 .4 % ')
3.52 ±0.81 
(175.5 ±12.4% )
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Figure 5.5 Specific depletion o f protein kinase C isoforms in 3T3-F442A 
adipocytes by antisense oligodeoxynucleotide treatment
3T3-F442A adipocytes were preincubated with ODNs for 48 h prior to the preparation 
of lysates for the assessment of immunoreactive PKC isoforms by immunoblotting. 
Immunoblots show the amount of each indicated isoform in 25 pg of homogenate 
prepared from rat brain (lane 1), control adipocytes incubated with lipofectin alone 
(lane 2), 3T3-F442A adipocytes treated with the appropriate sense ODN (lane 3) and 
3T3-F442A adipocytes treated with the appropriate antisense ODN (lane 4). 
Immunoblots are representative of results obtained on at least four occasions for each 
PKC isoform.
Table 5.5 The effect o f  lipofectin on growth hormone- and insulin-induced 
changes in the rate o f  lipogenesis in 3T3-F442A adipocytes
3T3-F442A adipocytes were preincubated in the presence or absence (control) of 
lipofectin reagent. Subsequently, adipocytes were incubated for 24 h in the absence of 
hormones (No additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), 
either alone, or in combination and the rate of lipogenesis determined as described in 
section 2.2.2.9. Results are means ± S.E.M. of six separate observations carried out on 
different cell preparations. The rate of lipogenesis following hormone treatment as a 
percentage of the rate of lipogenesis in control adipocytes incubated in the absence of 
hormones (100 %) is indicated in parenthesis.
Hormone
Rate of Lipogenesis (pmol acetate.h'\mg DNA'^)
Pretreatment
None Lipofectin
No Additions 2.14 ±0.20 2.21 ±0.28
(100 %) (100%)
GH 0.76 ±0.06 0.80 ±0.09
(36.7 ± 5.9 %) (37.1 ±6.1% )
INS 3.51 ±0.41 3.60 ±0.48
(166.5 ±18.4% ) (163.7 ± 17.6%)
GH + INS 2.29 ±0.19 2.31 ±0.21
(108.4 ±9.1 %) (106.2 ±10.7% )
Table 5.6 A The effect o f  protein kinase C Orspecific oligodeoxynucieotides on 
growth hormone- and insulin-induced changes in the rate o f  lipogenesis in 3T3- 
F442A adipocytes
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC a , or 
lipofectin alone (Control), prior to stimulation with hormones. During the final 16-18 
h of the ODN treatment period, exogenous hormones were removed from the culture 
medium. Subsequently, adipocytes were incubated for 24 h in the absence of 
hormones (No Additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), 
either alone, or in combination and the rate of lipogenesis determined as described in 
section 2.2.2.9. Results are means ± SEM of four separate observations carried out on 
different cell preparations. The rate of lipogenesis following hormone treatment as a 
percentage of the rate of lipogenesis in control adipocytes incubated in the absence of 
hormones (100 %) is indicated in parenthesis. The values for individual PKC isoforms 
that differ significantly (p < 0.05) carry different superscripts. Statistical analysis was 
by analysis of variance.
Rate of Lipogenesis (pmol acetate.h" .mg DNA" ) 
Oligodeoxynucleotide pretreatment
Hormone treatment Control Sense Antisense S.E.M
No Additions 2.10“ 2.12“ 2.22“ 0.16
( 100%) (100 %) (100 %)
GH 0.80’’ 0.91’’ 0.91’’ 0.16
(39.1 ±5 .2% ) (41.2 ±6.4% ) (40.7 ±3.7)
INS 3.48" 3.35" 3.27" 0.16
(168.3 ±17.5% ) (155.8 ±15.6% ) (147.4 ± 11.8%)
GH + INS 2.40“ 2.51“ 2.71“ 0.16
(115.3 ±11.2% ) (117.1 ±12.1% ) (102.0 ± 1.3%)
Table 5.6 B  The effect o f  protein kinase C y-specifîc oligodeoxynucieotides on 
growth hormone- and insulin-induced changes in the rate o f  lipogenesis in 3T3- 
F442A adipocytes
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC y, or 
lipofectin alone (Control), prior to stimulation with hormones. During the final 16-18 
h of the ODN treatment period, exogenous hormones were removed from the culture 
medium. Subsequently, adipocytes were incubated for 24 h in the absence of 
hormones (No Additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), 
either alone, or in combination and the rate of lipogenesis determined as described in 
section 2.2.2.9. Results are means ± SEM of four separate observations carried out on 
different cell preparations. The rate of lipogenesis following hormone treatment as a 
percentage of the rate of lipogenesis in control adipocytes incubated in the absence of 
hormones (100 %) is indicated in parenthesis. The values for individual PKC isoforms 
that differ significantly (p < 0.05) carry different superscripts. "  indicates the effect of 
hormone treatment differs significantly from that observed for control adipocytes 
incubated with lipofectin alone, p < 0.01. Statistical analysis was by analysis of 
variance.
Rate of Lipogenesis (pmol acetate.h' mg DNA' ) 
Oligodeoxynucleotide pretreatment
Hormone treatment Control Sense Antisense S.E.M
No Additions 2.00“ 1.94“ 1.70“ 0.18
(100%) (100%) ( 100%)
GH 0.75’’ 0.82’’ 1.02’’ 0.18
(35.4 ± 6 .6 %) (39.8 ±7.5% ) (60.5 ±8.5% )
INS 3.51" 3.54" 3.38" 0.18
(170.4 ±16.1% ) (180.4 ± 18.9%) (201.7 ±24.7% )
GH + INS 2.20“ 2.17“ 3.03" 0.18
(123.4 ±7.1% ) (114.8 ±8 .7% ) (181.1 ±17.1%**)
Table 5.6 C The effect o f  protein kinase C ô-speciflc oligodeoxynucieotides on 
growth hornwne- and insulin-induced changes in the rate o f  lipogenesis in 3T3- 
F442A adipocytes
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC Ô, or 
lipofectin alone (Control), prior to stimulation with hormones. During the final 16-18 
h of the ODN treatment period, exogenous hormones were removed from the culture 
medium. Subsequently, adipocytes were incubated for 24 h in the absence of 
hormones (No Additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), 
either alone, or in combination and the rate of lipogenesis determined as described in 
section 2.2.2.9. Results are means ± SEM of four separate observations carried out on 
different cell preparations. The rate of lipogenesis following hormone treatment as a 
percentage of the rate of lipogenesis in control adipocytes incubated in the absence of 
hormones (100 %) is indicated in parenthesis. The values for individual PKC isoforms 
that differ significantly (p < 0.05) carry different superscripts. Statistical analysis was 
by analysis of variance.
Rate of Lipogenesis (pmol acetate.h' .mg DNA ) 
Oligodeoxynucleotide pretreatment
Hormone treatment Control Sense Antisense S.E.M
No Additions 2.02“ 2.21“ 2.44“ 0.17
(100 %) (100 %) (100%)
GH 0.76’’ 0.93’’ 0.97’’ 0.17
(38.7 ± 5.3 %) (41.9 ±4.8% ) (40.8 ±5.0% )
INS 3.29" 3.51" 3.53" 0.17
(167.3 ±17.1 %) (160.2 ±15.4% ) (147.2 ± 11.2%)
GH + INS 2.05“ 2.32“ 2.44“ 0.17
(103.2 ±10.8% ) (105.3 ±11.2% ) (100.0 ±2.2%*)
Table 5.6 D The effect o f  protein kinase C e-specifîc oligodeoxynucieotides on 
growth hormone- and insulin-induced changes in the rate o f  lipogenesis in 3T3- 
F442A adipocytes
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC s, or 
lipofectin alone (Control), prior to stimulation with hormones. During the final 16-18 
h of the ODN treatment period, exogenous hormones were removed from the culture 
medium. Subsequently, adipocytes were incubated for 24 h in the absence of 
hormones (No Additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), 
either alone, or in combination and the rate of lipogenesis determined as described in 
section 2.2.2.9. Results are means ± SEM of four separate observations carried out on 
different cell preparations. The rate of lipogenesis following hormone treatment as a 
percentage of the rate of lipogenesis in control adipocytes incubated in the absence of 
hormones (100 %) is indicated in parenthesis. The values for individual PKC isoforms 
that differ significantly (p < 0.05) carry different superscripts. ' indicates the effect of 
hormone treatment differs significantly from that observed for control adipocytes 
incubated with lipofectin alone, p < 0.05. Statistical analysis was by analysis of 
variance.
Hormone treatment
Rate of Lipogenesis (pmol acetate.h"’.mg DNA"’)
Oligodeoxynucleotide pretreatment
Control Sense Antisense S.E.M
No Additions 2.48““ 2.45““ 1.96“ 0.28
(100%) (100%) (100%)
GH 0.74*’ 0.92’’ 0.86’’ 0.28
(30.8 ±3.0% ) (35.7 ±4.6% ) (45.2 ± 9.2 %)
INS 3.93" 3.75" 2.77“ 0.28
(163.5 ±7.2% ) (160.1 ±5.8% ) (138.1 ±1.3%*)
GH + INS 2.75““ 2.77““ 2.03“ 0.28
(108.0 ± 12.0%) (114.2 ± 11.2%) (103.5 ±4.4% )
Table 5.6 E  The effect o f  protein kinase C Ç-specifîc oligodeoxynucieotides on 
growth hormone- and insulin-induced changes in the rate o f  lipogenesis in 3T3- 
F442A adipocytes
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC Ç, or 
lipofectin alone (Control), prior to stimulation with hormones. During the final 16-18 
h of the ODN treatment period, exogenous hormones were removed from the culture 
medium. Subsequently, adipocytes were incubated for 24 h in the absence of 
hormones (No Additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), 
either alone, or in combination and the rate of lipogenesis determined as described in 
section 2.2.2.9. Results are means ± SEM of four separate observations carried out on 
different cell preparations. The rate of lipogenesis following hormone treatment as a 
percentage of the rate of lipogenesis in control adipocytes incubated in the absence of 
hormones (100 %) is indicated in parenthesis. The values for individual PKC isoforms 
that differ significantly (p < 0.05) carry different superscripts. Statistical analysis was 
by analysis of variance.
Rate of Lipogenesis (pmol acetate.h' .mg DNA' ) 
Oligodeoxynucleotide pretreatment
Hormone treatment Control Sense Antisense S.E.M
No Additions 2.40“ 2.44“ 2.46“ 0.26
(100%) (100%) (100%)
GH O.SO*’ 0.93’’ 0.92’’ 0.26
(36.7 ±0.6% ) (39.1 ±5.1 %) (39.5 ±9.6% )
INS 3.98" 3.87" 3.61" 0.26
(166.5 ±18.3% ) (161.3 ±17.2% ) (147.5 ±12.1% )
GH + INS 2.86“ 2.63“ 2.37“ 0.26
(119.8 ±10.5% ) (109.3 ±11.1% ) (95.6 ±2.5% )
Table 5,6 F  The effect o f  protein kinase C prspecifîc oligodeoxynucieotides on 
growth hormone- and insulin-induced changes in the rate o f  lipogenesis in 3T3- 
F442A adipocytes
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC p., or 
lipofectin alone (Control), prior to stimulation with hormones. During the final 16-18 
h of the ODN treatment period, exogenous hormones were removed from the culture 
medium. Subsequently, adipocytes were incubated for 24 h in the absence of 
hormones (No Additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), 
either alone, or in combination and the rate of lipogenesis determined as described in 
section 2.2.2.9. Results are means ± SEM of four separate observations carried out on 
different cell preparations. The rate of lipogenesis following hormone treatment as a 
percentage of the rate of lipogenesis in control adipocytes incubated in the absence of 
hormones (100 %) is indicated in parenthesis. The values for individual PKC isoforms 
that differ significantly (p < 0.05) carry different superscripts. '* and indicate the 
effect of hormone treatment differs significantly from that observed for control 
adipocytes incubated with lipofectin alone, p < 0.01 and p < 0.001 respectively. 
Statistical analysis was by analysis of variance.
Rate of Lipogenesis (pmol acetate.h ’.mg DNA'’) 
Oligodeoxynucleotide pretreatment
Hormone treatment Control Sense Antisense S.E.M
No Additions 2.59““ 2.61““ 3.13“" 0.29
(100%) (100%) (100%)
GH 0.78’’ 0.93’’ 2.05“ 0.29
(31.3 ±3 .1% ) (36.3 ±5.7% ) (65.2 ±6.1%**)
INS 3.90" 3.92" 3.00“ 0.29
(151.9 ±13.2% ) (150.9 ±11.3% ) (96.0 ±8.6%***)
GH + INS 2.95“ 2.77“ 2.62““ 0.29
(112.4 ±9 .9% ) (108.8 ±7.6% ) (83.9 ±1.9% )
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Figure 5.6 Specific depletion o f  protein kinase C y  and protein kinase C p  in 3T3- 
F442A adipocytes by combined antisense oligodeoxynucleotide treatment
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC y 
and PKC p in combination. Subsequently, cellular lysates were prepared and 
subjected to immunoblotting with isoform-specific monoclonal antibodies to PKC y 
and PKC p. Immunoblots show the amount of PKC y and PKC p in 25 pg of 
homogenate prepared from rat brain (lane 1), 3T3-F442A adipocytes treated with 
sense ODNs (lane 2) and 3T3-F442A adipocytes treated with antisense ODNs (lane 
3). Immunoblots are representative of results obtained on at least four occasions using 
different cell preparations.
Table 5,7 The effect o f  treatment with protein kinase C y- and p-specific 
oligodeoxynucieotides in combination on growth hormone- and insulin-induced 
changes in the rate o f  lipogenesis in 3T3-F442A adipocytes 
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKC y 
and PKC p in combination, or lipofectin alone (Control), prior to stimulation with 
hormones. During the final 16-18 h of the ODN treatment period, exogenous 
hormones were removed from the culture medium. Subsequently, adipocytes were 
incubated for 24 h in the absence of hormones (No Additions) or in the presence of 
4.5 nM GH or 8.7 nM insulin (INS), either alone, or in combination and the rate of 
lipogenesis determined as described in section 2.2.2.9. Results are means ± SEM of 
four separate observations carried out on different cell preparations. The rate of 
lipogenesis following hormone treatment as a percentage of the rate of lipogenesis in 
control adipocytes incubated in the absence of hormones (100 %) is indicated in 
parenthesis. The values for individual PKC isoforms that differ significantly (p < 
0.05) carry different superscripts, and indicate the effect of hormone treatment 
differs significantly from that observed for control adipocytes incubated with 
lipofectin alone, p < 0.01 and p < 0.001 respectively. Statistical analysis was by 
analysis of variance.
Rate of Lipogenesis (pmol acetate.h" mg DNA" ) 
Oligodeoxynucleotide pretreatment
Hormone treatment Control Sense Anti sense S.E.M
No Additions 2.53““ 2.49““ 2.63“ 0.19
(100 %) (100%) (100%)
GH 0.73*’ 0.80*’ 1.99“ 0.19
(29.5+2.3% ) (32.2 ± 4.6 %) (75.3 ±9.5%**)
INS 4.08" 4.10" 2.66“ 0.19
(165.6 ±13.1% ) (166.9 ±12.1% ) (104.7 ±5.0%***)
GH + INS 2.87“ 2.81“ 2.59“ 0.19
(111.6 ± 10.6%) (114.1 ±11.2% ) (98.6 ±1.5% )
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Figure 5.7 The effect o f protein kinase D-specific oligodeoxynucieotides on 
expression o f the 112 kDa protein detected with the monoclonal antibody specific 
fo r  protein kinase C p
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKD. 
Subsequently, cellular lysates were prepared and subjected to immunoblotting with a 
PKC p-specific monoclonal antibody . Immunoblots show the amount of the 112 kDa 
protein detected with the PKC p antibody in 25 pg of homogenate prepared from rat 
brain (lane 1), 3T3-F442A adipocytes treated with the sense ODN to PKD (lane 2) 
and 3T3-F442A adipocytes treated with the antisense ODN to PKD (lane 3). The 
immunoblot is representative of results obtained on at least four oeeasions using 
different eell preparations.
Table 5,8 The effect o f  protein kinase D-speciflc oligodeoxynucieotides on growth 
hormone- and insulin-induced changes in the rate o f  lipogenesis in 3T3-F442A 
adipocytes
3T3-F442A adipocytes were preincubated with sense or antisense ODNs to PKD, or 
lipofectin alone (control), prior to stimulation with hormones. During the final 16-18 h of 
the ODN treatment period, exogenous hormones were removed from the culture medium. 
Subsequently, adipocytes were incubated for 24 h in the absence of hormones (No 
additions) or in the presence of 4.5 nM GH or 8.7 nM insulin (INS), either alone, or in 
combination and the rate of lipogenesis determined as described in section 2.2.2.9. 
Results are means ± SEM of four separate observations carried out on different cell 
preparations. The rate of lipogenesis following hormone treatment as a percentage of the 
rate of lipogenesis in control adipocytes incubated in the absence of hormones (100 %) is 
indicated in parenthesis. Values that differ significantly (p < 0.05) carry different 
superscripts. "  and indicate the effect of hormone treatment differs significantly from 
that observed for control adipocytes incubated with lipofectin alone, p < 0.01 and p < 
0.001 respectively. Statistical analysis was by analysis of variance.
Rate of Lipogenesis (pmol acetate.h* mg DNA ) 
Oligodeoxynucleotide pretreatment
Hormone treatment Control Sense Antisense S.E.M
No Additions 2.73““ 2.69““ 3.21“" 0.30
(100%) (100%) (100%)
GH 0.81** 0.79*’ 2.22“ 0.30
(31.4 ±4.5% ) (30.9 ±3.2% ) (65.5 ±5.2%**)
INS 4.12" 4.10" 3.14“ 0.30
(153.2 ±14.0% ) (152.8 ±13.7% ) (95.8 ± 7.8 %***)
GH + INS 3.14“ 3.12“ 2.85““ 0.30
(113.5 ±10.4% ) (116.1 ±11.1% ) (85.8 ±1.7% )
5.4 Discussion
A number of studies suggest that PKC isoforms may assume distinct functional roles 
in adipocyte regulation. For example, studies with preadipocyte cell lines have 
revealed that PKC isoform expression is altered as a result of the differentiation of 
preadipocytes into adipocytes (Frevert and Khan, 1996; McGowan et al, 1996; data 
presented in Chapter four). In addition, selective changes in the expression of 
adipocyte PKC isoforms have been associated with diseased states such as obesity 
(Frevert and Khan, 1996). The metabolic pathways in the adipocyte are strictly 
regulated by a number of hormones. In order to investigate the possible functional 
roles of PKC iso forms in adipocytes, their involvement in the signalling pathways by 
which two important hormonal regulators of adipocyte metabolism, GH and insulin, 
alter the rate of lipogenesis was investigated using the 3T3-F442A adipocyte cell 
model.
Several studies suggest that the mechanisms by which GH exerts its metabolic effects 
in the adipocyte are, at least in part, mediated by one or more iso forms of PKC (see 
Section 1.6.3.4). In order to investigate the involvement of PKC iso forms in the GH- 
regulated signalling pathways in the adipocyte, the effects of GH on the expression of 
adipocyte PKC isoforms were examined. PKC isoform expression was examined 
initially in vivo in rat adipocytes in the absence of GH or in the presence of excess 
GH.
It was found that GH differentially regulated the expression of PKC isoforms in vivo 
in rat adipocytes. Levels of conventional PKC a  and y and novel PKC Ô were 
suppressed by GH whereas levels of atypical PKC Ç and p. were enhanced. The effects 
of GH on PKC s expression were complex and, at present, difficult to explain, since 
GH both enhanced and suppressed expression of PKC e depending on the hormone 
serum concentration. Collectively, these observations implied the individual or 
combinational involvement of PKC isoforms in GH-mediated responses in rat 
adipocytes.
When the effects of GH on PKC isoform expression were examined in vitro in 3T3- 
F442A adipocytes, however, GH had no direct effect on PKC isoform levels. This
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discrepancy may have been attributable to differences in the lengths of the treatment 
periods. 3T3-F442A adipocytes were incubated with GH for 24 h, whereas rat 
adipocytes were treated with anti-rat GH (± oGH) for a total of 96 h. Alternatively, 
the data obtained in vitro may indicate that the effects of GH on PKC isoform 
expression observed in vivo are not direct and are attributable to secondary changes in 
circulating levels of other hormones involved in adipocyte regulation.
It is less clear whether PKC is involved in the chronic metabolic effects of insulin in 
the adipocyte (see Section 1.6.5). This appears to be, at least in part, due to the 
existence of multiple isoforms. The effects of chronic exposure to insulin on the 
expression of PKC isoforms in 3T3-F442A adipocytes were therefore examined. 
However, as was the case with GH, treatment with insulin had no direct effect on the 
expression of PKC isoforms in 3T3-F442A adipocytes.
Thus, direct in vitro addition of GH or insulin to 3T3-F442A adipocytes was found to 
have no chronic effect on the expression of PKC isoforms. The fact that GH 
differentially regulated PKC isoforms in rat adipocytes, either directly or indirectly, 
however, suggests they may individually or combinationally regulate different GH- 
induced signal transduction events. At least in 3T3-F442A preadipocytes, GH acutely 
activates PKC y, Ô and s, as determined by translocation from the cytosol to the 
membrane (S. MacKenzie, E. Kilgour, N. Anderson and I. Fleming, unpublished 
observation), whereas no such effect was observed upon PKC a  and Ç No such 
studies have been done on PKC |i to date. Insulin has been shown to acutely 
translocate/activate PKC a , (3 and Ç in 3T3-L1 adipocytes (Bandyopadhyay et al,
1997) and PKC a , (3, y, s and Ç in rat adipocytes (Farese et al, 1992). The subsequent 
insulin-induced down-regulation of PKC isoforms was found to be attended by 
selective increases in their mRNAs in rat adipocytes (Avignon et al, 1995). Thus, 
although GH and insulin had no chronic effect on the expression of PKC isoforms in 
3T3-F442A adipocytes, a role for PKC isoforms in the signalling pathways utilised by 
these hormones in the adipocyte could not be ruled out. The studies presented here 
were therefore aimed at evaluating directly whether the individual isoforms expressed 
in 3T3-F442A adipocytes contribute to the effects of GH and insulin on a single major 
metabolic process which characterises adipocyte metabolism, namely lipogenesis.
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Studies with PKC activators suggest that both GH and insulin alter the rate of 
lipogenesis in the adipocyte by mechanisms that are, at least in part, PKC-dependent 
(Smal and De Meyts, 1987). The compounds used during these studies, however, 
cannot be construed as being totally specific. The involvement of PKC isoforms in the 
signalling pathway(s) utilised by GH and insulin to exert their effects on the rate of 
lipid synthesis was therefore investigated in 3T3-F442A adipocytes using an antisense 
procedure to deplete selectively specific PKC isoforms. Initial characterisation of the 
effects of GH and insulin on the rate of lipid synthesis in 3T3-F442A adipocytes 
revealed that insulin increased significantly the rate of lipogenesis (to approximately 
160 % of that observed in control adipocytes), whereas GH both decreased 
significantly the rate of lipogenesis (to approximately 40 % of that observed in control 
adipocytes) and completely prevented the increase in lipogenesis in response to 
insulin. Studies here with the MEK inhibitor, PD 98059 (Arcaro and Wymann, 1993; 
Powis et ai, 1994) revealed that the MAP kinase pathway was not required by either 
GH or insulin to exert these effects. Studies here with the PI 3-kinase inhibitor, 
wortmannin (Alessi et al, 1995) revealed that, whereas PI 3-kinase was found to be 
required for maintaining the basal rate of lipogenesis, the inhibitory effects of GH on 
lipid synthesis did not involve this pathway. In contrast, PI 3-kinase was found to be 
one of a number of components required for the stimulation of lipogenesis by insulin.
These observations, at least for insulin, are consistent with the results of others. It has 
been demonstrated that stimulation of MAP kinases by insulin is not required for its 
effects on glucose transport, glycogen synthesis or on the activity of the lipogenic 
enzymes, acetyl CoA carboxylase and pyruvate dehydrogenase (Lazar et al, 1985; 
Denton and Tavare, 1995). Similarly, activation of PI 3-kinase alone is not sufficient 
for mediating the metabolic effects of insulin (Krook et al, 1997; Wiese et al, 1995; 
Moule et al, 1995). PI 3-kinase appears to be, at least in part, required for the 
stimulation of glucose utilisation, glycogen synthesis and acetyl CoA carboxylase by 
insulin (Moule et al, 1995). However, stimulation by insulin of other lipogenic 
enzymes, such as pyruvate dehydrogenase and fatty acid synthase, appears not to 
involve the PI 3-kinase pathway (Moule et al, 1995). Thus, multiple signalling 
pathways appear to be involved in the stimulation of lipogenic enzymes and 
lipogenesis by insulin. The PI 3-kinase pathway, but not the MAP kinase pathway,
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appears to be involved.
In order to establish whether PKC isoforms were required for the GH- and insulin- 
mediated effects on lipid synthesis in 3T3-F442A adipocytes, antisense ODNs were 
used to deplete selectively individual isoforms from adipocytes prior to stimulation 
with hormones. Immunoblotting studies revealed that incubation with antisense ODNs 
resulted in the complete depletion of the appropriate PKC isoform whereas incubation 
with the appropriate sense ODN (or lipofectin alone) had no effect on expression of 
PKC isoforms in 3T3-F442A adipocytes.
Depletion of PKC a , 5 and Q from adipocytes was found to have no effect on the 
suppression of lipogenesis by GH or the stimulation of lipogenesis by insulin. This 
suggested that these PKC isoforms were not essential for the GH- and insulin- 
mediated effects on lipid synthesis in 3T3-F442A adipocytes. It is possible that these 
isoforms may functionally substitute for each other in the signalling pathways utilised 
by GH and insulin to regulate the rate of lipid synthesis. However, PKC 5 has been 
shown to be required for MAP kinase activation by GH in 3T3-F442A preadipocytes 
(MacKenzie et al, 1997). Therefore, the lack of involvement of PKC ô in the 
signalling pathway utilised by GH to reduce the rate of lipid synthesis in adipocytes 
would appear consistent with the observation that the MAP kinase pathway is not 
involved.
Depletion of PKC 8 from 3T3-F442A adipocytes had no effect on the ability of GH to 
suppress the basal or insulin-stimulated rate of lipogenesis. However, following 
depletion of PKC s, the stimulation of lipogenesis by insulin was reduced slightly, but 
significantly. This indicated that PKC 8 is one of the multiple components utilised by 
insulin to increase the rate of lipogenesis in 3T3-F442A adipocytes. These results also 
indicated that other, PKC 8-independent signalling pathway(s), are involved. 
Calcium-independent PKC isoforms such as PKC 8 can be activated by the products 
of PI 3-kinase (Nakanishi et al, 1993; Toker et al, 1994). The insulin response was 
reduced by approximately 20 % both following the inhibition of PI 3-kinase and in the 
absence of PKC 8. This suggests that PKC 8 may be activated in a PI 3-kinase- 
dependent manner during the stimulation of lipogenesis by insulin in 3T3-F442A
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adipocytes.
Depletion of PKC |i totally abolished the ability of insulin to stimulate the rate of lipid 
synthesis in 3T3-F442A adipocytes. Thus, PKC p, appears to be an essential 
component of the signalling mechanism by which insulin increases the rate of 
lipogenesis in 3T3-F442A adipocytes. The antisense sequence used to deplete PKC p 
was derived from the human protein coding sequence. The results obtained with the 
PKC p ODN were, therefore, confirmed by making use of an antisense ODN directed 
against PKD, which is thought to be the murine homologue of this protein (Van Lint 
et al, 1995). That identical results were obtained using the PKD ODN suggested that 
PKC p and PKD were indeed human/murine homologues and that this protein was 
essential for the insulin-mediated effects on lipid synthesis in 3T3-F442A adipocytes.
Insulin alters the rate of lipid synthesis in 3T3-F442A adipocytes by a mechanism that 
is, at least in part, mediated by PKC s and apparently totally dependent on PKC p. 
Interestingly, PKC p (PKD) can be activated via PKC s in intact cells (Zugaza et al,
1996). This suggests the simultaneous activation by insulin of a signalling pathway 
involving PKC 8, possibly that of PI 3-kinase, and the activation of other PKC 8- 
independent pathway(s) which diverge at the level of PKC p in stimulating the rate of 
lipid synthesis.
Thus, at least with regard to the stimulation of lipogenesis, insulin exerts its metabolic 
effects in the adipocyte via signalling pathways that are mediated by the activation of 
PKC. The phorbol ester-sensitive PKC 8 isoform is, at least in part, required for the 
stimulation of lipogenesis by insulin. Therefore, the results of Smal and De Meyts 
(1987), who, using phorbol esters, observed that PKC was partially required for the 
lipogenic effects of insulin, are likely to reflect down-regulation of the PKC 8 
isoform. However, seemingly contradictory reports suggest that insulin responses are 
unimpaired in cells in which PKC isoforms have been down-regulated by chronic 
exposure to phorbol esters (reviewed in Blackshear, 1994). The data presented in 
Chapter three and the results of others (Olivier and Parker, 1992) indicate that PKC 8 
is relatively resistant to down-regulation by such treatment. This fact, coupled to the 
observation that the insulin response is only partially dependent on the presence of
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PKC s, could account for an intact insulin response following prolonged exposure of 
cells to phorbol esters. In addition, PKC |i, which is essential for the insulin- 
stimulated increase in the rate of lipogenesis, is not down-regulated by chronic 
phorbol ester treatment (Johannes et al, 1995; Rennecke et al, 1996).
PKC |i was also found to be an important component of the signalling mechanism by 
which GH exerts its effects on the rate of lipid synthesis. Following the depletion of 
PKC [L from 3T3-F442A adipocytes, the ability of GH to suppress basal lipogenesis 
was reduced significantly. This indicated that PKC | l i  was an important component of 
the signalling mechanism by which GH suppresses the basal rate of lipogenesis in 
3T3-F442A adipocytes and that other PKC ^-independent signalling pathways were 
also required. When PKC p/PKD-depleted adipocytes were incubated with GH and 
insulin in combination, the rate of lipogenesis did not differ significantly from that 
observed when cells were incubated with insulin alone. This is most likely due to the 
fact that PKC p. is, at least in part, required for the suppression of basal lipogenesis by 
GH in 3T3-F442A adipocytes, although interpretation of these results is, of course, 
complicated by the fact that insulin exerts no response in the absence of PKC p. and 
there is therefore no response for GH to antagonise.
Depletion of PKC y from 3T3-F442A adipocytes had no effect on the ability of 
insulin to enhance the rate of lipogenesis and did not effect significantly the ability of 
GH to suppress the basal rate of lipid synthesis. However, PKC y was found to be 
essential for the ability of GH to antagonise the insulin-mediated increase in the rate 
of lipid synthesis in 3T3-F442A adipocytes. Given that PKC p, is essential for the 
stimulation of lipogenesis by insulin, it is possible that activation of PKC y by GH 
prevents the insulin-induced activation of PKC p., or alters its subsequent down­
stream effects.
Thus, in 3T3-F442A adipocytes, GH alters the basal rate of lipid synthesis by a 
mechanism that is, at least in part, mediated by PKC p., although other PKC- 
independent signalling pathways appear to be involved. PKC y is not essential for the 
suppression of basal lipogenesis by GH but is an essential component of the signal 
transduction mechanism by which GH antagonises the insulin-stimulated increase in
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the rate of lipid synthesis. Thus, both the direct anti-lipogenic and the insulin- 
antagonistic effects of GH involve isoforms of PKC. The results of these studies also 
suggest that the mechanisms by which GH exerts its direct anti-lipogenic effects and 
its insulin-antagonisitc effects on the rate of lipid synthesis in 3T3-F442A adipocytes 
are distinct, at least with respect to the activation of PKC. From these studies, it 
appears that PI 3-kinase is the basal regulator of lipogenesis in 3T3-F442A adipocyes 
that is inhibited by wortmannin and by GH and this does not involve PKC y. A PI 3- 
kinase-independent process also affects the lipogenic parhway that is stimulated by 
insulin and which may be blocked by GH through PKC y.
PKC p. was found to be an important component of the signalling mechanism by 
which both GH and insulin exert their metabolic effects in the adipoctye, at least with 
regard to altering the rate of lipid synthesis. Support of a role for PKC p. (PKD) in 
mediating insulin responses also comes from studies of the desensitisation of hormone 
receptors. PKC|i (PKD) has been shown to be involved in mediating glucagon 
desensitisation of adenylate cyclase in cos cells (Tobias et al, 1997). This could be 
considered as an insulin-like effect in that it is a process that antagonises glucagon 
action and hence is anti-gluconeogenic. Since PKC p. is also important for the effects 
of GH on lipid synthesis, at least in 3T3-F442A adipocytes, it is tempting to speculate 
that this PKC isoform could have an involvement in GH-induced insulin resistance in 
adipocytes.
PKC p., like a number of other signalling molecules (see Sections 1.4 and 1.5), is 
utilised by both GH and insulin in order to exert opposite effects. PKC p. has now 
been shown to be activated by a number of hormones and growth factors (Zugaza et 
al, 1997) and may therefore be an important target for hormones in mediating down­
stream events. This suggests that either the timing or duration of activation, or the 
down-stream substrates, are likely to be crucial in determining the final response 
following hormonal stimulation. Given that PKCs are regulated by phosphorylation 
(see Section 1.6.2.3), it is possible that GH and insulin (and other hormones) induce 
the phosphorylation of PKC p. at distinct sites, or in different sub-cellular 
compartments, which alters its specificity/affinity for, or regulation of, down-stream 
substrates. Studies to date suggest that PKC (i is activated by hormones in a PKC-
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dependent manner and that PKC isoforms such as PKC s and rj are involved (Zugaza 
et al, 1996 and 1997) Indeed, the results of the studies presented here suggest that 
PKC p, may be activated down-stream of PKC 8 in response to insulin stimulation. 
However, other signalling mechanisms appear to be required for the stimulation of 
lipogenesis by insulin as PKC s is only one of a number of components required for 
the response to insulin and PKC p appears to be essential for the insulin response. 
Furthermore, PKC p appears to be required for the suppression of basal lipogenesis 
by GH and no other PKC isoform was found to be essential for this response. 
Interestingly, PKC y was found to be required for the antagonism of insulin- 
stimulated lipogenesis by GH, suggesting that PKC y may be involved in the 
regulation of PKC p. From these studies it appears that, either PKC-independent 
mechanisms are involved in the activation of PKC p by both GH and insulin in 3T3- 
F442A adipocytes, or that other PKC isoforms can functionally substitute for each 
other in the activation of PKC p.
The results of these studies clearly indicate that both GH and insulin exert their 
metabolic effects in the adipocyte by signalling pathways involving PKC. At present 
the mechanisms by which individual PKC isoforms regulate the GH- and insulin- 
mediated responses on the rate of lipogenesis in adipocytes are unclear. The lipogenic 
pathway comprises a number of strictly regulated enzymes (see Figure 1.1). There 
are, therefore, multiple potential points at which PKC isoforms could regulate the 
pathway, including the rate of enzyme substrate synthesis and degredation as well as 
the expression and activity of lipogenic enymes. To date, the effects of GH and 
insulin on the rate of lipogenesis have been largely attributed to alterations in the 
expression and activity of key lipogenic enzymes such as acetyl CoA carboxylase, 
fatty acid synthase and pyruvate dehydrogenase (Dietz and Schwartz, 1991; Bauman 
and Vernon, 1993; Harris et al, 1993; Vernon et al, 1993; Denton and Tavare, 1995; 
Moule et al, 1995). GH has been shown to suppress both the activation status and 
expession of acetyl CoA carboxylase and fatty acid synthase (Dietz and Schwartz, 
1991; Bauman and Vernon, 1993; Harris et al, 1993; Vernon et al, 1993) and prevent 
the activation of acetyl CoA carboxylase by insulin (Vernon et al, 1991). It would 
therefore be of interest to determine the effects of antisense depletion of PKC
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isoforms, particularly that of PKC p and PKC y, on the expression and activation 
status of such lipogenic enzymes following stimulation with GH and insulin.
It is also unclear at present which, if any, PKC isoforms are involved in the signalling 
pathways utilised by GH and insulin to regulate other aspects of adipocyte 
metabolism. However, studies with PKC activators and inhibitors imply a role for 
PKC isoforms in the regulation of lipolysis by GH (Gorin et al, 1990; Doris et al,
1998) and glucose transport by insulin (Standaert et al, 1990; Grunberger, 1991; Yano 
et al, 1993; Chalfant et al, 1995). Further support of a role for PKC in the regulation 
of lipolysis comes from the observation that PKC appears to phosphorylate the 
inhibitory G protein, Gi-2, at least in rat hepatocytes (Morris et al, 1994), and Gi-2 
appears to play a pivotal role in the functioning of adenylate cyclase (Bushfield et al, 
1991).
In summary, both GH and insulin alter the rate of lipid synthesis in 3T3-F442A 
adipocytes via signalling pathways involving isoforms of PKC. PKC a , 5 and are 
not essential for the stimulation of lipogenesis by insulin or the suppression of basal 
or insulin-stimulated lipogenesis by GH. PKC 8 is one of a number of components 
required by insulin to increase the rate of lipogenesis. PKC y is an essential 
component of the signalling mechanism utilised by GH to antagonise the stimulation 
of lipogenesis by insulin. PKC p. is, at least in part, required for the direct anti- 
lipogenic effect of GH. This PKC isoform is also an essential component of the signal 
transduction mechanism by which insulin stimulates lipogenesis in 3T3-F442A 
adipocytes. These results indicate that PKC isoforms assume differential functional 
roles in 3T3-F442A adipocytes.
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Chapter 6
General Discussion
Initial interest in the role of PKC in the regulation of cellular function arose from the 
discovery that the enzyme was activated by tumour promoting phorbol esters 
(Gschwendt et al, 1991; Bell and Bums, 1991). Phorbol esters have, therefore, been 
used widely as a pharmacological tool to investigate the biological functions of PKC 
in cells. By this approach, PKC has been implicated in a wide range of cellular 
processes, including growth and differentiation, tumourigenesis, apoptosis and a 
variety of cell functions (Hug and Sarre , 1993; Kindregan et al, 1994; Li et al, 1994; 
Glazer, 1994; Borner et al, 1995; Blobe et al, 1996; Acs et al, 1997; Deacon et al,
1997). In addition, it has been established that PKC activity is provided for by a 
family of closely related kinases, perhaps suggesting an explanation for the range of 
processes in which PKC has been implicated. The marked difference in tissue 
distributions of PKC isoforms indicates that their functions are both isoform- and 
tissue-specific (Borner et al, 1992; Hata et al, 1993; Hug and Sarre, 1993; Stabel and 
Parker, 1993; Selbie et al, 1993; Akimoto et al, 1994; Dekker and Parker, 1994; Hirai 
et al, 1994; Dieterich et al, 1996;). However, as of yet, little is known about the 
functions of individual PKC isoforms in any system. The purpose of this study was to 
investigate the functional roles of individual PKC isoforms in the regulation of 
adipocyte development and function using the 3T3-F442A preadipocyte cell model.
Knowledge of the PKC isoforms in 3T3-F442A cells was required initially to enable 
the subsequent evaluation of the roles of individual isoforms in adipocyte regulation. 
The PKC complement of 3T3-F442A cells was characterised by immunoblotting 
using a panel of antibodies with application of strict criteria to ensure the correct 
identification of PKC isoforms. These criteria were employed due to the high degree 
of sequence homology shared between PKC sub-species and exploited the known 
structural and regulatory properties of the PKC sub-types in order to assess the 
specificty of the antibodies used for characterisation of the cells. Using this approach, 
both 3T3-F442A preadipocyte and adipocytes were found to express PKC a , y, 5, s, Ç 
and [I. The PKC complement of 3T3-F442A adipocytes was found to be identical to 
that of rat adipocytes. This supported the suitability of using 3T3-F442A cells as a 
model system of adipocyte development and function.
A number of potential problems exist in assigning functional roles to individual PKC
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isoforms. Importantly, most PKC activators and inhibitors cannot be construed as 
being isoform-specific (Castagna et al, 1982; Blobe et al, 1996; Taken, 1996; Quest, 
1996; Hofmann, 1997). In this study, an alternative approach was, therefore, taken to 
investigate the roles of individual PKC isoforms in 3T3-F442A cells. Changes in 
expression of PKC isoforms were examined throughout adipocyte development in 
order to gain initial insight into the roles of PKC isoforms in 3T3-F442A cell 
regulation. Subsequently, antisense oligonucleotides were employed to deplete 
individual PKC isoforms selectively from 3T3-F442A cells in an attempt to define the 
dependence of specific cellular processes on individual PKC isoforms.
PKCs are involved in a number of the signalling pathways that are known to modulate 
the preadipocyte differentiation process (Anderson, 1993; Nakanishi et al, 1993; 
Toker et al, 1994; Cobb and Goldsmith, 1995; Sale et al, 1995; Uehara et al, 1995, 
Yeh et al, 1995). Thus, fluctuations in cellular levels of PKC isoforms throughout 
adipocyte development are likely to be important for the modulation and integration 
of the variety of signals that regulate the differentiation process. Indeed, differential 
changes in the expression of individual PKC isoforms were observed to accompany 
the differentiation process in 3T3-F442A cells, implying distinct functional roles for 
PKC isoforms in the regulation of adipocyte development and function. Comparison 
of the cellular levels of PKC isoforms during 3T3-F442A preadipocyte differentiation 
with cellular levels of PKC isoforms in two separate control systems, gave an 
indication of the functional roles of individual isoforms in adipogenesis. Cellular 
levels of PKC were unchanged during the differentiation process suggesting that 
this isoform played no obligatory role in preadipocyte differentiation. Although 
cellular levels of PKC p were elevated in adipocytes, this was not attributable to the 
differentiation process per se. Following the induction of differentiation, cellular 
levels of PKC a , y and Ô increased rapidly, peaking at around day 2, correlating with 
the time-point at which clonal expansion of the differentiating cells was observed. 
Subsequently, cellular levels of these isoforms decreased such that a significant 
reduction in their expression was observed as cells attained the adipocyte phenotype. 
Thus, following the clonal expansion stage, these isoforms may exert an inhibitory 
influence on the differentiation process. Cellular levels of PKC e increased during 
adipocyte development implying a requirement for this isoform for the induction and
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maintenance of the adipocyte phenotype.
To define the dependence of 3T3-F442A preadipocyte differentiation on PKC 
isoforms, antisense ODNs were used to achieve the selective depletion of individual 
isoforms prior to the induction of differentiation. By this approach it was confirmed 
that PKC Ç is not essential for any stage of the differentiation process in 3T3-F442A 
preadipocytes. PKC a , 5 and p each exert an inhibitory influence upon the early 
stages of adipocyte development and are therefore likely to modulate this stage of the 
differentiation process. PKC 8 and y are both essential for 3T3-F442A preadipocyte 
differentiation. Further antisense studies revealed that PKC y and PKC 8 are required 
for distinct stages of the differentiation process. PKC y is essential for the clonal 
expansion of differentiating 3T3-F442A cells that is necessary for subsequent 
differentiation to occur (Smas and Sul, 1995; Mandrup and Lane, 1997). PKC 8 is not 
required for clonal expansion but is essential for later stages of the differentiation 
process, when its expression is markedly elevated, for the attainment of the adipocyte 
phenotype.
Thus it was shown that PKC y and PKC 8 were essential for preadipocyte 
differentiation and that no other PKC isoforms could functionally substitute for these 
isoforms during the differentiation process. Both PKC y and PKC 8 were found to be 
required for stages of the differentiation process when their expression levels were 
markedly elevated. Although, like PKC y, expression of PKC a  and 5 was elevated 
during the clonal expansion phase of preadipocyte differentiation, neither isoform was 
found to be essential for the process to occur. The increase in expression of these 
isoforms upon induction of differentiation is, therefore, difficult to explain. It is 
possible that PKC a  and 5 can functionally substitute for each other during the clonal 
expansion stage of the preadipocyte differentiation process. This could be established 
by depletion of both PKC a  and ô by combined antisense ODN treatment prior to the 
initiation of differentiation.
PKC a , Ô and \i are expressed in a wide variety of tissues (see Quest, 1996). Such 
ubiquitous expression implies a general role in the regulation of cell growth, 
differentiation or fiinction. That the rate of adipocyte development was enhanced in
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the absence of PKC a, 5 and \i suggested that these isoforms modulate the early 
stages of the differentiation process. In addition, antisense depletion of these PKC 
isoforms increased the growth rate of 3T3-F442A preadipocytes (as assessed by 
morphological examination of cells; I. Fleming, S. MacKenzie and E. Kilgour, 
unpublished observation). Thus, loss of PKC a, ô or ji from 3T3-F442A 
preadipocytes led to enhanced cell growth and differentiation. These isoforms could, 
therefore, be part of a mechanism acting as a brake on signal transduction, perhaps by 
inducing the suppression of a down-stream kinase or the activation of a down-stream 
phosphatase. Thus, loss of these isoforms could ultimately result in the disorganised 
cell growth associated with tumourigenesis.
PKC Ç is also a ubiquitously expressed PKC isoform (see Quest, 1996). Although 
depletion of PKC Ç from 3T3-F442A cells had no detectable effects on cell growth or 
differentiation, it is possible that other ubiquitously expressed PKC isoforms can 
functionally substitute for PKC Ç in the regulation of proliferation and differentiation. 
It would be relatively simple to investigate whether, for example, the PKC a , Ô and C, 
isoforms functionally substitute for each other in the regulation of cell growth and 
differentiation by performing multiple depletion of isoforms using a combination of 
antisense ODNs.
At present the mechanisms by which the PKC family regulate preadipocyte 
differentiation are uncertain. However, the results of these studies indicate that PKC 
isoforms assume distinct functional roles during preadipocyte differentiation and may 
therefore target different cellular substrates. Members of the C/EBP and the PPAR 
family of transcription factors are especially prominent in the control of adipogenesis 
(see Yeh and McKnight, 1995). A role for PKC isoforms in the regulation of such 
adipogénie treanscription factors has been implied by studies demonstrating that 
suppression of adipogenesis by phorbol esters involves the MAP kinase-mediated 
phosphorylation of PPAR y and attenuation of its transcriptional activity (Hu et al, 
1996). In addition, these transcriptional regulatory proteins display similar temporal 
expression profiles to individual PKC isoforms during preadipocyte differentiation 
(see Yeh and McKnight; Figure 1.3 and Figures 4.5 A-F). In particular C/EBP p and 
C/EBP 5, which are induced during the early stages of differentiation, peak during the
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clonal expansion phase and subsequently decline as cells attain the adipocyte 
phenotype, follow a similar temporal pattern of expression to PKC a , y and 5. In 
addition, PPAR y, which is induced during the clonal expansion phase of 
differentiation and continues to increase as cells attain the adipocyte phenotype, 
follows a similar temporal pattern of expression to PKC s and \i. C/EBP P and 5 and 
PPAR y are thought to induce the expression and channel the adipogénie potential of 
CEBP a , the ultimate regulator of terminal adipogenesis (see Yeh and McKnight,
1996). It would, therefore, be extremely interesting to determine the effects of 
antisense depletion of individual PKC isoforms on the expression and transcriptional 
activity of members of the C/EBP and PPAR family of transcription factors and 
establish whether these proteins are the ultimate down-stream targets of individual 
PKC isoforms during preadipocyte differentiation.
In order to investigate the functional roles of PKC isoforms in adipocytes, their 
involvement in the signalling pathways of two important hormonal regulators of 
adipocyte metabolism, GH and insulin, was examined in 3T3-F442A adipocytes. As 
studies with PKC activators suggested that both GH and insulin alter the rate of 
lipogenesis in the adipocyte by PKC-dependent mechanisms (Smal and DeMeyts, 
1987), the involvement of PKC isoforms in the signalling mechanisms by which GH 
and insulin alter the rate of lipid synthesis was investigated.
Using the anti sense approach it was established that PKC a , 5 and Ç are not essential 
components of the signalling mechanisms by which either GH or insulin alter the rate 
of lipid synthesis in 3T3-F442A adipocytes. PKC 8 is not required for the suppression 
of basal or insulin-stimulated lipogenesis by GH but is one of the multiple 
components required by insulin for the stimulation of lipogenesis. Studies with the PI 
3-kinase inhibitor, wortmannin (Alessi et al, 1995) suggested that PKC 8 may be 
activated via PI 3-kinase during the stimulation of lipogenesis by insulin. PKC p, is an 
important component of the signalling mechanism by which GH suppresses basal 
lipogenesis in 3T3-F442A adipocytes. The results of these studies indicated that PKC 
p-independent mechanisms were also required for the suppression of lipogenesis by 
GH. PKC p also appears to be an essential component of the signal transduction
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mechanism by which insulin stimulates lipogenesis in 3T3-F442A adipocytes. The 
stimulation of lipogenesis by insulin was reduced in the absence of PKC 8 but no 
stimulation of lipogenesis by insulin was observed in the absence of PKC p. This 
suggests the simultaneous activation by insulin of a signalling pathway involving 
PKC 8, and other PKC 8-independent signalling pathway(s), which diverge at the 
level of PKC p in the stimulation of lipogenesis. PKC y is an essential component of 
the signalling mechanism by which GH antagonises the stimulation of lipogenesis by 
insulin. This suggests that activation of PKC y by GH may prevent the activation of 
PKC p by insulin, or its subsequent down-stream events.
Thus, PKC y, 8 and p were found to be involved in the signalling mechanisms by 
which GH and insulin alter the rate of lipid synthesis in 3T3-F442A adipocytes. 
Cellular levels of PKC 8 and p are markedly elevated in 3 T3-adipocytes as compared 
to preadipocytes. This implied a functional role for these PKC isoforms in adipocyte 
regulation. Indeed, PKC p appears to be an important component of the signalling 
mechanisms by which both GH and insulin exert their effects on the lipogenic 
pathway. In addition, PKC 8 appears to be a component of the signalling mechanism 
by which insulin alters the rate of lipid synthesis in the adipocyte. In contrast, cellular 
levels of PKC y were dramatically reduced following differentiation of 3T3-F442A 
cells, implying that PKC y played a minimal role in adipocyte regulation. However, 
this PKC isoform was found to be essential for the antagonism of insulin action by 
GH, at least with regard to lipogenesis. Thus, although 3T3-F442A adipocytes exhibit 
reduced levels of PKC y at the protein level, adipocyte PKC y may possess increased 
sensitivity or affinity for substrates following hormonal stimulation.
The mechanisms by which individual PKC isoforms regulate the lipogenic pathway 
are unclear. That PKC |i is targeted by both GH and insulin in exerting opposing 
effects on the rate of lipogenesis, suggests that this isoform may be differentially 
regulated by these hormones. For example, phosphorylation at distinct sites in 
response to hormones may mediate distinct down-stream events such as the activation 
or suppression of down-stream substrates. In addition, that PKC y is essential for the 
antagonism of insulin-stimulated lipogenesis by GH suggests that this PKC isoform 
may be involved in the regulation of PKC p. or subsequent down-stream events
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mediated by PKC p..
Given that PKC p. was found to be an important component of the signal transduction 
mechanism by which both GH and insulin exert their effects on lipid synthesis in the 
adipocyte, it would be interesting to determine how PKC p is regulated by these 
hormones. PKC p has been shown to be activated by a number of hormones and 
growth factors (Zugaza et al, 1997) and studies to date suggest PKC p activation is 
dependent on other PKC isoforms such as PKC e and r\ (Zugaza et al, 1996 and
1997). Indeed, the results of the studies presented here suggest that PKC p may be 
activated down-stream of PKC 8 in response to insulin stimulation. However, other 
signalling components, in addition to PKC 8, appear to be required for the stimulation 
of lipogenesis by insulin. PKC p is also required for the suppression of basal 
lipogenesis by GH and no other PKC isoform was found to be essential for this 
response. From these studies it appears that, either, PKC-independent processes are 
involved in the activation of PKC p by both GH and insulin in 3T3-F442A 
adipocytes, or, that other PKC isoforms can functionally substitute for each other in 
the activation of PKC p. This could again be established by performing multiple 
depletion of PKC isoforms using a combination of antisense ODNs.
At present the mechanisms by which individual PKC isoforms regulate the GH- and 
insulin- mediated responses on the rate of lipogenesis in adipocytes are unclear. The 
lipogenic pathway comprises a number of strictly regulated enzymes (see Figure 1.1). 
To date, the effects of GH and insulin on the rate of lipogenesis have been largely 
attributed to hormone-induced alterations in the expression and activity of key 
lipogenic enzymes such as acetyl CoA carboxylase, fatty acid synthase and pyruvate 
dehydrogenase (Dietz and Schwartz, 1991; Bauman and Vernon, 1993; Harris et al, 
1993; Vernon et al, 1993; Denton and Tavare, 1995; Moule et al, 1995). It would, 
therefore, be of interest to determine the effects of antisense depletion of PKC 
isoforms from 3T3-F442A adipocytes on the expression and activation status of such 
enzymes following hormonal stimulation in order to establish if these key lipogenic 
enzymes are the ultimate down-stream targets of PKC isoforms in the lipogenic 
pathway.
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It is also unclear at present which, if any PKC isoforms, are involved in the signalling 
pathways utilised by GH and insulin to regulate other aspects of adipocyte 
metabolism in 3T3-F442A adipocytes. However, in theory, the anti sense approach 
could be used to provide further insight into the roles of individual PKC isoforms in 
the signalling mechanisms used by GH and insulin or, indeed, other hormones 
involved in adipocyte regulation, to exert their effects on other aspects of adipocyte 
metabolism. The selective depletion of PKC isoforms from adipocytes could be used 
to analyse the involvement of specific isoforms in hormone-controlled processes such 
as changes in the rate of glucose transport, glucose transporter translocation, 
alterations in the rate of lipolysis, changes in the activity of key lipolytic enzymes and 
altered regulation of cyclic AMP phosphodiesterases. Given that the functional roles 
of PKC Ç in 3T3-F442A cells remain undefined following the present study, it would 
be of particular interest to determine if this isoform is required for GH- and insulin- 
induced alterations in the rate of lipolysis and glucose transport, particularly as a role 
for PKC Ç in the stimulation of glucose transport by insulin has been implied in 3T3- 
L1 adipocytes (Bandypadhyay e /ûf/, 1997).
In summary, PKC isoforms were found to assume distinct functional roles in 3T3- 
F442A cell regulation. Cellular levels of PKC Ç were maintained throughout the 
differentiation of preadipocytes, suggesting that this isoform plays an as yet 
unidentified role in 3T3-F442A cell regulation. PKC a  and ô play a modulatory role 
in the early stages of the differentiation process whereas PKC y and PKC s are both 
essential for preadipocyte differentiation to occur. In fully differentiated adipocytes, 
PKC s is one of a number of components required for the stimulation of lipogenesis 
by insulin and PKC y appears to be an essential component of the signal transduction 
mechanism by which GH antagonises the stimulation of lipogenesis by insulin. PKC 
|i, like PKC a  and 5, appears to modulate the early stages of the preadipocyte 
differentiation process. In addition, this PKC isoforms appears to play an important 
role in the regulation of adipocyte metabolism by hormones, at least with regard to 
lipogenesis. PKC p is an important component of the signalling mechanism by which 
GH suppresses basal lipogenesis in adipocytes and this isoform appears to be essential 
for the stimulation of lipogenesis by insulin.
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Although, the precise mechanisms by which individual PKC isoforms regulate 
adipocyte development and function remain to be determined, the results of these 
studies clearly indicate that individual PKC isoforms assume distinct functional roles 
in 3T3-F442A cells. These findings may, therefore, be relevant to our understanding 
of the diseased state of obesity which involves both changes in the turnover of 
adipocyte cells in adipose tissue (Prins and O'Rahilly, 1997) and selective changes in 
the expression of adipocyte PKC isoforms (Frevert and Kahn, 1996).
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